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While caffeine withdrawal has been well-characterized, research on caffeine intake and factors 
associated with withdrawal has been limited.  The present study examined prevalence rates of 
caffeine use and identified psychosocial factors associated with having caffeine withdrawal 
headaches (CWH).  Participants were N = 1,989 college freshmen who participated in the 2011 
Spit for Science project.  Caffeine use was reported by 80% of the sample.  Females were more 
likely than males to consume caffeine, and soda was the primary source of caffeine for both 
genders.  As hypothesized, daily caffeine users were more likely to report CWH than non-daily 
users.  When multivariable analyses examined other variables identified through univariable 
analyses, the most parsimonious model for distinguishing between those with and without CWH 
included the following set of predictor variables: daily caffeine use; female; non-white minority; 
peers with alcohol problems; greater neuroticism, and those reporting maternal depression or 
anxiety. 
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Predictors of Caffeine-Related Withdrawal Symptoms in College Freshmen 
 
 
Introduction 
 
 The markedly different means of caffeine self-administration, in addition to the widely 
different social and cultural contexts in which caffeine is consumed, has branded caffeine as the 
most widely used psychoactive drugs in the world (Benowitz, 1990; Gilbert, 1984; Griffiths & 
Chausmer, 2000; Griffiths & Mumford, 1996, 2000; Juliano, Ferré & Griffiths, 2014; Smith, 
2005; Winston, Hardwick, & Jaberi, 2005).  While population-level data on caffeine intake 
throughout the world and the United States has been examined (Frary, Johnson, & Wang, 2005; 
Fulgoni, Keast, and Lieberman, 2015; Mitchell, Knight, Hockenberry, Teplansky, & Hartman, 
2014), accurate estimates of caffeine consumption has proven challenging since caffeine intake 
varies across different population groups and caffeine content varies considerably across 
different beverage types (coffee, tea, energy drinks).   
 Most caffeine users consume it without experiencing adverse consequences.  However, 
like many psychoactive substances, regular (daily) use of caffeine can lead to a variety of 
physical and psychosocial problems (e.g., heart disease, sleep disturbance).  Furthermore, 
caffeine use can lead to physical dependence and abrupt cessation of such use can produce 
symptoms of withdrawal.  Empirical research has supported the addition of Caffeine Withdrawal 
to the DSM-5 (APA, 2013), and headaches are considered the hallmark symptom of this disorder 
among regular caffeine users (Juliano et al., 2014).  Apart from caffeine consumption itself, 
however, little is known about other variables associated with caffeine withdrawal (Juliano & 
Griffiths, 2004). 
 The present study examined prevalence rates of caffeine use in males and females, and 
investigated potential predictors of caffeine-related withdrawal symptoms in college freshmen.  
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Specifically, this study examined the extent to which certain environmental factors contribute to 
risk for caffeine withdrawal in a sample of caffeine using college students.   
 The study utilized the first year (Fall, 2011) freshman cohort of the VCU Spit for Science 
Survey (Dick & Kendler; NIH R37 AA011408).  This unique dataset contains survey 
information from 2056 participants about recent caffeine use, as well as use of alcohol and other 
substances, personality measures, and other emotional and behavioral symptoms (Dick et al., 
2014).  Statistical analyses were used to identify potential demographic and psychosocial 
variables associated with having caffeine withdrawal headaches (p <.25) to determine which of 
these variables, in combination with caffeine use measures, best predict caffeine withdrawal 
headache.  Direct univariable and multivariable logistic regression analysis were then used to 
provide a parsimonious model for predicting caffeine withdrawal headaches.   
 Together, this information added to the validity of self-report frequency measures of 
caffeine consumption by examining their relationship to the experience of caffeine withdrawal 
headache, which provided insight regarding the efficiency and accuracy of self-report 
assessments of caffeine use.  This investigation also provided evidence which may inform 
practitioner ability to identify persons at greatest risk for negative consequences of caffeine 
dependence, including withdrawal.   
Physical and Chemical Properties of Caffeine 
Caffeine (Mr 194.19), also systematically called 1,2,7-trimethylxanthine, 1,3,7-trimethyl-
2,6-dioxopurine or 3,7-dihydro-1,3,7-trimethyl-1-H-purine-2,6-dione, was discovered during the 
period 1820-1827 and belongs to a class of methylxanthines, which are defined as purine 
alkaloids.  At room temperature caffeine consists of an odorless, bitter, white powder with a 
density of 1.23 (d18/4), but may also consist of flexible, silky needles upon crystallization from 
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water (Arnaud, 1999; Tarka & Hurst, 1998).  Caffeine’s chemical formula is C8H10N4O2  
(Weinberg & Bealer, 2001). 
Caffeine occurs naturally in a variety of foods, seeds, plant species, and beverages (e.g., 
coffee, tea, chocolate, kola nuts), with the highest caffeine concentrations found in guarana seeds 
(Paulinia cupana), followed by tea leaves (Camellia thea, C. sinensis), and then coffee beans 
(Coffea arabica).  Additionally, caffeine has been discovered in more than sixty other plant 
species worldwide (Arnaud, 1999; Barone, & Roberts, 1996; IFIC 2008). Pure caffeine is 
chemically extracted by a number of methods including the decaffeination process of coffee and 
black or green tea, as well as biosynthesis, methylation, and total chemical synthesis of other 
methylxanthines (theophylline and theobromine) (Arnaud, 1999; Tarka & Hurst, 1998; Weinberg 
& Bealer, 2001).  Caffeine’s physical and chemical properties are described in Table 1. 
 
Table 1.   
 
Physical and Chemical Properties of Caffeine. 
 
 
 
Property  
 
Value  
  
 
Molecular weight 
 
194.19g 
  
Melting Point 234-2390C   
Sublimation point 1780C  
Specific gravity  1.2   
Volatility  0.5%   
Solubility (in water)  2.2%    
Vapor pressure (at 1780C)  760 mm Hg   
Vapor density 6.7  
pH (1% solution)  6.9  
Median lethal dose 150-200 mg kg-1  
 
       From Arnaud, 1999; Mumin, Akhter, Abedin, & Hossain, 2006;  
       Tarka & Hurst, 1998 
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Pharmacology of Caffeine 
Pharmacokinetics 
After oral ingestion, caffeine is rapidly and completely absorbed from the gastrointestinal 
track, with peak blood levels occurring 45 – 60 minutes following oral doses of 5-8 mg per 
kilogram of body weight and yield peak plasma concentrations of 8 to 10 mg/l (Bonatie, Latini, 
Galletti, Young, Tognoni, & Garattini, 1982; Griffiths, Juliano, & Chausmer, 2003).  Therefore, 
one cup of coffee, which contains a dose of 0.4 to 2.5 mg/kg, provides an estimated peak 
concentration of 0.25 to 2 mg/l or approximately 1 to 10 μM (Fredholm, Bättig, Holmén, Nehlig, 
& Zvartau, 1999).  
Caffeine is quickly eliminated with a typical half-life of 3 – 6 h. (Arnaud, 1999; 
Benowitz, 1998; Juliano & Griffiths, 2004) and is metabolized by the demethylation to 
dimethylxanthines, with the primary metabolites being paraxanthine, theobromine and 
theophylline (Benowitz 1990; Griffiths, Juliano, & Chausmer, 2003; Spiller, 1998; Weinberg & 
Bealer, 2001).  Ring hydroxylated urates and acetylated uracil also account for a portion of 
caffeine metabolism.  Caffeine’s metabolism mostly occurs in the liver via catalysis by the 
cytochrome P450 1A2 (CYP1A2) enzyme and by the catalytic action of CYP2E1, the ethanol-
inducible CYP (Carrillo & Benitez, 2000; Gu, Gonzalez, Kalow, & Tang, 1992; Juliano, Ferré, 
& Griffiths, 2014).    
Various environmental, biological and gender-based factors are known to modify the rate 
at which caffeine is metabolized.  For instance, females metabolize caffeine 20 to 30% faster 
than males (Nawrot, Jordan, Eastwood, Rotstein, Hugenholtz, & Feeley, 2003; Weinberg & 
Bealer, 2001).  Additionally, cigarette smoking increases the elimination of caffeine (Arnaud, 
1999; Brown, Jacob, Wilson, & Benowitz, 1988; Weinberg & Bealer, 2001) by decreasing 
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caffeine’s half-life by 30-50% and doubles the rate at which caffeine is eliminated (Fredholm et 
al., 1999).  Conversely, obesity, alcohol consumption, and chronic liver disease decrease caffeine 
elimination rate (Arnaud, 1999; Benowitz, 1990; Weinberg & Bealer, 2001).  Also, decreased 
caffeine elimination is reported in both pregnant women and those who are taking oral 
contraceptives (Arnaud, 1999).  Genetic polymorphisms in the CYP1A2 enzyme are also 
associated with different rates of caffeine metabolism, which will be discussed further.   
Urinary excretion is the main elimination route of caffeine, with only 2-5% of ingested 
caffeine being excreted through feces (Arnaud, 1999; Benowitz, 1990), and only 10% of caffeine 
is excreted unchanged (Julian, Advokat, & Comaty, 2011).  
Mechanism of Action 
Caffeine is a central nervous system (CNS) stimulant (Arnaud, 1999) and research has 
identified three biochemical mechanisms that help to explain the pharmacological and 
physiological properties of caffeine.  The primary mechanism of action of caffeine, and the most 
recently studied mechanism, is the competitive antagonism at A1, A2, and A3 adenosine receptors 
(Arnaud, 1999; Benowitz, 1998; Fison, Borgkvist, & Usiello, 2004; Fredholm et al., 1999). 
These receptors are found in the brain, adipose tissue cardiovascular, respiratory, renal, and 
gastrointestinal systems, and are classified as a neuromodulator, which influences the release of 
various neurotransmitters in the CNS (Julien et al., 2011).  Additionally, they promote lipolysis, 
platelet aggregation, are inotropic and chronotropic to the heart, and cause bronchodilation and 
diuresis (Arnaud, 1999).   
According to this mechanism, caffeine non selectively blocks both adenosine receptors 
and competitively inhibits the actions of adenosine.  At the presynaptic level, adenosine inhibits 
neuronal release of acetylcholine and other neurotransmitters such as norepinephrine, dopamine, 
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gamma amino butyric acid (GABA), and serotonin.  Therefore caffeine’s ability to block 
adenosine’s inhibitory affect contributes to the release of these neurotransmitters (Benowitz, 
1990; Daly & Fredholm, 1998; Nehlig, Daval, & Debry, 1992), and also “increases circulating 
catecholamines consistent with reversal of the inhibitory effects of adenosine on these systems” 
(Benowitz, 1990, p. 279; Griffiths et al., 2003; Nehlig et al., 1992).  Strong experimental 
evidence exists supporting that the adenosine modulation of dopaminergic neurotransmission in 
the brain is what plays a key role in the psychostimulant effects of caffeine, a similar mechanism 
involved with classical psychostimulants (Fison et al., 2004; Juliano et al., 2014).  
It has also been suggested that caffeine’s ability to inhibit cyclic nucleotide 
phosphodiesterase might contribute to the discriminative stimulus effects of caffeine (Griffiths & 
Mumford, 1996; Weinberg & Bealer, 2001).  According to this mechanism, caffeine is known to 
increase cyclic adenosine 3’,5’-monophosphate (cAMP) concentrations in various tissues, while 
phosphodiesterase catalyzes the breakdown of cAMP concentrations.  However, because most 
selective phosphodiesterase inhibitors are behavioral depressants, it is unlikely that 
phosphodiesterase inhibition would be involved in low-dose caffeine discriminative effects.  
Moreover, there are mixed results implicating phosphodiesterase inhibition being involved in the 
discriminative effects of higher caffeine dose as well (Griffiths & Mumford, 1996).  
Furthermore, the caffeine concentrations required for this mechanism are produced only with 
millimolar concentrations (i.e., toxic concentrations) and therefore, further research is needed to 
conclude that this mechanism significantly contributes to the in vivo pharmacology of moderate 
caffeine doses (Debry, 1994).  
 The third mechanism of action is the effect of methylxanthines on the mobilization of 
intracellular calcium from skeletal, cardiac, and neuronal tissue (Carrillo & Benitez, 2000; 
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Debry, 1994).  At certain concentrations caffeine lowers the excitability threshold and prolongs 
the duration of muscle contraction by promoting translocation of calcium through the plasma 
membrane and the sarcoplasmic reticulum.  A minimum concentration of 250 μM of caffeine is 
necessary to produce effects of calcium shifts, while plasma concentrations of caffeine after 
ingestion of coffee is usually less than 100 μM; therefore, this mechanism of action is also not 
representative of an essential mechanism of caffeine in the CNS (Debry, 1994).   
Physiological & Behavioral Effects of Caffeine 
 As a CNS stimulant, caffeine produces a number of physiological effects, in addition to a 
number of positive cognitive and affective effects (Fredholm et al., 1999; Meredith, Juliano, 
Hughes, & Griffiths, 2013; Smith, 2002).  Such effects of caffeine are generally dose dependent 
and can produce a variety of positive and negative physiological health effects, impacting the 
cerebral vascular system, cardiovascular system (e.g., increasing blood pressure and low-density 
lipoproteins), neuroendocrine system, renal system, respiratory system, hepatic, and 
gastrointestinal systems (Arnaud, 1999; Griffiths et al., 2003; Juliano et al., 2014; Nawrot et al., 
2003; Smith, 2005; Wolk, Ganetsky, & Babu, 2012).  However, scientific evidence suggests that 
among the healthy adult population, moderate daily caffeine consumption (400-450 mg/day, or 
about 5.7 mg/kg body weight per day for a 70-kg person, equivalent to four or fewer cups of 
coffee per day) is not associated with adverse health effects (Heckman, Weil, & De Mejia, 2010; 
Nawrot et al., 2003).    
In humans, the subjective and discriminative stimulus effects of caffeine at low to 
moderate doses (20 – 400-450 mg/day) can be characterized by an overall increase in arousal.  
These arousal effects have been characterized as an increase in frequency of positive mood self-
reports (e.g., sense of wellbeing, happiness) (Griffiths et al., 2003; Juliano et al., 2014), energy 
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(e.g., stimulating locomotor activity), alertness, reduced fatigue, attention, sociability, and certain 
complex cognitive functioning (i.e., mental performance in work settings) (Arnaud, 1999; 
Griffiths & Mumford, 1996, 2000; Juliano & Griffiths, 2004; Winston et al., 2005).   
Furthermore, caffeine is associated with increased vigilance (Silverman, Mumford, & 
Griffiths, 1994) and sustained response, reduced depressive symptoms, and decreases in the risk 
of suicide (Penolazzi, Natale, Leone, & Russo, 2012).  Additionally, caffeine acts as an 
ergogenic aid (Lamarine, 1998), and caffeine consumption enhances information processing, 
memory performance, and psychomotor functioning, such as: improvement of delayed recall, 
recognition memory, semantic memory, verbal memory, and visual selection and fine motor 
control (Jarvis, 1993; Smith & Tola, 1998).  The profile of these effects are similar to that of 
other psychostimulants, such as cocaine, where in an experimental study approximately 300 
mg/70 kg of caffeine was shown to produce similar stimulant effects similar to that of 25 mg of 
cocaine (Rush, Sullivan, & Griffiths, 1995). 
Caffeine has also been characterized as a therapeutic agent and is associated with 
improved glucose tolerance and subsequent reduced risk of type II diabetes, weight loss, lowered 
risk for incidence of Parkinson’s disease and improvement in Parkinson’s symptoms, reduced 
risk for some types of cancer at several anatomical sites, in addition to treatment for post-surgical 
withdrawal headaches and migraine headaches (Butt & Sultan, 2011; Floegel, Pischon, 
Bergmann, Teucher, Kaaks, & Boeing, 2012; Higdon & Frei, 2006; Juliano et al., 2014; Sinha, 
Cross, Daniel, Graubard, Wu, Hollenbeck, Gunter, Park, & Freedman, 2012).   
Alternatively, higher and excessive doses (acute doses ≥ 200 mg in non-habitual users, or 
habitual daily use > 500 – 600 mg, approximately four to seven cups of coffee or seven to nine 
cups of tea) can lead to dysphoric feelings of anxiety, jitteriness, restlessness, 
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irritability/aggression, tinnitus, muscle twitching, palpitations, headaches, upset stomach, and 
other health risks (Arnaud, 1999; Griffiths & Mumford, 1996; Griffiths et al., 2003; Heckman, et 
al., 2010; Nawrot et al., 2003; Smith & Tola, 1998; Chait & Griffiths, 1983; Charney, Galloway, 
Heninger, 1984; Loke, 1998; Oliveto, Bickel, Hughes, Terry, Higgins, & Badger, 1993; Reissig, 
Strain, & Griffiths, 2009).   
Additional behavioral effects resulting for CNS stimulation include a delay in sleep 
onset, and impaired sleep quality characterized by an increased number of spontaneous 
awakenings and body movements, which results in decreased total sleep time (Alford, Bhatti, 
Leigh, Jamieson, & Hindmarch, 1996; Arnaud, 1999; Hinmarch, Rigney, Stanley, Quinlan, 
Rycroft, & Lane, 2000).  Administration of higher doses of caffeine has led to significant number 
of caffeine users who consume caffeine regularly endorsing dependence/abuse criteria and 
meeting criteria for “caffeinism,” a psychophysiological syndrome first described in the 
American Psychiatric Association’s (APA) Diagnostic and Statistical Manual of Mental 
Disorders, Third Edition – Revised (DSM-III-R, APA, 1987), also known as acute or chronic 
Caffeine Intoxication in the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV, APA, 1994), in the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition – Text Revised (DSM-IV-TR, APA, 2000), and also in the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5, APA, 2013) (Arnaud, 1999; 
Griffiths & Mumford, 2000; Hughes Oliveto, Liguori, Carpenter, & Howard, 1998; Weinberg & 
Bealer, 2001).  
Dietary Sources of Caffeine 
 
There is a current proliferation of caffeinated food and beverage products within the U.S. 
and around the world.  The amount of caffeine in these products varies depending on a number 
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of factors, including serving size and type of product.  For example, an eight-ounce cup of 
brewed coffee typically has 65-120 mg caffeine; an eight-ounce serving of brewed tea has 20-90 
mg, and a 12- ounce canned soft drink has 30-60 mg (Julien et al., 2011; Knight, Knight, 
Mitchell, & Zepp, 2004).  However, an eight-ounce cup of coffee from Starbucks can contain up 
to 165 mg caffeine (Mayo Clinic, 2014) and it is estimated that coffee is higher in caffeine 
content than tea by approximately 60 to 70% (Lundsberg, 1998), and chocolate or cocoa 
confectionery products usually contain the least amount of caffeine (see Table 2) (IFIC, 2008). 
 The average caffeine contents of various foods and beverages are presented in Table 2, 
and are reported in milligrams.  However, to create a standard measure of caffeine intake for 
individual consumers, caffeine intakes (in mg) are converted to a body weight basis (mg/kg body 
weight) based on the actual weights of each individual, and therefore, an individual’s caffeine 
intake is commonly reported in mg kg-1 (Barone & Roberts, 1996).  For example, an average 8 – 
12 oz. cup of coffee contains approximately 100 – 200 mg of caffeine (Juliano et al., 2014; Julien 
et al., 2011; Weinberg & Bealer, 2001), and a dose level up to 400 mg day-1 is equivalent to 6 mg 
kg-1 body weight day-1 in a 65-kg person, or 143.3 lbs. person (Nawrot et al., 2003).  
 
Table 2.  
 
Average Caffeine Content of Common Foods and Medications.  
 
 
Beverages     
& Foods (volume or weight) 
 
Avg. caffeine (mg) 
  
 
Coffee 
   
Brewed/drip (12 oz.) 200   
Instant (12 oz.) 140  
Espresso (1oz.) 70  
    
Tea    
Instant tea (6 oz.) 30   
Brewed tea (6 oz.) 40  
   
  11 
Cola Drinks   
Coca-Cola Classic (12oz.) 33  
Mountain Dew/Diet Mountain Dew (12oz.) 55   
Pepsi Max/Diet Pepsi Max 69  
   
Energy Drinks/Shots    
Red Bull Energy Drink (8.4oz.)      78  
5-Hour Energy (shot; 2oz.)             207   
Other    
NoDoz, Max. Strength (1 tab)        200   
Excedrin, Extra Strength (2 tabs)    30   
Foosh Energy Mints (1)     100 
 
  
Jolt Gum (1 piece)  33   
Hersey’s Kisses (9 pieces)          9 
 
  
      Juliano et al., 2014 
 
 More recently, much attention has focused on other caffeinated beverages, such as energy 
drinks and energy shots, which have become a common source of caffeine worldwide and in the 
United States (U.S.) (Reissig et al., 2009).  First introduced in the USA in 1997, the market and 
consumption for these beverages has grown exponentially.  For example, from 2002 to 2006 the 
estimated total U.S. retail market value for energy drinks was $5.4 billion, with nearly 200 
brands launched in U.S. in just a 12-month period ending in 2007 (Reissig et al., 2009).  
Together, sales of caffeinated energy drinks and shots rose 60% in the United States between 
2008 and 2012 to $12.5 billion/year.  Sales are expected to grow at a similar rate until reaching 
$21.5 billion/year in 2017 (Packaged Facts, 2013).   
While the U.S. Food and Drug Administration (FDA) has limited the caffeine content of 
sodas to 65 mg per 12 oz. (18 mg/100 mL), energy drinks are not currently subject to the same 
FDA regulations (McCusker, Goldberger, & Cone, 2006) since they are marketed as dietary 
supplements, and they often contain high amounts of caffeine compared to other caffeinated 
beverages (Arria & O’Brien, 2011).  Therefore, the safety standards concerning these beverages 
are made solely by the manufacturers, and their only requirement is to include caffeine on the 
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ingredient list (U.S. FDA, 2013).  It is difficult to determine the caffeine content in these 
beverages, but reported amounts vary widely (see Table 2), with the caffeine content and 
concentration ranging from 80-120 mg per eight-ounce serving (American Beverage 
Association, 2009) and up to a startling 505 mg per in a 24-ounce can (the equivalent of 14 cans 
of soda or several cups of coffee) (Reissig et al., 2009).  The most popular caffeinated energy 
drinks in the U.S. are called Red Bull (Red Bull GmbH), Amp (PepsiCo, Inc.), Monster (Monster 
Beverage Company), Rock Star (Rockstar Inc.), Vault (Coca-Cola Company), and FullThrottle 
(Coca-Cola Company).  
These beverages also contain caffeine from guarana and other added sources with 
unknown safety profiles, such as: taurine, riboflavin, pyridoxine, niacin, glucuronolactone, L-
Carnitine, nicotinamide, other B vitamins, and various herbal derivatives not normally 
announced as caffeine (Aranda & Morlock, 2006; Higgins, Tuttle, & Higgins 2010; IFIC 2008; 
Wolk et al., 2012).  
  Similar to caffeinated energy drinks, an emerging and more accessible form of caffeine 
has been developed in the form of “energy shots.” These “shots” claim to produce similar 
beneficial mental and/or physical energy effects as any other caffeinated beverage but are 
generally only 59-88 milliliters in volume.  They can contain 80-140 mg of caffeine and a blend 
of other ingredients comparably found in energy drinks (B vitamins, taurine, glucuronolactone, 
etc.).  Additionally, this alternative form of caffeinated beverage has taken on a variety of flavor 
combinations and product line extensions that are appealing to a diverse set of consumers, which 
has led to markedly impressive sales (Peterson, 2013).  Furthermore, these beverages have 
become a particular trend among athletes, as they are believed to be a possible pre-competition 
supplement given caffeine’s stimulating effects (Heckman et al., 2010; Nawrot et al., 2003; 
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Schubert, Astorino, & Azevedo, 2013).  Additionally, numerous studies have documented that 
young adults, teenagers, college students, and military personnel (Heckman, Sherry, & de Mejia, 
2010; Lieberman, Stavinoha, McGraw, White, Hadden, & Marriott, 2012; Norton, Lazev, & 
Sullivan, 2011) are commonly consuming these caffeinated beverages.  
In addition to caffeine occurring in a number of foods and beverages, caffeine is also an 
active ingredient in a number of over-the-counter and prescription compounds, including 
antidrowisness pills, non-drowsy cold remedies, pain relief tablets, and weight-loss pills given 
caffeine’s appetite suppressant and analgesic effect. Caffeine is even added to some commercial 
water, mints, candy, chewing gum, potato chips, ice cream, and oatmeal (Barone & Roberts, 
1996; IFIC, 2008; Julien et al., 2011; Temple, 2009; Lundsberg, 1998; Weinberg & Bealer, 
2001).  Substances called “energy sheets” (PureBrands, Boca Raton, FL, USA), sheets of paper 
that contain 100mg of caffeine per serving and are made from dissolvable pieces of paper that 
are placed on the tongue (Wolk et al., 2012) are also available.  
Epidemiology 
Caffeine Consumption World Wide 
  The markedly different and broad vehicles of caffeine self-administration, along with the 
widely different social/culture/population contexts caffeine is consumed (e.g. tea/coffee breaks in 
the United Kingdom, U.S., Europe, and Asia) and kola nut chewing in Nigeria (Barone & 
Roberts, 1996; Frary et al., 2005; Knight, et al., 2004; Lundsberg, 1998; Weinberg & Bealer, 
2001), has made caffeine one of the most researched substances, however, there is a lack of 
population-level empirical data on caffeine intakes around the world (Meredith et al., 2013) and 
most studies cite information dating back to the 1990s.  For example, Barone and Roberts (1996) 
collected information from available product usage data and food consumption survey data\and 
  14 
estimated the mean daily caffeine intake in the United Kingdom to be at 4 mg kg-1 for adult 
consumers.  In Denmark, caffeine intake is reported to be the highest among adults with 7.0 mg 
kg-1, whereas African countries like Algeria, Nigeria, and Tanzania consume some of the lowest 
levels at 4 and 7 mg/person/day, respectively (< 1.0 mg kg-1) (Fredholm, et al., 1999). 
Caffeine Consumption in the U.S. 
 Caffeine consumption is equally ubiquitous in much of North America, with 80-90% of 
U.S. adults reporting use (Drewnowski & Rehm, 2016; Frary et al., 2005; Fulgoni et al., 2015; 
Lundsberg, 1998; Mitchell et al., 2014; Meredith et al., 2013).  The most common sources of 
caffeine include coffee, soft drinks, and tea (Drewnowski & Rehm, 2016; Barone & Roberts, 
1996; Frary et al., 2005; Fulgoni et al., 2015; Somogyi, 2010).  Comprehensive population-level 
data on caffeine intake in the U.S. is quite limited (Ahuja, Goldman, & Perloff, 2006; Frary et 
al., 2005; Knight et al., 2014; Mitchell et al., 2014), with data often cited from the 1980’s and 
1990’s, with the most current data being from the year 2012 (Drewnowski & Rehm, 2016).  
 For example, based on the 1989 Market Research Cooperation of America, the mean 
daily caffeine consumption was reported to be approximately 3 mg kg-1 in the US general 
population and 4 mg kg-1 in adult U.S. consumers (Barone & Roberts, 1996). Furthermore, in 
1994 Debry found individuals in the US general population aged 1-5, 6-11, 12-17, & 18+ 
consumed 1.20, 0.85, 0.74, and 2.60 mg kg-1 of caffeine daily, respectively, from combined 
sources of caffeine including coffee, tea, soft drinks, & chocolate.  Debry (1994) also found that 
for individuals aged 18+, in the United States of American, coffee was the primary source of 
daily caffeine consumption (80.7%), compared to tea, soft drinks and chocolate, while tea 
outsourced soft drinks and chocolate as the primary source of daily caffeine consumption 
(48.2%) for individuals aged 6-11 and 12-17 (45.9%).  
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In 2005, Frary and colleagues published caffeine intake data from a representative sample 
of the U.S. population using the U.S.D.A 1994 to 1996 and 1998 CSFII (sample N = 18,081; 
caffeine consumers N = 15,716; ages 2-54 years).  They found eighty-seven percent of the entire 
sample of caffeine users consumed food and beverages containing caffeine, with an average of 
193 mg caffeine per day and 1.2 mg kg-1 per day.  Frary et al., (2005) also found that men and 
women aged 35 to 64 years were among the highest consumers of caffeine (336 mg/day) and that 
caffeine consumption was positively correlated with increases in age (among people aged 2 to 54 
years).  Major sources of caffeine were coffee (71%), soft drinks (16%), and tea (12%), with 
coffee as the major source of caffeine among adults and soft drinks were the primary source for 
children and teens.     
In 2004, data were reported by Knight and colleagues using the 1999 US Share of Intake 
Panel (beverage survey) (N = 10,712 caffeine consumers).  The authors found per capita 
consumption level of caffeine for all consumers (of all ages) in the US general population to be 
approximately 120 mg per day, or a mean intake of 1.73 mg kg-1 per day.  This data suggests that 
mean caffeine intake has decreased over the years, and is within recommended safe levels, where 
moderate amounts of caffeine are generally considered to be 400–450 mg/day (5.7–6.4 mg kg-1) 
(Nawrot et al., 2003).  In regards to heavier US caffeine consumers, Knight et al., (2004) found 
that caffeine intake at the 90th percentile was 287 mg/day or 4.03 mg kg-1 per day, which has 
also decreased from the mean daily caffeine intake of 5-7 mg kg-1 for heavier consumers (90th 
percentile) reported by Barone and Roberts (1996).     
The most recent available literature on caffeine intake and its primary sources rely 
heavily rely on nationally representative samples. Two primary surveys are what provide key 
sources of newer quantitative data on caffeine intake. They are the Kantar Worldpanel (KWP) 
  16 
Beverage Consumption Panel (formerly the Share of Intake Panel), and the National Health and 
Nutrition Examination Survey (NHANES), which monitors the nation’s nutrition data 
(Ahluwalia & Herrick, 2015).   
The KWP beverage consumption survey involves a U.S. representative sample and 
provides population-based estimates of beverage consumption by using a 7-day diary recorded 
by participants over the Internet.  Respondents recorded details regarding their caffeine 
consumption, such as type, brand, preparation, location (home or away from home), and amount 
of all beverages consumed. To be able to describe caffeine consumption in relation to body 
weight (mg kg-1), information on height, weight, and demographic characteristics was also 
collected at the same time (Ahluwalia & Herrick, 2015; Mitchell et al., 2014). 
The NHANES is a series of large, stratified, multistage surveys of the U.S. civilian, 
conducted by the National Center for Health Statistics, CDC (Ahluwalia & Herrick, 2015).  
Since 1999, the NHANES has been conducted annually and data are publicly released every 2 
years for approximately 10,000 individuals. Participants are administered a series of 
questionnaires asking for details on the type and quantity of all foods and beverages consumed in 
a 24-h period (Ahluwalia & Herrick, 2015). 
In 2015, Fulgoni and colleagues, using the NHANES (2001 to 2010), examined dietary 
intake of caffeine from all caffeine-containing foods and beverages (excluding dietary 
supplements and medicines) for adults 19 years of age (N = 24,808).  The authors estimated that 
89% of the adult U.S. population consumes caffeine on any given day, with an equal percentage 
of men and women consuming caffeine.  Among caffeine consumers, intake at the 90th 
percentile has increased to 436 mg/day, and 99th percentile of intake was estimated at 1066 
mg/day.  This is contrary to what Knight et al. (2004) found when the highest caffeine intakes 
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were below this recommended level (Knight et al., 2004).  The authors also estimated that among 
caffeine consumers, the mean intake of caffeine was 161 mg/day for those aged 19 years, with 
men having a higher average intake, 211 mg/day, compared with females who consumed on 
average 183 mg/day.  Overall, caffeine consumption was highest in males aged 31–50 years and 
lowest in females aged 19–30 years (Fulgoni et al., 2015).   
More recently, Mitchell and colleagues (2014), reported on 2010-2011 U.S. population 
data about consumption of caffeinated beverages from the Kantar Worldpanel (KWP) Beverage 
Consumption Panel.  Of the 42,851 respondents aged ≥2 years (N = 37,602 caffeine consumers), 
approximately 85% of the U.S. population reported consuming at least one caffeinated beverage 
and over 98% of all beverages consumed came from coffee (specialty coffee drinks, iced coffee, 
brewed, instant, and decaffeinated coffee, tea (e.g., green tea, white tea and other varieties, iced 
tea), caffeinated/carbonated soft drinks, and energy drinks (other beverages included chocolate 
drinks, and energy shots).  Coffee accounted for eighty percent of all caffeine consumed.   
 Overall, caffeine intakes from all caffeinated beverages were 380 mg/day or 5.0 mg kg-1 
at the 90th percentile in all ages, and caffeine intakes at this percentile remained slightly above 
400 mg/per day for adults aged ≥35 years (420-467 mg/day or 5.1–5.7 mg kg-1).  Among 
caffeine consumers ages 18-24 years, the mean caffeine intake of coffee was approximately 130 
mg/day.  Also among caffeine consumers, coffee drinkers consumed the most caffeine with the 
highest mean amount of caffeine (223 mg/day) ingested by adults aged 50–64 years (Mitchell et 
al., 2014).  The percentage of energy drink consumers across all age groups was surprisingly low 
(4.3%) and accounted for less that 2% of the total daily mean caffeine among all caffeinated 
beverage consumers.  However, the greatest proportion of caffeinated beverage consumers 
consuming energy drinks were teenagers, ages 13-17 years and young adults, ages 18-24 years, 
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the groups central to most of caffeinated energy drink consumption patterns (Mitchell et al., 
2014).  In conclusion, Mitchell and colleagues (2014) found that among adult caffeine 
consumers in the U.S., the mean daily caffeine consumption was estimated at 165 mg/day, the 
equivalence to about three 6-oz cups of coffee or five 16-oz bottles of cola soft drink (Barone & 
Roberts, 1996; Griffiths et al., 2003; Juliano, et al., 2014).  
  The latest study conducted by Drewnowski & Rehm (2016) using the most recent 
NHANES 2011-2012 data (N = 24,808) estimated adult (≥20 years) caffeine consumption to be 
196 mg/day for men and 151 mg/day for women, numbers that slightly deviate from what 
Fulgoni and colleagues (2015) estimated.  For adults, Drewnowski & Rehm (2016) found 
caffeine consumption to be lowest in the non-Hispanic black population and highest in the non-
Hispanic white population.  The authors reported that overall, among both children (ages 4-19 
years) and adults (≥20 years), caffeine intake has declined from 175 mg/day in 1999–2000 to 142 
mg/day in 2011–2012, with the largest drop in caffeinated soda consumption (41 mg/day to 21 
mg/day).  For adults specifically, caffeine intake decreased from 217 mg/day to 173 mg/day, also 
attributed by a marked decrease in caffeine from soda (from 43.9 mg/day to 23.0 mg/day); there 
was no evidence of an increase in caffeine from coffee or tea (Drewnowski & Rehm, 2016).  
Among adults, caffeine from energy drinks increased significantly from zero in 1999–2000, to 
0.31 mg/day in 2003–2004, and 2.9 mg/day in 2011–2012; however, when considering these 
trends, there was still evidence of a decline in caffeine consumption overall.  Beverages 
continued to be the bulk of caffeine consumed, and coffee, tea, and soda remain predominate 
sources, while energy drinks accounted for 2% of caffeine (2.7 mg/day) and foods contributed 
2.0 mg/day or 1.5% of total caffeine (Drewnowski & Rehm, 2016; Fulgoni et al., 2015; Mitchell 
et al., 2014). 
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Because energy drinks and energy shots were fairly new in 1999, the aforementioned 
population-level studies conducted by Barone & Roberts, (1996), Knight et al., (2004), and Frary 
et al., (2005) did not include these caffeinated beverages as a category.  The increased popularity 
of energy drinks has led them to become a major source of caffeine consumption, especially 
among adolescents and young adults (Babu, Church, & Lewander, 2008; Seifert, Schaechter, 
Hershorin, & Lipshultz, 2011; Temple, 2009).  In addition to the above data examining energy 
drink consumption patterns, Branum, Rossen, & Schoendor (2014) found caffeine intake from 
energy drinks in those aged 19-22 years, based on the NHANES 1999-2010 data, to be an 
estimate of 10%.  Moreover, Bailey, Saldanha, & Dwyer (2014) estimated that 3% of the U.S. 
population (age ≥1 years) use caffeine-containing energy products after examining data from the 
NHANES (2007-2010; N = 19, 142).  The authors also reported the highest usage of these 
products was among males between the ages of 19 and 30 years (7.6%), corroborating the data 
reported by Mitchell et al., (2014).  Furthermore, data from a 2012 cross-sectional survey of 
adolescents attending public schools (grades 7th through 12th) in Atlantic Canada found that 62% 
reported consuming caffeinated energy drinks at least once in the past month, and approximately 
20% reported use once or more per month (Azagba, Langille, & Asbridge, 2014).  It is also 
estimated that 30% of high school students consume energy drinks, and 51% of college students 
consume greater than one energy drink each month (Malinauskas, Aeby, Overton, Carpenter-
Aeby, & Barber-Heidal, 2007; Terry-McElrath, O’Malley, & Johnston, 2014).  These results are 
similar those reported in studies of energy drink use among college students (Arria, Caldeira, 
Kasperski, O’Grady, Vincent, Griffiths, & Wish, 2010; Buxton & Hagan, 2012; Hoyte, Albert, & 
Heard, 2013; Miller, 2008a; Norton et al., 2011; Velazquez, Poulos, Latimer, & Pasch, 2012).  
However, both Arria et al., (2011) and Miller, (2008a) reported that 10% of college students 
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were “weekly” consumers, while Skewes, Decou, & Gonzalez, 2013 reported higher estimates 
for weekly consumption (39.2%).   
The most recent data examined by Arria, Bugbee, Caldeira, &Vincent (2015) using the 
National Institutes of Health-funded Monitoring the Future (MTF) Survey (2010 and 2011 
surveys), found that 35% of eighth graders and 29% of both tenth and twelfth graders reported 
energy drink consumption.  Eighth graders were also most likely to report daily use for energy 
drinks (18%) (Arria et al., 2015).  Further, for every grade, males were more likely than females 
to use energy drinks.  African American individuals had the lowest prevalence of energy drinks 
use regardless of grade, and the highest prevalence was observed among Hispanic eighth graders 
(43%), and the lowest among African American twelfth graders (19%) (Arria et al., 2015).  
Overview of Caffeine and Caffeine Dependence 
 
Reinforcing Properties of Caffeine 
 
The reinforcing efficacy of a drug is dependent on the delivery of the drug and its related 
effectiveness in establishing or sustaining behavior (Griffiths & Mumford 2000, 1996).  A 
number of laboratory animal and human studies have been published focused on reinforcing 
effects of caffeine.  In a review of this literature, Griffiths & Mumford (2000) & Griffiths et al., 
(2003) found a number of intravenous caffeine self-injection studies in laboratory animals 
affirmed that caffeine can function as a reinforcer under certain conditions.  However, the 
findings from such research also suggested that caffeine’s reinforcing ability is more analogous 
to that of self-injection studies of nicotine as compared to other stimulants (e.g., amphetamines 
and cocaine).   
The reinforcing effects of caffeine have also been found in human laboratory studies.  
Numerous studies using various subject populations (moderate and heavy caffeine users with and 
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without histories of alcohol or drug abuse); various methodological approaches (variations on 
choice and ad libitum self-administration procedures), and different caffeine vehicles (coffee, 
soda or capsules), and various contexts of different behavioral requirements after drug ingestion 
(vigilance vs. relaxation activities) positively suggested that caffeine could function as a 
reinforcer in humans (Evans, Critchfield, & Griffiths, 1994; Hale, Hughes, Oliveto, & Higgins, 
1995; Hughes, Higgins, Bickel, Hunt, Fenwick, Gulliver, & Mireault, 1991; Hughes, Hunt, 
Higgins, Bickel, Fenwick, & Pepper, 1992a; Hughes, Oliveto, Bickel, Higgins, & Valliere, 
1992b; Hughes, Oliveto, Bickel, Higgins, Badger, & Gary, 1995, Garrett & Griffiths, 1998; 
Griffiths & Mumford, 1995, 1996, 2000; Griffiths, Bigelow, & Liebson, 1986a, 1989; Griffiths, 
Bigelow, Liebson, O’Keefee, O’Leary, & Russ, 1986b, 1986b; Griffiths et al., 2003; Griffiths & 
Woodson, 1988a, 1988b; Lieuori & Hughes, 1997; Liguori, Hughes, & Oliveto, 1997; Mitchell, 
de Wit, & Zacny, 1995; Oliveto, Hughes, Higgins, Bickel, Pepper, Shea, & Fenwich, 1992a; 
Oliveto, Hughes, Pepper, Bickel, & Higgins, 1990; Silverman, Mumford, & Griffiths, 1994; 
Schuh & Griffiths, 1997).  It has been demonstrated that caffeine reinforcement occurs in 
approximately 45% of normal subjects with histories of moderate and heavy caffeine use 
(Griffiths & Woodson, 1988a, Hughes, Oliveto et al., 1993; Evans, et al., 1994; Silverman et al., 
1994; Hale et al., 1995; Liguori & Hughes, 1997; Liguori et al., 1997).  
This extensive body of research has also shown that caffeine reinforcement follows an 
inverted U-shaped function in relation to dose (Griffiths & Mumford, 1996, 2000; Griffiths et al., 
2003).  That is, the reinforcing effect of caffeine appears to be stronger when low doses (25mg 
per cup of coffee and 33 mg per serving of cola) are self-administered repeatedly throughout the 
day (Hughes, et al., 1992a; Oliveto, et al., 1995; Liguori et al., 1997), while increasing doses 
beyond 50mg or 100mg decrease caffeine self-administration rates and caffeine choice (e.g., 
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coffee, soda, or capsules) (Griffith et al., 1986b; Griffiths & Woodson, 1988a; Hughes et al., 
1992b; Stern, Chait, & Johanson, 1989).  Moreover, high doses of caffeine (e.g., 400mg or 
600mg single doses) have been shown to produce caffeine avoidance (Griffiths & Woodson, 
1988a).   Overall, both the available animal and human research suggests that caffeine is a 
reliable reinforcer, but the evidence claims caffeine to be a less robust reinforcer than other 
psychoactive stimulants, such as cocaine or d-amphetamine, and instead is more similar to 
nicotine (Griffiths & Mumford, 2000). 
Caffeine Intoxication 
 Historically, few studies have examined the prevalence of caffeine’s potential to cause 
adverse effects or clinically significant distress (i.e., caffeine intoxication) in the general 
population.  Case reports, however, did exist indicating incidences of caffeine intoxication; 
therefore, the DSM-III-R (1987) Task Force recognized that acute and/or chronic caffeine use 
can result in caffeine toxicity, and the syndrome Caffeine Intoxication, or caffeinism, was first 
recognized as a syndrome in the DSM-III-R (1987) (Griffiths et al., 2003; Juliano et al., 2014).    
 The Diagnostic and Statistical Manual of Mental Disorders has continued to recognize 
the clinical importance of these effects and have included the diagnosis of acute or chronic 
Caffeine Intoxication (DSM-IV-TR, 2000; DSM-5, 2013). This diagnosis must be 
indistinguishable from medical and/or mental conditions, and is manifested by restlessness, 
nervousness, excitement, insomnia, flushed face, diuresis, gastrointestinal disturbance, and other 
somatic complaints (Griffiths & Mumford, 2000), which emerge in response to recent 
consumption of caffeine.   
 Moreover, patients may experience chronic or recurrent forms of caffeinism without 
recognizing the administration of caffeine-containing beverages and foods as problematic and 
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therefore may seek treatment for anxiety, insomnia, cardiovascular, gastrointestinal, or other 
medical/mental conditions (Greden & Walters, 1992).  This diagnosis as a category may occur in 
about 7% of the population (Greden & Walters, 1992; Hughes et al., 1998), and has been known 
to occur after recent consumption of caffeine at doses as low as 250mg; however, most instances 
of caffeine intoxication occur after consumption of much higher dose, such as greater than 
500mg (Juliano, Ferré, & Griffiths, 2009).  Additionally, with emergence of caffeinated energy 
drink products and concentrated marketing efforts targeting adolescents and young adults, those 
whom are less likely to be dependent on caffeine, cases of caffeine intoxication/withdrawal may 
occur (Juliano et al., 2009).  For example, there has been a large increase in the number of 
emergency department visits between 2005 (1,128) and 2008 and 2009 (16,053 and 13,114 
visits, respectively) involving energy drink use and caffeine intoxication (SAMHSA, 2011).  
Physical Dependence 
 Physical dependence upon a drug is defined as “time-limited biochemical, physiological, 
and behavioral disruptions (i.e., a withdrawal syndrome) upon termination of chronic or repeated 
drug administration” (p. 330, Griffiths & Mumford, 1996).  In humans, clinical evidence of 
physical dependence on caffeine was sparse (Hughes et al., 1992c).  In animal studies, physical 
dependence upon caffeine has been demonstrated following cessation of chronic caffeine dosing.  
In rats, a 50%-80% reduction in spontaneous locomotor activity, i.e., lever pressing (Finn & 
Holtzman, 1986; Holtzman 1983), and a 20%-50% reduction in operant responding (Carney, 
1982) were found.  Such symptoms of withdrawal have been demonstrated at doses ranging from 
6mg/kg per day (Vitiello & Woods, 1977) to 190 mg/kg per day (Boyd, Dolman, Knight, & 
Sheppard, 1965), and across caffeine dosing frequencies ranging from once daily (Carney, 1982) 
to several times per day (Holtzman, 1983) (Griffiths & Mumford, 1996).  More recently, 
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preclinical studies of physical dependence on caffeine continued to demonstrate reductions in 
operant conditioning (Carroll, Hagen, Asencio, & Brauer, 1989; Mumford, Neill, & Holtzman, 
1988) and reductions in reinforcing threshold during electrical brain stimulation (Mumford et al, 
1988), in addition to significant changes in sleep patterns (Sinton & Petitjean, 1989).   
 At the human level, scientists estimate that about one-third of the general population may 
be physically dependent on caffeine.  However, caffeine dependence has never been recognized 
as a mental disorder in the DSM.  Instead, studies of caffeine dependence have focused on 
criteria analogous to the DSM for other drugs.  In a review of this research, Ogawa and Ueki 
(2007) found four studies that used structured interviews to evaluate subjects using criteria for 
Substance Dependence. All four studies examined how the DSM-III-R or DSM-IV criteria for 
Substance Abuse or Dependence might be applied to caffeine (Hughes et al., 1993; Strain, 
Mumford, Silverman, & Griffiths, 1994; Hughes et al., 1998; Svikis, Berger, Haug, & Griffiths, 
2005).   
The first study by Hughes and colleagues (1993) interviewed 162 caffeine users with a 
structured phone interview and applying DSM Substance Dependence criteria modified to focus 
on caffeine.  They found 44% of current caffeine users (about 36% of the general population 
sample) met criteria for Caffeine Dependence.  Further, this sample included 27% of participants 
with mild caffeine dependence (three-four criteria), 14% with moderate dependence (five-six 
criteria), and 3% with severe dependence (seven-nine criteria).   
Strain and colleagues (1994) focused on adults who self-identified as psychologically or 
physically dependent on caffeine and found 59% of subjects met at least three of the following 
four criteria: desire to cut down, use despite harm, tolerance, and withdrawal.  The other criteria 
were not used (use more than intended; use results in role dysfunction; use despite interpersonal 
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problems; great deal of time spent with drug, and cravings), as they were deemed inapplicable 
for a licit drug like caffeine.  The third study, conducted by Hughes et al., (1998) found that 30% 
of current caffeine users sampled in a random digit telephone survey in Vermont endorsed three 
or more of the seven DSM-IV (1994) dependence criteria with mean caffeine intake of 222 
mg/day.  The fourth study conducted by Svikis et al., (2005) found that more than one-half 
(57%) of a group of employed pregnant women who reported current caffeine use, met DSM-IV 
criteria for lifetime Substance Dependence as applied to caffeine.  
Together, these studies found caffeine exhibited clinical features similar to those for other 
psychoactive drugs of abuse and that caffeine use led to problems for some individuals.  
Moreover, findings offer support for reviewing caffeine dependence as a clinical syndrome so 
that behavioral disruptions associated with its use can be addressed (Juliano et al., 2014; Strain et 
al., 1994).  
In the recently published DSM-5 (2013), the Substance Use Disorder workgroup 
determined there was insufficient evidence to include Caffeine Use Disorder in the Substance 
Use and Addictive Disorders chapter.  In a more recent review of literature, Meredith et al., 
(2013) and Addicott (2014) affirmed the critical need for more epidemiological, clinical, and 
even genetic research on caffeine dependence, as several recent reports have shown that caffeine 
dependence can result in clinically significant distress and functional impairment.  A review of 
all the caffeine dependence criteria lies beyond the scope of this thesis.  However, tolerance and 
caffeine withdrawal, two hallmark symptoms of physical dependence, will be reviewed.  Please 
refer to Meredith and colleagues (2013) for a more comprehensive review of the other diagnostic 
criteria as applied to caffeine.    
 
  26 
Tolerance 
  Tolerance is defined as “an acquired change in responsiveness of an individual as a 
result of exposure to drug such that an increased dose of drug is necessary to produce the same 
degree of response, or that less effect is produced by the same dose of drug” (p. 327, Griffiths & 
Mumford, 1996).  Chronic self-administration of caffeine can produce tolerance to many of its 
physiological, behavioral, and subjective effects (Hirsh, 1984; Finn & Holtzman, 1986, 1987, 
1988).   
 In animal studies, Griffiths & Mumford (1996, 2000) and Griffiths and colleagues (2003) 
identified 15 laboratory studies demonstrating caffeine tolerance. Tolerance was seen at caffeine 
dosing frequencies ranging from once every other day (Wayner, Jolicoeur, Rondeau, & Barone, 
1976) to several times daily over periods of days or weeks (Holtzman, 1983), and with doses 
ranging from 10mg/kg per day (Chou, Khan, Forde, & Hirsh, 1985) to 222 mg/kg per day 
(Ahlijanian & Takemori 1986).  Tolerance was evident for a number of caffeine effects, 
including schedule-controlled responding, reinforcement thresholds of electrical brain 
stimulation, discriminative responding in caffeine-trained animals, and locomotor activity 
(Griffiths & Mumford, 1996). 
Human studies have also reported evidence of caffeine tolerance.  However, specific 
parameters under which tolerance can develop warrant further study (Griffiths & Mumford, 
1996, 2000).  For example, Evans and Griffiths (1992) found evidence using a procedure in 
which subjects were stratified based on caffeine preference and then chronically exposed to 
either caffeine (300 mg) or placebo three times a day for 18 days.  During the last 14 days, 
participants who completed the chronic dosing regimen of caffeine did not differ significantly on 
mood ratings and ratings of subjective effects compared to the placebo group.  Also, when 300 
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mg of caffeine was administered two times per day, caffeine produced significant subjective 
effects (tension-anxiety, jittery/nervous/shaky, and active/stimulated/energetic) in the placebo 
group but not in the caffeine group.  This type of tolerance, which occurs after repeated 
administration of relatively high caffeine doses spread throughout the day for across consecutive 
days is called “complete tolerance,” with no differentiation between caffeine effects and placebo 
(Griffiths & Mumford, 2000).   
Several studies have demonstrated caffeine tolerance to sleep disruption (Bonnet & 
Arand, 1992; Hicks, Kilcourse, & Sinnott 1983; Zwyghuizen-Doorenbos, Roehrs, Lipschutz, 
Timms, & Roth, 1990), and there is substantial evidence that repeated caffeine administration 
produces decreased physiological effects of caffeine, such as diuresis, parotid gland salivation, 
increased metabolic rate, increased blood pressure, increased plasma norepinephrine and 
epinephrine, and increased plasma renin activity (Griffiths & Mumford, 2000).  Several studies 
have shown development of complete tolerance to caffeine’s effects on blood pressure and other 
cardiovascular and physiological responses after repeated daily dosing with caffeine (Ammon, 
Bieck, Mandalaz, & Verspohl, 1983; Denaro, Brown, Jacob, & Benowitz, 1991; Robertson, 
Wade, Workman, Woosley, & Oates, 1981).  
As with many drugs, the degree of tolerance appears to vary as a function of caffeine 
dose, dose frequency, and number of doses received, as well as individual differences in caffeine 
elimination rates (Shi, Benowitz, Denaro, & Sheiner, 1993).  Research also suggests that the 
upregulation of the A1 receptors (i.e., increases in the number of brain adenosine receptors) by 
chronic caffeine exposure is what may contribute to the development of caffeine tolerance 
(Arnaud, 1999; Griffiths & Mumford, 1996).  However, because changes have been found in a 
variety of other neurotransmitter receptors following chronic caffeine administration (Shi et al., 
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1993), it is unclear exactly which mechanism(s) may contribute to the development of caffeine 
tolerance.  For example, tolerance may be due to adaptive changes at the level of gene 
transcription (Fredholm et al., 1999) or compensatory changes in the dopaminergic system 
secondary to chronic adenosine receptor antagonism (Garrett, & Holtzman, 1994). 
Withdrawal 
 
 Caffeine withdrawal was only recently classified as a DSM-5 diagnosis (APA, 2013).  
Prior to that time, there were many published reports of caffeine withdrawal (Juliano & Griffiths, 
2004; Juliano et al., 2014).  More recent research identified as a clinical syndrome, and 
researchers have been instrumental in adding caffeine withdrawal to the diagnostic nomenclature 
(Hasin, O'Brien, Auriacombe, Borges, Bucholz, Budney, Compton, Crowley, Ling, Petry, 
Schuckit, & Grant, 2013; Hughes et al., 1992c).  
Withdrawal is defined as “a maladaptive behavioral change, with physiological and 
cognitive concomitants, that occurs when blood or tissue concentrations of a substance decline in 
an individual who had maintained prolonged heavy use of the substance” (p.195, APA, 2000).  
Withdrawal is generally thought of in context of physical dependence, and has been historically 
seen as a hallmark symptom of dependence.  After chronic use of caffeine, abrupt cessation can 
produce caffeine withdrawal (Griffiths & Chausmer, 2000; Juliano, Huntley, Harrell, & 
Westerman, 2012).   
 
Table 3.  
 
Diagnostic Criteria for 292.0 Caffeine Withdrawal. 
 
 
A. Prolonged daily use of caffeine. 
B. Abrupt cessation of or reduction in caffeine use, followed within 24 hours by three (or more) of the following 
signs of symptoms: 
 1. Headache. 
 2. Marked fatigue or drowsiness. 
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 3. Dysphoric mood, depressed mood, or irritability. 
 4. Difficulty concentrating. 
 5. Flu-like symptoms (nausea, vomiting, or muscle pain/stiffness) 
C. The signs of symptoms in Criterion B cause clinically significant distress or impairment in social, occupational, 
or other important areas of functioning. 
D. The signs or symptoms are not associated with the physiological effects of another medical conditions (e.g., 
migraine, viral illness) and are not better explained by another mental disorder, including intoxication or withdrawal 
from another substance. 
 
(APA, 2013) 
 
 
 The first comprehensive review of caffeine withdrawal was published in 1998c by 
Griffiths & Woodson.  They found, in laboratory animal studies, caffeine withdrawal was 
demonstrated by decreases in locomotor activity (Boyd, Dolman, Knight, & Sheppard, 1965; 
Finn and Holtzman, 1986; Holztman, 1983; Kaplan, Greenblatt, Kent, & Cotreau-Bibbo, 1993; 
Nehlig & Derby, 1994), decreases in operant behavior (Carney, 1982; Carroll et al., 1989), 
decreases in reinforcement threshold for electrical brain stimulation (Mumford et al., 1988), an 
increase in the ratio of time spent in slow wave sleep stages I and II (Sinton & Petitjean, 1989), 
and avoidance of preferred flavor when paired with caffeine abstinence (Vitiello & Woods, 
1977).   
Studies of caffeine withdrawal in humans were summarized in a review by Juliano & 
Griffiths (2004).  They found a variety of experimental procedures had been used to study 
caffeine withdrawal, including: “acute abstinence versus preceding caffeine baseline (not 
counterbalanced); acute abstinence versus caffeine; acute abstinence in caffeine consumers 
versus non-consumers; acute abstinence versus chronic abstinence; time-limited abstinence 
effects; variation in caffeine maintenance dose; acute decreases in caffeine maintenance dose; 
manipulation of duration of caffeine maintenance and re-administration of caffeine reverses 
abstinence effects (p. 11-12, Juliano & Griffiths, 2004).  A detailed review of these 
methodological procedures lies beyond the scope of this thesis. 
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In the review, they summarized 42 experimental and 9 survey studies focused on 
validation of caffeine withdrawal.  Across these studies, 13 symptoms of withdrawal were 
supported by strong empirical evidence. These include: headache, fatigue, decreased 
energy/activeness, decreased alertness, drowsiness, decreased contentedness, depressed mood, 
difficulty concentrating, irritability, and foggy/not clearheaded, flu-like symptoms, 
nausea/vomiting, and muscle pain/stiffness.  Evans & Griffiths (1999) reported the “most 
common withdrawal symptoms include increases in headaches, drowsiness, and work difficulty 
(including impaired concentration) and decreases in feelings of contentment and sociability” (p. 
285); however, the overall most frequently reported withdrawal symptoms is headache, which is 
characterized as a gradual onset, being diffuse, throbbing, and at times severe (APA, 2013; 
Griffiths & Woodson, 1988c).  Further, by the end of the first day of abstinence approximately 
50% of regular caffeine users reported headache (Juliano et al., 2014).      
Several other behavioral, cognitive, and psychomotor withdrawal symptoms have been 
described, as well as subjective reports of physical ailments such as: fatigue/lethargy, and muscle 
pain, dysphoric feelings of anxiety, blurred vision, decreased alertness, jitteriness, irritability, 
increased reporting of stress, changes in quantitative electroencephalography (EEG), decreased 
blood pressure, tremors, and upset stomach (Arnaud, 1999; Griffiths & Mumford 1996, 2000, 
2006; Griffiths & Woodson, 1988c; Griffiths et al., 2003; Griffiths, Evans, Heishman, Preston, 
Sannerud, Wolf, & Woodson; 1990; Jones, Herning, Cadet, & Griffiths, 2000; Juliano & 
Griffiths, 2004; Rizzo, Stamps, & Fehr, 1988; Silverman, Evans, Strain, & Griffiths, 1992; Strain 
et al. 1994; Schuh & Griffiths, 1997; Weinberg & Bealer, 2001).  Furthermore, large doses of 
caffeine (above 250 mg) have been found to act as a diuretic, which may potentially result in a 
fluid imbalance (Maughan & Griffin, 2003). 
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The inclusion of Caffeine Withdrawal in the DSM-5 (2013) as a substance-related 
disorder has brought more attention to the recognition clinical relevance and significance 
(Hughes et al., 1992c; APA, 2013).  The criteria for the disorder of caffeine withdrawal are 
summarized in Table 3 described by the APA (2013).  What follows is a review of the animal 
and human research studies that contributed to this decision.   
Caffeine-Related Withdrawal Symptoms 
 
Headache 
  
 Headaches are the hallmark symptoms of caffeine withdrawal and have been the focus of 
much research (Juliano et al., 2014).  In their review, Juliano & Griffiths 2004 found that 
headache was the most frequently assessed and reported symptom, with 48 experimental studies 
and 6 survey studies providing evidence.  The average percentage of caffeine consumers 
reporting headache across the 19 experimental studies was 47%, with a range from 9% to 100% 
(Juliano & Griffiths, 2004).  Among experimental studies assessing the severity of reported 
caffeine withdrawal headache, moderate to several headaches were reported 50% of consumers 
in the experimental studies, and 24% of caffeine consumers in the survey studies (Juliano & 
Griffiths, 2004).  
 In regards to the different methodologies used to draw inferences about the prevalence of 
headaches as a caffeine withdrawal symptom, Juliano & Griffiths (2004) reported headaches 
have been demonstrated in various studies comparing acute caffeine abstinence versus a 
preceding baseline condition (Couturier Laman, van Duijn, & van Duijn, 1997; Edelstein, 
Keaton-Braster, & Burg, 1983; Griffiths et al., 1986a; Höfer & Bättig 1994a; Höfer & Bättig 
1994b; Lader, Cardwell, Shine, & Scott, 1996; Naismith, Akinyanju, Szanto, & Yudkin, 1970; 
Roller, 1981; Silverman et al., 1992), and versus a caffeine consumption condition (Brauer, 
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Buican, & de Wit, 1994; Bruce, Scott, Shine, & Lader, 1991; Driesbach & Pfeiffer, 1943; Evans 
& Griffiths, 1999; Comer, Haney, Foltin, & Fischman, 1997; Evans & Griffiths, 1992; Goldstein, 
1964; Goldstein, Kaizer, & Whitby, 1969; Griffiths et al., 1990; Hughes et al., 1992a; Hughes, 
Hunt, Higgins, Bickel, Fenwick, & Pepper 1991; Hughes et al., 1995; James, 1998; Lane, 1994; 
Lane, 1997; Lane & Phillips-Bute, 1998; Liguori, et al., 1997b; Mitchell, de Wit, & Zacny, 1995; 
Oliveto et al., 1992a, Oliveto, et al., 1992b; Schuh & Griffiths, 1998; Silverman et al., 1992; 
Strain et al., 1994; Duseldor & Katan, 1990; Van Soeren & Graham, 1998).    
Signs and symptoms of caffeine withdrawal headache were also compared during acute 
caffeine abstinence and chronic caffeine abstinence conditions (Griffiths et al., 1990; Bruce et 
al., 1991; James, 1998; Tinley, Yeomans, & Durlach, 2003) as well as acute caffeine abstinence 
in caffeine consumers with non-consumers (Richardson, Rogers, Elliman, & O’Dell, 1995).  
Juliano & Griffiths (2004) also reported that several “studies have also shown that abstinence 
induced headache is time-limited and is rapidly (usually within 30–60 min) and often completely 
reversed after re-administration of caffeine (Driesbach & Pfeiffer 1943; Goldstein et al. 1969; 
Roller 1981; Couturier et al. 1997; Tinley et al. 2003), with the magnitude of reversal being an 
increasing function of the re-administered caffeine dose (Goldstein et al. 1969)” (p. 12).   
Caffeine withdrawal headache has been described as having a gradual onset (Driesbach & 
Pfeiffer 1943; Greden, Victor, Fontaine, & Lubetsky, 1980; Roller 1981; Griffiths et al. 1990), 
severe (Griffiths & Woodson 1988), diffuse (Driesbach & Pfeiffer 1943; Greden 1974; Greden et 
al. 1980; Lader et al. 1996), and throbbing (Driesbach and Pfeiffer 1943; Greden 1974; Greden et 
al. 1980; Lader et al. 1996), but are distinct from migraine headaches (Driesbach & Pfeiffer 
1943) (Juliano & Griffiths, 2004).  Also, important to note is that the incidence of caffeine 
withdrawal headache does not necessarily correlate with the occurrence of other symptoms (e.g., 
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fatigue), which suggests that other signs and symptoms of caffeine withdrawal are not merely a 
result of headache (Griffiths et al., 1990; Griffiths & Woodson, 1988).  Research has 
demonstrated that caffeine abstinence produces rebound cerebral vasodilatation and increased 
cerebral blood flow, which has been speculated as the primary mechanism contributing to 
caffeine withdrawal headache (Jones et al., 2000; Sigmon, Herning, Better, Cadet, & Griffiths, 
2009). 
Marked fatigue or drowsiness  
 Marked fatigue and drowsiness were combined to form a single criterion.  Marked fatigue 
or tiredness is defined by feelings of laziness; being sluggish, lethargic, sleepy, or worn out.  In 
contrast, drowsiness is characterized by feelings of sleepiness, sedation, or decreased 
wakefulness.  Fatigue was demonstrated in 32 of 38 studies (84%), with 27% o caffeine 
consumers in experimental reporting fatigue.  Drowsiness was reported in 21 of 27 experimental 
studies (78%), with approximately 45% of consumers reporting the symptom.   
 Several methodological approaches have also been used to demonstrate the occurrence of 
marked fatigue and drowsiness.  For example, signs and symptoms of fatigue were demonstrated 
in studies comparing acute caffeine abstinence with a preceding baseline condition (Griffiths et 
al, 1986; Lader et al., 1996; Naismith et al., 1970; Roller, 198; Silverman et al., 1992), as was 
drowsiness (Griffiths et al., 1986; Höfer & Bättig 1994a; Höfer & Bättig 1994b; Lader et al., 
1996; Silverman et al., 1992).  Both fatigue (Bruce et al., 1991; Comer et al., 1997; Driesbach & 
Pfeiffer, 1943; Evans & Griffiths, 1999; Garrett and Griffiths, 1998; Goldstein et al., 1969; 
Griffiths et al., 1990; Hale et al., 1995; Hughes et al., 1992a; Hughes et al., 1991; Hughes et al., 
1995; Lane, 1994; Lane, 1997; Lane and Phillips-Bute, 1998; Liguori et al., 1997; Liguori & 
Hughes, 1997; Mitchell et al., 1995; Oliveto et al., 1992a; Oliveto et al., 1992b; Phillips-Bute & 
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Lane, 1998; Richardson et al., 1995; Rodgers, Richardson, Elliman, 1995; Schuh & Griffiths, 
1997; Silverman et al., 1992; Strain et al., 1994; Streufer, Pogash, Miller, Gingrich, Landis, 
Lonardi, Severs, & Roache, 1995; Van Soeren & Graham, 1998) and drowsiness (Bruce et al., 
1991; Comer et al., 1997, Hale et al., 1995; Hughes et al., 1995; Hughes et al., 1992a; Hughes et 
al., 1991; Goldstein et al., 1969; Griffiths et al., 1990; Lane, 1994; Lane, 1997; Lane & Phillips-
Bute, 1998; Liguori & Hughes, 1997; Liguori et al., 1997; Oliveto et al., 1992a; Oliveto et al., 
1992b; Phillips-Bute & Lane, 1998; Richardson, et al., 1995; Silverman et al., 1992; Streufert et 
al., 1995) have been demonstrated in studies comparing acute caffeine abstinence versus caffeine 
consumption conditions (Juliano & Griffiths, 2004). 
 Only Richardson and colleagues (1995) demonstrated caffeine withdrawal fatigue after 
comparing acute caffeine abstinence in caffeine consumers versus non-consumers, but both 
Goldstein et al., (1969) and Richardson et al., (1995) demonstrated caffeine withdrawal 
drowsiness using the same methodological procedures.  When acute abstinence was compared 
with chronic abstinence, caffeine withdrawal fatigue was demonstrated in 4 studies (Bruce et al., 
1991; Garrett and Griffiths, 1998; Griffiths et al., 1990; Richardson et al., 1995) and drowsiness 
in 3 studies (Garrett & Griffiths, 1998; Griffiths et al., 1990; Richardson et al., 1995).  Similar to 
what was found for caffeine withdrawal headache, several studies shown that abstinence-induced 
fatigue and drowsiness are time limited (Griffiths et al., 1986; Griffiths et al., 1990; Höfer & 
Bättig 1994a; Lader et al., 1996; Naismith et al., 1970; Richardson et al., 1995).  Further, 
caffeine withdrawal fatigue (Roller 1981) and drowsiness (Goldstein et al. 1969) are completely 
reversed after re-administration of caffeine; however, caffeine withdrawal drowsiness is more 
rapidly reversed (30-60min.).  In addition, severity of both fatigued and drowsiness symptoms 
are positively correlated with daily caffeine dose before abstinence (Rogers et al.1995; 
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Silverman et al. 1992) (Juliano & Griffiths, 2004). 
Dysphoric Mood, Depressed Mood, or Irritability 
 This symptom of caffeine withdrawal is present when the individual presents with 
depressed or dysphoric mood (feelings of sadness or dejection) and/or irritability (feeling angry, 
cross or grumpy.  Juliano & Griffiths (2004), in their review, found depressed mood reported in 
9 of 29 experimental studies (31%) and irritability in 8 of 23 experimental studies (35%).  The 
average percentage of consumers reporting depressed mood across experimental studies was 
16% (range 11-36%) and in 2 survey studies, 4% (Hughes et al., 1998) and 9% (Oberstar, 
Berstein, & Thuras, 2002). The average percentage reporting irritability was 29% in one 
experimental study (Griffiths et al., 1990) and 9% in another (Hughes et al., 1995) with 21% 
(Goldstein & Kaizer, 1969) and 20% (Hughes et al., 1998) being reported in 2 survey studies.   
 Depressed mood and irritability were found in numerous studies using various 
methodological approaches, such as, comparing acute caffeine abstinence to a baseline condition 
(Silverman et al., 1992), and to active caffeine consumption (depressed mood: Griffiths et al., 
1990; Hale et al., 1995; Hughes et al., 1995; Lane & Phillips-Bute, 1998; Richardson et al., 
1995; Silverman et al., 1992; Strain et al., 1994; irritability: Goldstein et al., 1969; Griffiths et 
al., 1990; Lane & Phillips-Bute, 1998; Liguori et al., 1997b; Silverman et al., 1992; Streufer et 
al., 1995).  Depressed mood (Garret & Griffiths 1998; Griffiths et al., 1990; Richardson et al., 
1995) and irritability (Garret & Griffiths, 1998; Griffiths et al., 1990) were also evident in 
comparisons of acute and chronic caffeine abstinence conditions, and in comparing acute 
caffeine abstinence in caffeine consumers and non-consumers (Goldstein et al., 1969; 
Richardson et al., 1995). Only one study found abstinence-induced depressed mood and 
irritability were time limited (Griffiths et al., 1990), and only Goldstein et al., (1969) found 
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caffeine withdrawal irritability to be completely reversed after re-administration of caffeine.  
Similar to other caffeine withdrawal symptoms, the degree of reversal is an increasing function 
of the re-administered caffeine dosage (Goldstein et al. 1969) (Juliano & Griffiths, 2004). 
Difficulty Concentrating 
 Difficulty concentrating or decreased ability to concentrate was associated with caffeine 
withdrawal in 8 of 12 experimental studies (67%) with over three-fourths (79%) of participants 
in one study reporting trouble concentrating (Griffiths et al., 1990).  In contrast, only 11% of 
participants in one survey study reported trouble concentrating (Juliano & Griffiths, 2004).  The 
methodological approaches included comparing the signs and symptoms of difficulty 
concentrating during acute caffeine abstinence versus baseline (Lader et al., 1996) to a caffeine 
administration condition (Garrett & Griffiths, 1998; Griffiths et al., 1990; Jones et al., 2000; 
Lane, 1997; Lane & Phillips-Bute, 199; Streufert et al., 1995) and versus chronic caffeine 
abstinence conditions (Garrett & Griffiths, 1998; Griffiths et al., 1990).  Griffiths and colleagues 
(1990) found that abstinence-induced difficulty concentrating is time limited and that symptom 
severity is positively correlated with daily caffeine dose prior to abstinence (Lane, 1997) (Juliano 
& Griffiths, 2004). 
Flu-like Symptoms (nausea, vomiting, or muscle pain/stiffness) 
 Flu-like symptoms (feeling sick, queasy or dizzy; perspiring) were reported in 9 of 17 
(53%) experimental studies of caffeine withdrawal with an incidence rate of 31% (Lane, 1997).  
Flu-like symptoms were seen in studies comparing acute caffeine abstinence with a preceding 
baseline condition (Silverman et al., 1992), a caffeine administration condition (Griffiths et al., 
19990; Evans & Griffiths, 1999; Lane, 1997; Schuh & Griffiths, 1998; Silverman et al., 1992; 
Van Soeren & Graham, 1998), and a chronic caffeine abstinence condition (Griffiths et al., 
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1990).  Only one study has shown that abstinence-induced flu-like symptoms are time-limited 
(Griffiths et al., 1990); however, as of 2004 no study has been able to demonstrate an incidence 
of these symptoms after comparing acute caffeine abstinence in consumers versus non-
consumers (Juliano & Griffiths, 2004).   
 Consistent with other caffeine withdrawal symptoms, the severity of flu-like symptoms is 
also an increasing function of caffeine maintenance dose prior to abstinence (Lane and Phillips-
Bute 1998; Evans and Griffiths 1999).  Juliano & Griffiths (2004) found that because most of the 
experimental studies demonstrating empirically supported increases in flu-like symptoms 
involved comparisons of caffeine abstinence to a caffeine administration condition, the category 
of these symptoms as a single symptom failed to meet Juliano & Griffiths (2004) validity 
criteria.  However, Juliano & Griffiths (2004) report that, “the category appears to reflect a 
genuine withdrawal effect because endorsement of flu-like symptoms is time limited (Griffiths et 
al. 1990) and it is implausible that such placebo versus caffeine differences represent a direct 
effect of caffeine in suppressing naturally occurring flu-like symptoms” (p. 13).  Given this 
incidence of data, Juliano & Griffiths (2004) believe the category appears to be a valid caffeine 
withdrawal effect, and based on factor analysis studies, the DSM-5 Work Group included flu-
like symptoms as part of the diagnosis (APA, 2013; Hasin et al., 2013). 
 Nausea/vomiting (feeling nauseated or having an upset stomach, or vomiting) can be 
characteristic of flu-like symptoms, and has been demonstrated in 6 of 24 experimental studies 
(25%), and across experimental studies demonstrating these symptoms, the median percentage of 
individuals reporting nausea/vomiting was 21% (range 10–33%). Two survey studies found the 
percentage of subjects reporting nausea/vomiting during caffeine abstinence was 3% (Hughes et 
al., 1998) and 21% (Bernstein, Carroll, Thuras, Cosgrove, & Roth, 2002). These symptoms have 
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only been demonstrated in studies comparing acute caffeine abstinence with a caffeine 
administration condition (Driesbach & Pfeiffer; Höfer & Bättig 1994a; Liguori & Hughes, 1997; 
Liguori et al., 1997b; Swederlow, Eastvold, Gerbranda, Uyan, Hartman, Doan, & Auerbach, 
2000).  However, instances of caffeine withdrawal induced nausea/vomiting have been reported 
in experimental studies (Griffiths et al. 1990; Silverman et al. 1992; Strain et al. 1994) and 
survey studies (Hughes et al. 1998; Oberstar et al. 2002), in addition to, case reports (Cacciatore, 
Helbling, Jost, & Hess, 1996; Rainey, 1985).  Nausea/vomiting also failed to meet Juliano & 
Griffiths (2004) validity criteria; however, they judged these symptoms to be valid criteria for 
caffeine withdrawal syndrome, and the DSM-5 Work Group also decided to include these 
symptoms given their factor analysis studies (APA, 2013; Hasin et al., 2013). 
 The cluster of symptoms identified as muscle pain/stiffness, which can also be 
characteristic of flu-like symptoms, has been demonstrated in 4 of 15 experimental studies 
(27%), with one study reporting an incidence of muscle pain/stiffness as high as 43% (Griffiths 
et al., 1990).  These symptoms have been demonstrated in studies comparing acute caffeine 
abstinence with a preceding baseline condition (Höfer & Bättig 1994b; Roller, 1981).  Griffiths 
and colleagues (1990) demonstrated muscle pain/stiffness after comparing acute caffeine 
abstinence versus a caffeine administration condition and a chronic caffeine abstinence 
condition, in addition to providing evidence showing that abstinence-induced muscle 
pain/stiffness is time limited.   
 Additionally, muscle pain/stiffness has also been described in case reports (Cobbs 1982; 
Stringer & Watson 1987), including one report where a musculoskeletal examination was 
administered during caffeine abstinence (Reeves, Struve, & Patrick, 1997).  These symptoms 
also failed to meet the validity criteria set forth by Juliano & Griffiths (2004); however 
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consistent with other symptoms associated with caffeine withdrawal flu-like signs, Juliano & 
Griffiths (2004) believe that “muscle pain/stiffness represents a true withdrawal symptom 
unconfounded by the direct effects of caffeine seems reasonable because it is improbable that 
caffeine suppresses naturally occurring muscle pain/ stiffness” (p. 16).  Ultimately, the DSM-5 
Work Group also chose to include this symptom in the diagnosis given the results of their factor 
analysis studies (APA, 2013; Hasin et al., 20130). 
Characteristics of Caffeine Withdrawal Syndrome 
Functional Impairment & Prevalence 
 In regards to Criterion C of caffeine withdrawal, the aforementioned symptoms represent 
clinical importance given that they may induce significant distress or impairment in daily 
functioning (Evans & Griffiths, 1998; Juliano et al., 2014).  This has been demonstrated in the 
literature indicating that for caffeine users who abruptly abstain, caffeine withdrawal signs and 
symptoms may occur at clinically significant levels in about 10 to 50% of caffeine consumers 
(APA, 2013; Griffiths & Mumford, 1996; Juliano & Griffiths, 2004; Juliano et al., 2014).  
 Functional impairment has been described in the literature as being unable to care for 
children, or inability to go to work, school, or church (Strain et al., 1994).  In recent years, there 
have been several reports of caffeine withdrawal incidences.  Aside from information pertaining 
to caffeine dependence, Hughes et al., (1992a) found 42% of their current caffeine users also 
reported withdrawal headaches, fatigue or drowsiness when they abstained from caffeine after 24 
hours.   
 Additionally, Silverman and colleagues (1992) investigated 62 individuals from the 
general community and administered caffeine in doses similar to that of the general population in 
the United States at that time (mean 235 mg/day).  Under 48-hr, double-blind caffeine abstinence 
  40 
trials the investigators found that during caffeine withdrawal, 52% reported moderate or severe 
headache, and 8-11% reported abnormally high scores on standardized depression, anxiety, and 
fatigue scales.  Also, in 1999, Dews, Curtis, Hanford, and O’Brien surveyed 1,112 individuals 
and found that 61% reported daily caffeine consumption, and among those consumers, 11% 
reported symptoms of caffeine withdrawal after stopping caffeine.  Overall, it has been reported 
that more than 70% of individuals experience at least one caffeine withdrawal symptom after 
attempting to permanently discontinue their caffeine use (APA, 2013).     
Dosing Parameters and Time Course of Withdrawal 
 Cessation of caffeine intake among habitual users may induce symptoms of caffeine 
withdrawal among those who regularly consume low to moderate amounts of caffeine (20-200 
mg) and in doses as low as 100 m/day, which is the equivalent of about one cup of coffee or two 
cans of cola, or doses as high as 900 mg/day (Bruce, Scott, Shine, & Lader, 1991; Evans & 
Griffiths, 1999; Griffiths et al., 1990; Nehlig, 1999; Weinberg & Bealer, 2001).  There is sound 
clinical evidence that the incidence and/or severity of caffeine withdrawal are positively 
correlated with increases in chronic daily caffeine maintenance dose.  In 1999, Evans & Griffith 
established a parametric range describing the effect of caffeine withdrawal as a function of 
caffeine dosing conditions.  The authors demonstrated the severity of caffeine withdrawal 
symptoms of headache and poor mood was substantially higher after abstinence from 600mg of 
caffeine compared to 100mg/day.  Additionally, the authors concluded that the higher the 
substitution doses of caffeine administered compared to the usual maintenance dose (25, 50, 100, 
200, or 300 mg), the less severe the withdrawal symptoms (Evans & Griffiths, 1999).   
 Caffeine withdrawal symptoms follows an orderly time course, meaning it can begin 
within 12 to 24 hours after caffeine cessation, peak at 20 to 51 hours, and last approximately one 
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week (Griffiths & Chausmer, 2000; Griffiths & Mumford, 2000; Juliano & Griffiths, 2004; 
Juliano et al., 2014).  Research has also demonstrated that the duration of caffeine withdrawal 
ranges from 2-9 days (Juliano & Griffiths, 2004). However, it has been reported that a gradual 
reduction in caffeine consumption over a period of days or weeks may reduce the severity and 
incidence of caffeine withdrawal symptoms (APA, 2013).  For example, re-administration of low 
doses of caffeine is sufficient to suppress significant caffeine withdrawal headache (Juliano et 
al., 2014).     
Caffeine Withdrawal and Habitual Caffeine Consumption 
 Among regular caffeine consumers, the avoidance of caffeine withdrawal symptoms 
plays a critical role in the reinforcing effects of caffeine (Juliano et al., 2014; Schuh & Griffiths, 
1997).  For example, an experimental study conducted by Hughes and colleagues (1993) showed 
participants who reported caffeine withdrawal symptoms after consuming decaffeinated coffee 
were found twice as likely to choose caffeinated coffee over decaf during a choice test.  
Additionally, Griffiths et al., (1986a) and Garrett & Griffiths (1989) experimentally manipulated 
caffeine physical dependence and demonstrated that participants choose caffeine more than twice 
as often while physically dependent compared to when not physically dependent.  Furthermore, a 
retrospective questionnaire study conducted by Goldstein & Kaizer (1969) and multiple double-
blind experimental studies (Garrett & Griffiths 1998; Griffiths et al. 1986; Hughes et al. 1993; 
Liguori & Hughes 1997; Schuh & Griffiths, 1997) aimed at assessing behavioral measure of 
caffeine reinforcement found that the avoidance of caffeine withdrawal symptoms is directly 
related to habitual caffeine consumption.  Furthermore, several studies have demonstrated the 
relationship between abstinence-associated caffeine withdrawal and beverage flavor preferences 
(Rogers et al. 1995; Tinley et al. 2003; Yeomans et al. 1998, 2000, 2001, 2002) (Juliano & 
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Griffiths, 2004).  
Biological Basis of Caffeine Withdrawal 
 Research has suggested that the pharmacological and physiological mechanism 
underlying caffeine physical dependence and withdrawal is also related to the endogenous 
neuromodulator adenosine, similarly as it is related to caffeine tolerance (Griffiths & Mumford, 
1996).  Given that caffeine is a competitive antagonist of adenosine (Juliano et al., 2014), 
chronic caffeine administration has been reported to increase brain adenosine receptors (Daly, 
1993; Daly & Fredholm, 1998), to shift brain A1 adenosine receptors to a high affinity state 
(Green & Stiles, 1986), and to increase functional sensitivity to adenosine (Ahlijanian & 
Takemori, 1986; Biaggioni, Paul, Puckett, & Arzubiaga, 199; Green & Stiles, 1986; von Borstel, 
Wurtman, & Conlay, 1983).  This increase in functional sensitivity to endogenous adenosine has 
also been proposed as the underlying mechanism associated with caffeine withdrawal headache 
and fatigue (Hirsh, 1984; von Borstel et al., 1983); although, research on these mechanisms 
regarding dependence and withdrawal need to be expanded considerably (Griffiths & Mumford, 
1996).   
Individual Differences in Caffeine Use & Withdrawal 
 Considerable within and between subject variability has been found in the occurrence 
caffeine withdrawal.  Studies to-date suggest that in addition to chronic use of caffeine, the 
likelihood of experiencing caffeine withdrawal may differ by gender, personality traits, and other 
substance use histories, including cigarette smoking (Juliano & Griffiths, 2004).  Genetic 
polymorphisms may also play a role (e.g., A1 and A2A adenosine receptor gene). 
Gender 
 For many substance use disorders, the etiology, course, and treatment varies considerably 
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by gender.  Overall, substance use disorders are more prevalent in men than women (SAMHSA, 
2016).  Females, however, show accelerated progression from first use of a substance to onset of 
dependence and admission to treatment. (i.e., telescoping) (Greenfield et al., 2010).  
Furthermore, research on sex differences from the field of addiction found that among daily 
users, females were more sensitive than men to subjective effects of marijuana (Cooper & 
Haney, 2014) and that women with lifetime cannabis use disorder were more likely to develop a 
psychiatric disorder (Khan et al., 2013; Zilberman, Tavares, Blume, & el-Guebaly, 2002).  
Research has also suggested that nicotine metabolism is faster in women than men (Benowitz et 
al., 2006) and faster nicotine metabolizers have poorer smoking cessation outcomes from 
nicotine replacement therapy (e.g., nicotine patch) (Lerman et al., 2006).  Additionally, research 
has suggested that among prescription opioid users, the rates of psychological distress are 
significantly higher among women than men, and that there were significant gender differences 
associated with the likelihood of developing prescription opioid abuse or dependence (Back, 
Payne, Simpson, & Brady, 2010). 
With regard to caffeine, Temple and colleagues (2009) reported that adolescent males 
may be more susceptible to the reinforcing properties of caffeine than adolescent females.  
Research has also found that physiological responses to caffeine are moderated by gender and 
chronic caffeine consumption (Temple et al., 2010; Temple & Ziegler, 2011).  For example, 
Adan and colleagues (2008), found among undergraduate students, lower doses of caffeine 
induced greater physiological effects in men than in women, whereas decaffeinated beverages 
produced greater effects in women compared to men.   
Gender differences in amounts of caffeine consumption have been reported, but findings 
are mixed.  A population-level study conducted by Mitchell and colleagues (2014) found that 
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among adult (≥ 18 years) caffeine users, men consumed more total caffeine from beverages than 
adult women; however, when the investigators adjusted for body weight (i.e., mg/kg/day), they 
found that women consumed slightly more for all combined caffeinated beverages (e.g., coffee, 
tea, caffeinated carbonated soft drinks, chocolate drinks, energy drinks, and energy shots).  No 
gender differences were found among those who consumed only carbonated soft drinks or 
energy drinks (Mitchell et al., 2014).  This is in contrast to a study conducted of active duty 
military personnel (18+ years) where women consumed less caffeine than men after adjusting for 
body weight (Lieberman et al., 2012).  Moreover, a study conducted by Demura, Aoki, 
Mizusawa, Soukura, Noda, & Sato (2013) found that among 1189 young people (567 males aged 
19.3 ± 1.5 years; 622 females aged 19.1 ± 1.2 years), coffee consumption rates were significantly 
higher in males (50.8%) than in females (32.8%).  Also, and as mentioned above, Drewnowski & 
Rehm (2016) and Fulgoni and colleagues (2015) both found mean caffeine intake to be higher in 
men than in women.  Additionally, in a sample of U.S. college students Landrum (1992) found 
females reported lower weekly caffeine consumption than males (713.72 mg vs. 822.20 mg, 
respectively).       
 Kendler, Myers, & Gardner (2006), in a population-based twin study, found that after 
controlling for age, mean daily caffeine consumption was greater in males than in females, with 
heavy caffeine use also more common in men (17.3%) than in women (11.4%).  The frequency 
of caffeine toxicity did not differ by gender; however, with mean number of caffeine dependence 
symptoms was significantly greater in males than in females.  Furthermore, 47.8% of men versus 
36.6% of women reported one or more symptoms of caffeine dependence. 
While the above findings found men consume more caffeine than women, others found 
the opposite pattern.  Jacobson & Bouher, (1991) for example, found in the general population, 
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females consumed more caffeine than males (393.4mg and 349.1mg per day, respectively). 
Moreover, in another study conducted by Frary et al., (2005), adult men had higher caffeine 
intakes compared to women, also after adjusting for weight; although, this was not found among 
18- to 24-year-olds where only little differences were observed (1.2 vs. 1.1 mg/kg/day).  In 
addition, a study of caffeine intake among U.S. adults using the 2007-2012 NAHNES data found 
that caffeine consumption was not significantly associated with gender (Lieberman, Agarwal, & 
Fulgoni, 2016). 
 As mentioned previously, energy drink consumption has gained popularity since the 1997 
debut of Red Bull.  A study conducted by Malinauskas and colleagues (2007) found that female 
college students reported higher rates of energy drink consumption than males, but a study 
conducted by Attila & Çakir (2011) found that men were 1.5 times more likely than women to 
use energy drinks. Also, according the Drug Abuse Warning Network (DAWN) report, since 
2007 more emergency department visits involving energy drinks were made by males when 
compared to females, and visits by both genders have doubled from 2007 to 2011 (SAMHSA, 
2013).  
  Many reasons for why gender differences exist within substance abusers have been 
hypothesized.  For example, it is suggested that ovarian hormones (e.g., estrogen) can contribute 
to the gender differences observed in humans and animals, along with pharmacokinetics in 
hepatic metabolism, and other biological vulnerabilities, such as gender differences in body fat, 
water proportions, and differences in gastric enzymatic activity.  In regards to caffeine, females 
metabolize caffeine 20% to 30% faster than males (Franconi, Brunelleschi, Steardo, & Cuomo, 
2007; Nawrot, et al., 2003); however, women who use oral contraceptives have approximately 
double the caffeine half-life compared to those who do not use them (Patwardhan, Desmond, 
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Johnson, & Schenker, 1980).  Additionally, Temple & Ziegler (2011), found gender differences 
in cardiovascular responses to caffeine, suggesting that these differences may be related to 
steroid hormone concentrations.   
The role of sex/gender differences in outcomes from the field of drug addiction is 
becoming an important topic among National Institute of Health-funded research (Clayton & 
Collins, 2014).  There has been a growing recognition and concern that animal model research is 
largely male only, and that human research lacks gender/sex analyses.  Therefore, the NIH 
expects that sex as a biological variable will be factored into research designs, analyses, and 
reporting in vertebrate animal and human studies (Clayton & Collins, 2014).   Overall, reasons 
for gender differences in drug abuse are not yet clear and further research regarding 
pharmacodynamics, pharmacodynamics, and psychosocial factors is warranted (Greenfield, 
Back, Lawson, & Brady, 2010; Roth et al., 2004; Zilberman, Tavares, el-Guebaly, 2003) and 
analyzing data by sex/gender at all levels of analysis in both animal and human studies will lead 
to better outcomes and potentially fill in knowledge gaps. 
Co-morbid Alcohol & Nicotine Use     
 Heavy caffeine use has been observed among individuals who abuse alcohol or meet 
diagnosis for clinical dependence on alcohol, which may increase their risk for caffeine 
withdrawal after acute caffeine cessation (APA, 2013; Hughes et al., 1993; Istvan & Matarazzo, 
1984; Swanson, Lee, & Hopp, 1994; Kozlowski, Henningfield, Keenan, Lei, Leigh, Jelinek, 
Pope, & Haertzen, 1993).  One study examining individuals fulfilling a generic DSM-IV (1994) 
substance dependence diagnostic criteria for caffeine found that approximately 60% had a past 
diagnosis of alcohol abuse or dependence (Strain et al., 1994).  Among the general population, it 
is common belief that caffeine reverses the impairing effects of alcohol; however, research 
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investigating such effects is largely incomplete and demonstrates discrepancies across various 
subjective and behavioral measures (Aubin, Laureaux, Tilikete, & Barrucand, 1999; Juliano et 
al., 2009).  It has also been demonstrated that long-term alcohol use slows caffeine elimination 
rate (Benowitz, 1990, James, 1991).  
 Moreover, it has been demonstrated that caffeine intake is strongly associated with 
cigarette smoking (Brice & Smith, 2002; Gurpegui, Jurado, Luna, Fernádez-Molina, Moreno-
Abril, & Gálvez, 2007; Lieberman et al., 2016) such that cigarette smokers consume more 
caffeine than nonsmokers (Swanson et al., 1994).  Research applying an event time-series 
analysis suggested that cigarette smoking and coffee drinking conditionally covary (Emurian, 
Nellis, Brady, & Ray, 1982).  Studies also suggest that smoking decreases caffeine’s half-life by 
30 to 50% (Hart, Farrell, Cooksley, & Powell, 1976; Joeres, Klinker, Heusler, Epping, Zilly, & 
Richter, 1988; Murphy, Mcivor, Yap, Cooksley, Halliday, & Powell, 1988).   
 Preclinical (Gasior, Jaszuna, Munzar, Witkin, & Goldberg, 2002; Liu & Jernigan, 2012; 
Shoaib, Swanner, Yasar, & Goldberg, 1999) and clinical investigations (Jones & Griffiths, 2003) 
have also demonstrated caffeine’s ability to increase the discriminative stimulus effects and 
reinforcing effects of intravenous nicotine (Juliano et al., 2014; Tanda & Goldberg, 2000).  
However, research has failed to reliably show caffeine’s ability to alter the effects of nicotine or 
increase cigarette/nicotine self-administration (Blank, Kleykamp, Jennings, & Eissenbert, 2007; 
Chait & Griffiths, 1983; 253-255; Perkins, Fonte, Stolinski, Blakesley-ball, & Wilson, 2005).  
The pharmacologic effects of caffeine have been hypothesized to influence this coffee-smoking 
interaction; however, the above research suggests other factors also effect this interaction 
(Juliano et al., 2014).   
 One study has demonstrated that caffeine can increase the analgesic effects of cigarette 
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smoking (Nastase, Ioan, Braga, Zagrean, & Moldovan, 2007) and several studies (Benowitz, 
Hall, & Modin, 1989; Brown, Jacob, Wilson, & Benowitz, 1988) have shown that “cigarette 
smoking abstinence can produce substantial increases in caffeine blood levels among heavy 
caffeine consumers, presumable because of the reversal of cigarette smoking-induced caffeine 
metabolism” (p.193, Juliano et al., 2014).  Environmental factors also contribute to the 
correlation between cigarette smoking and caffeine use, as suggested by twin and co-occurrence 
studies (Hetterman, Corey, & Kendler, 1999; Kozlowski et al., 1993; Swan, Carmelli, & Cardon, 
1996; Swan, Carmelli, Cardon, 1997).  
 Furthermore, Kozlowski and colleagues (1993) also suggested that caffeine, alcohol, and 
nicotine disorders cluster together, while Strain et al., (1994) found that caffeine dependence is 
concurrent with past substance use disorders, namely alcohol abuse/dependence.  
Personality 
 One area of research directed at advancing the knowledge of interindividual differences 
and susceptibility to drug reinforcement and substance abuse has focused on personality traits.  
Several personality factors, such as anxiety proneness, depression-proneness, impulsivity, and 
sensation seeking, have all been shown to be associated with risk for substance use patterns and 
disorders (Jones & Lejuez, 2005; Woicik, Stewart, Pihl, & Conrod, 2009).  Specifically, 
reactions to caffeine have been found to depend on certain personality types, particularly 
extroversion versus introversion (Primavera, Simon, & Camisa, 1975; Revelle, Humphreys, 
Simon, & Gilliand, 1980; Smith, Wilson, & Jones, 1983), which has similarly been found among 
those who abuse cocaine and alcohol (Johnson, Tobin, & Cellucci, 1992; Richards, Zhang, 
Mitchell, & DeWit, 1999).  As defined by Smith (2012) extroversion “reflects the degree to 
which a person is outgoing and interactive with other people” and…seek excitement and social 
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activity in an effort to heighten their arousal level, whereas introverts tend to avoid social 
situations in an effort to keep such arousal to a minimum” (p. 71).     
 In 1992, Landrum administered the Caffeine Consumption Questionnaire (CCQ) and 
various personality measures to 57 female and 59 male college students and found that high 
caffeine consumers were significantly positively correlated with extraversion as described by 
Eysenck.  Furthermore, research conducted by Smillie and Gokcen (2010) has demonstrated 
interactions between caffeine use (200 mg), extraversion, and working memory tasks, where 
caffeine was found to provide a greater benefit to those who are extraverted.  In 2012, Smith 
found similar results.  Even though findings suggest associations between personality traits and 
caffeine consumption, some studies provided little evidence to suggest personality traits are 
connected with caffeine consumption (Brice & Smith, 2002; Hewlett & Smith, 2006; Liguori, 
Grass, & Hughes, 1999; Primavera, Simon, & Camisa, 1975), and very little research has 
focused on caffeine dependence (Jones & Lejuez, 2005), which emphasizes the necessity for 
future research focused on understanding the psychological characteristics of caffeine 
consumers. 
Anxiety, Depression & Family History 
 Other psychological characteristics have also been related to caffeine use (Kendler, 
Myers, & Gardner, 2006), such as anxiety and depression (Broderick & Benjamin, 2004; 
Gilliland & Andress, 1981; James & Crosbie, 1987; Richards & Smith, 2015).  A study 
conducted by Juliano et al., (2012) examining individuals seeking treatment for problematic 
caffeine use found that anxiety and mood disorders were the most prevalent co-occurring 
diagnoses (17% each), and 26% of individuals reported a lifetime diagnoses of anxiety while 
42% reported a lifetime diagnoses of mood disorders.   
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 Caffeine’s anxiogenic properties have been recognized for quite some time  (Juliano et 
al., 2009), and individuals diagnosed with anxiety disorders appear to be especially sensitive to 
the subjective and physiological effects of caffeine, in addition to reporting greater symptoms of 
anxiety arousal after consuming caffeine versus control subjects (Beck & Berisford, 1992; Bruce, 
Scott, Shine, & Lader, 1992; Boulenger, Uhde, Wolff, & Post, 1984; Charney, Heninger, & 
Jatlow, 1985; Lee, Cameron, & Greden 1985; Lee, Flegel, Greden, & Caeron, 1988; Masdrakis, 
Papakostas, Vaidakis, Papageorgiou, & Phlivanidis, 2008; Trapp, Allen, O’Sullivan, Robinson, 
Jacoby, & Oddy, 2013).  Caffeine use has also been associated with increased scores on the Beck 
Anxiety Inventory (Dosh, Helmbrecht, Anestis, Guenthner, Kelly, & Martin, 2010).  
Additionally, it has been posited that persons with anxiety disorders tend to find the stimulus 
effects of caffeine as aversive, and several studies have demonstrated those with anxiety 
disorders, particularly panic disorders, report lower levels of caffeine intake when compared to 
healthy controls (Juliano et al., 2009; Lee et al., 1985; Lee et al., 1988; Rihs, Muller, & 
Baumann, 1996; Uhde, 1990); however, some studies have failed to replicate this association of 
greater anxiety levels and caffeine use (Charney et al., 1985; Hewlett & Smith, 2006; Holle, 
Heimberg, Sweet, & Holt, 1995).  Therefore, as Juliano and colleagues (2009) state, “it seems 
reasonable to conclude that some but not all individuals with high anxiety levels will naturally 
avoid caffeine” (p. 169).  Moreover, it has been demonstrated that individuals with A1 and A2a 
adenosine receptor gene polymorphisms are at greater risk of caffeine-induced anxiety (Alsene, 
Deckert, Sand, & de Wit, 2003). 
 Another variable that influences caffeine consumption is depressed mood.  Kendler, 
Myers, & O’Gardner (2006) found within a sample of Caucasian same-sex twin pairs, that 
caffeine intake, heavy caffeine use, and symptoms of caffeine toxicity and dependence to be 
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associated with an increased risk for developing major depressive disorder (MDD).  Also, in 
1984, Veleber and Templer found caffeine to increase depression after healthy subjects were 
administered an affect screener, and in 2011 after a 10-year longitudinal study of 50,730 U.S. 
women who were previously free of clinical depression at baseline, roughly 5% of the subjects 
reported a positive correlation between clinical depression and caffeine intake at follow-up 
(Lucas, Mirzaei, Pan, Okereke, Willett, O’Reilly, Koenen, & Ascherio, 2011).  Additionally, 
those with depressive disorders expressed higher sensitivity to the anxiogenic effects of caffeine 
despite consuming similar amounts of caffeine as individuals without psychiatric disorders (Lee 
et al., 1988).  Levels of caffeine intake (Greden, Fontaine, Lubetsky, & Chamberline, 1978) and 
caffeine use in general has been associated with higher depression scores on the Beck Depression 
Inventory (Dosh et al., 2010). What is also interesting to note is that Greden and colleagues 
(1980) found that individuals experiencing caffeine-related withdrawal headache report 
significantly more symptoms of anxiety and depression.  However, in conclusion, although 
several studies have found caffeine to be associated with depression, the causal nature of this 
association remains uncertain (Kendler et al., 2006).  
 A family history of substance use problems is another potential correlate of caffeine use 
and related problems.  This relationship has been well established throughout literature, 
concluding for example, that individuals with a family history of alcoholism are more likely to 
be alcohol dependent (Svikis et al., 2005).  Few studies, however, have directly examined the 
relationship between family histories of substance abuse/dependence and caffeine consumption.  
Although, one study conducted by Svikis and colleagues (2005) found that among pregnant 
caffeine dependent women, those reporting a lifetime diagnosis of caffeine dependence 
(according to fulfillment of the DSM-IV (1994) diagnostic criteria for substance dependence 
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tailored to caffeine use) and family history of alcoholism had higher rates of caffeine use.  
Furthermore, the authors found that those with a family history of alcoholism who went on to 
meet their caffeine dependence criteria were least able to reduce or stop caffeine use during 
pregnancy (Svikis et al., 2005).  
Genetics 
 Twin and adoption studies have demonstrated genetic factors play a role in alcohol 
dependence and other substance use disorders (Pickens, Elmer, LaBuda, & Uhl, 1996).  
Moreover, specific genetic influences may underlie additional risk factors associated with drug 
use, including personality/psychopathological characteristics, by altering pharmacokinetic or 
pharmacodynamics mechanisms, or by enhancing other reinforcing effects, such as peer pressure 
(Pickens, Elmer, LaBuda, & Uhl, 1996).   
 Much of the human research investigating the etiology of genetic vulnerability to 
substance abuse has involved twin and adoption studies.  Historically, the preponderance of 
research has focused on alcoholism (e.g., Pickens et al., 1996).   However, genetic factors have 
been found to play a role in the development of other substance use disorders (Heath, Cates, 
Martin, Meyer, Hewitt, Neale, & Eaves, 1993; Jardine & Martin, 1984; Kaprio, Koskenvuo, & 
Langinvainio, 1984; Kendler, Heath, Neal, Kessler, & Eaves, 1992; McGue, 1994; Tsuang, 
Lyons, Eisen, Goldberg, True, Meyer, & Eaves, 1996).   
 Twin studies of caffeine use and problems have yielded results similar to those found for 
common licit psychoactive drugs – nicotine (Health et al., 1993; Boomsama, Koopmans, Van 
Doornen, & Orlebeke, 1994) and alcohol (Kendler et al., 1992; McGue, 1994).  Additionally, 
studies have established common genetic factors underlying the heritable effects of heavy 
caffeine use in combination with alcohol and nicotine use (Hetterman, Corey, & Kendler, 1999; 
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Swan, Carmelli, & Cardon, 1996; Swan, Carmelli, & Cardon, 1997).  Moreover, recent 
population-based twin studies have found that similar genetic factors play a role in the 
development of caffeine and nicotine dependence, but that these genetic influences appear to 
differ for these licit drugs as compared to illicit drugs (Kendler, Myers & Prescott, 2007; 
Kendler, Chen, Dick, Maes, Gillespie, Neale, & Riley, 2012), suggesting that a substantial 
proportion of the genetic influences on caffeine dependence appears to be specific to caffeine 
alone.  Given these findings regarding genetic factors influences the use and dependence of 
psychoactive drugs, it has been postulated that genetic variation might additionally influence 
individual differences in caffeine use, toxicity, tolerance, dependence, and withdrawal (Kendler 
& Prescott, 1999).   
 A number of twin studies have investigated genetic influences on quantity and frequency 
of caffeine consumption (Juliano et al., 2009) and have found heritable influences (Carmelli, 
Swan, Robinette, & Fabsitz, 1990; Conterio & Chiarelli, 1962; Kaprio, Sarna, Koskenvuo, & 
Rantasalo, 1978; Partanen, Bruun, & Markkanen, 1966; Pedersen, 1981In 1999).  Kendler and 
Prescott (1999) examined the role of genetic factors in the development of caffeine toxicity, 
tolerance, and withdrawal.  They found that among 1,934 female twins, concordance rates for 
caffeine withdrawal were higher in monozygotic (41%) as compared to same-sex dizygotic 
(18%) twins, and they estimated heritabilities for caffeine toxicity, tolerance, and withdrawal to 
range between 35% and 45% (Kendler & Prescott, 1999).  The results of this study were 
replicated in a twin study by Yang, Palmer, and de Wit (2010).  In their study, monozygotic 
twins were found to have higher concordance rates for caffeine consumption than dizygotic 
twins, with heritabilities ranging from 30% to 77% for caffeine intoxication, withdrawal, and 
tolerance.  
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 The Cytochrome P450 1A2 (CYP1A2) gene has been shown to be primarily responsible 
for caffeine metabolism (Gu, Gonzalez, Kalow, & Tang, 1992; Juliano et al., 2014), while the 
primary gene associated with caffeine use and the effects of caffeine is the ADORA2A gene 
(codes for the adenosine A2a receptor) (Cornelis, El-Sohemy, & Campos, 2007).  Variability in 
the CYP1A2 gene has been associated with differences in caffeine consumption (Yang et al., 
2010; Josse, De Costa, Campos, El-Sohemy, 2012; Rodenburg, Eijgelsheim, Geleijnse, Amin, 
van Duijn, Hofman, Uitterlinden, Stricker, & Visser, 2012) such that certain allele substitutions 
within this gene (CYP1A2*1F) attribute to slower caffeine metabolism, while carries of the 
homozygous for the *1A allele (CYP1A2*1A) are more rapid caffeine metabolizers (Han, Ou-
Yang, Lu, Jiang, Shu, Chen, Tan, & Zhou, 2001; Sachse, Brockmoller, Bauer, & Roots, 1999).   
 A study conducted by Lader and colleagues (1996) also found that slow metabolizers of 
caffeine were less likely to experience caffeine withdrawal sedation or anxiety after caffeine re-
administration.  Additionally, Cornelis and coworkers (2006) examined slow versus rapid coffee 
metabolizers in a group of Costa Rican caffeine users and found isoenzyme differences in their 
CYP-1A2 gene, also suggesting a genetic basis for differences in caffeine metabolism.  These 
variations in caffeine metabolism have been demonstrated in the literature to be associated with 
an increased risk for coffee-associated hypertension and myocardial infarction (Cornelis, El-
Sohemy, Kabagambe, & Campos, 2006; Palatini, Ceolotto, Ragazzo, Dorigattie, Saladini, 
Papparelle, Mos, Zanata, & Santonastaso, 2009), in addition to differences in sensitivity and 
tolerance, meaning the physiological and subjective effects of caffeine may be experienced by 
some after consuming doses of caffeine substantially lower than that of a regular user (Juliano et 
al., 2009).  
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 Additionally, polymorphisms of the ADORA2A receptor gene have been associated with 
caffeine consumption (Juliano et al., 2014), and caffeine’s association with psychomotor 
vigilance (Bodenmann, Hohoff, Freitag, Deckert, Rétey, Bachmann, & Landolt, 2011), anxiety 
(Childs, Honoff, Deckert, Xu, Badner, & de Wit, 2008; Rogers, Hohoff, Heatherley, Mullings, 
Maxfield, Evershed, Deckert, & Nutt, 2010), and sleep (Bodenmann et al., 2011; Byrne, 
Johnson, McRae, Nyhold, Medland, Gehrman, Heath, Madden, Montgomery, Chenevix-Trench, 
& Martin, 2012; Rétey, Adam, Khatami, Luhmann, Jung, Berger, & Landolt, 2007) (Juliano et 
al., 2014).  Genetic factors also “appear to substantially influence a woman’s vulnerability to 
caffeine use, heavy use, intoxication, tolerance, and withdrawal” (p. 226, Kendler & Prescott, 
1999).  Overall, the genetic data presented above highlights the underlying biological basis for 
caffeine use and its associated problems (Juliano, et al., 2009); however, research has not 
identified specific genes that increase an individual’s vulnerability specific to caffeine 
withdrawal syndrome (APA, 2013). 
Statement of Problem 
 Like many psychoactive substances, daily use of caffeine can lead to dependence and 
abrupt cessation of use can produce symptoms of withdrawal.  Research findings have provided 
significantly robust evidence to include caffeine withdrawal in the DSM-5 (APA, 2013). The 
incidence of clinically significant distress or functional impairment as a result of caffeine 
withdrawal in normal subjects varies from 10% to 55%, with a median of 13% (Juliano & 
Griffiths, 2004).  Many consider headaches to be the hallmark symptom of withdrawal among 
regular caffeine users, with 11% of caffeine consumers reporting headaches and at least on other 
symptom following caffeine abstinence (Juliano et al., 2014).  
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 While the symptoms of caffeine withdrawal have been characterized, not all chronic 
caffeine users experience caffeine withdrawal during periods of caffeine abstinence.  Much less 
is known about other correlates (predictors) of caffeine withdrawal (Hughes et al., 1993; Juliano 
& Griffiths, 2004), providing little evidence regarding the variability in risk for having 
headaches and other symptoms of caffeine withdrawal.  For example, Juliano and Griffiths 
(2004) stated that “very little is known about the determinants of individual differences in 
caffeine withdrawal” (p. 23).  Furthermore, only a few studies exist examining treatment for 
caffeine use, including best practices to promote caffeine reduction and cessation (Meredith et 
al., 2013).   
 To advance the caffeine withdrawal literature, the present study will examine prevalence 
rates of recent caffeine in males and females, looking separately at coffee, tea, soda, energy 
drinks, energy shots, and other forms of caffeine use as well as symptoms of caffeine 
withdrawal.  In addition, univariable analyses will be used to identify psychosocial factors 
associated with caffeine withdrawal headache (CWH), drawing not only from caffeine use 
frequency measures but also personal and parental histories of alcohol use and problems, as well 
as symptoms of depression and anxiety and other psychosocial factors.  These findings will also 
be examined separately for males and females, a novel methodological approach in the field of 
caffeine withdrawal research.  It is hypothesized that the likelihood of experiencing a CWH will 
not only increase as frequency of caffeine use (days/weeks) increases, but that daily caffeine 
users will also be more likely to report CWH than non-daily caffeine users. The ability to 
identify the predisposing factors associated with caffeine dependence and related problems are of 
paramount importance so that education can be targeted to prevent and treat those at risk for 
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caffeine dependence.  This information may also inform future development of tailored 
prevention and intervention programs targeting caffeine and other substance use in young adults. 
 Caffeine is considered the most widely used psychoactive drug in the world, but because 
caffeine concentration varies considerably within and across foods and beverages, researchers 
have struggled to develop effective methods to assess caffeine consumption frequently and 
accurately (Addicott et al., 2009; Meredith et al., 2013).  In particular, quantity of caffeine 
consumed has been difficult to measure without a detailed assessment.  Such interviews are labor 
intensive and often not practical in survey research.  As a result, many studies rely solely upon 
retrospective frequency measures of caffeine use.   The present study also examined validity of 
self-report frequency measures of caffeine consumption by examining their relationship to the 
experience of a caffeine withdrawal headache.  This information will help inform methods for 
developing accurate caffeine consumption assessments in future research. 
Aims and Hypothesis 
The present study used year 1 freshman cohort data from the Virginia Commonwealth 
University (VCU) Spit for Science project to examine caffeine use patterns and psychosocial 
factors associated with self-reports of caffeine withdrawal.  Given that headaches are the 
hallmark feature of caffeine withdrawal, headaches after cessation of caffeine use for a day or 
more served as the primary dependent outcome measure.  The present study had 2 specific aims.  
First (Aim 1), prevalence rates of recent caffeine use were examined in males and females, 
looking separately at coffee, tea, soda, energy drinks, energy shots, and other forms of caffeine 
use as well as symptoms of caffeine withdrawal.  Second (Aim 2), univariable analyses were 
used to identify psychosocial factors associated with caffeine withdrawal headache (CWH).  
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Those significant at p ≤ .25 were then examined together using multiple backward stepwise 
regression and other modeling approaches to identify a final parsimonious model.   
This study tested 2 hypotheses: Hypothesis 1: Likelihood of experiencing a CWH would 
increase as frequency of caffeine use (days/weeks) increased.  Hypothesis 2: Daily caffeine users 
would be more likely to report CWH than non-daily caffeine users.  
Methods 
Data set 
The present study utilized the 2011 freshman survey collected as part of the Spit for 
Science project, which was funded by the National Institute on Alcohol Abuse and Alcoholism 
(NIAAA) (Kendler & Dick; NIH R37 AA011408).  This university-wide survey was 
administered to undergraduate students attending a large, urban, public university in Richmond, 
Virginia.  The overall purpose of the Spit for Science project was to understand how genetic 
influences interact with environmental and developmental influences to impact substance use 
and emotional health outcomes in college students.  The Spit for Science baseline survey queried 
college freshman about alcohol and other substance use, as well as mental health, personality, 
and a variety of behavioral and life experiences, with follow-up surveys at the end of each 
participant’s freshman, sophomore, junior, and senior year.  In addition, DNA samples were 
obtained, providing an opportunity to examine how genetic factors contribute to the development 
of alcohol use disorders and other mental health problems.  [See Dick et al., (2014) for a full 
description of the Spit for Science project].   
Participants 
The present sample included N = 2,056 freshmen who participated in the Fall, 2011 Spit 
for Science baseline survey.  The survey response rate was 57%, with 97% (n = 1884) of 
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participants also providing a saliva sample for DNA analysis.  Only students over the age of 18 
were eligible for the study.  Demographically, over half the sample was female (57%), with 50% 
White, 20% African American, 15% Asian, and 7% Hispanic.   
Study Procedures 
Recruitment began with information about the study being mailed to all incoming 
freshmen and (separately) to their parents.  Then, during the week before “Welcome Week,” all 
freshmen over age 18 received an invitation via their university e-mail account to participate in 
the survey.  The invitation e-mail contained a link to the online survey.  E-mail reminders were 
also sent to non-responders.  Upon completion of the survey, students went to a central site at the 
university to collect compensation ($10 and a free Spit for Science t-shirt).  At that time, they 
were also invited to provide a saliva DNA sample for which they received an additional $10.     
Informed Consent 
Informed consent was obtained separately for the online survey and DNA sample and 
students could participate in just the survey portion of the project or both the survey and DNA 
components.  
Data and DNA Collection 
Study data were collected and managed using REDCap, a secure, web-based application 
designed to support data capture for research studies.  Oragene collection tubes were used to 
obtain four milliliters of saliva from each participant (DNA Genotek, Kanata, Ontarios).  DNA 
was isolated from these samples following manufacturer's instructions, and each isolation sample 
was quantified by spectrophotometry using a Thermo Nanodrop (Thermo Fisher Scientific, 
Waltham, MA).  [Further details regarding these Spit for Science procedures can be found in 
Dick et al., 2014].  
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Measures 
 The baseline survey required 15-30min. to complete and focused on the domains listed in 
Table 4 (in order presented during the online survey).  The response options to each question 
varied but participants were able to skip (not answer) specific questions.  Potential correlates of 
CWH were selected from the domains noted with an asterisk (Table 4) and are summarized 
further in the following paragraphs.  
Demographics 
Participants provided their date of birth, gender (male, female), and race (response 
options included: American Indian/Alaska Native; Asian; Black/African American; 
Hispanic/Latino; More than one race; Native Hawaiian/Other Pacific Islander; Unknown; 
White). 
Recent Caffeine Use 
Participants were asked, “Do you drink any caffeinated beverages?”  This included 
instant or filtered/brewed coffee, tea (e.g., sweet, green, black, and others), caffeinated sodas 
(e.g., Coke, Pepsi, Mountain Dew), energy drinks (e.g., Red Bull, Monster, Rock Star), and 
energy shots (e.g., 5-Hour Energy).”  Participants who answered yes were then asked about 
frequency of caffeine use (past 30 days), with separate queries for each of the following caffeine 
sources: coffee; hot or cold tea; caffeinated sodas; energy drinks; energy shots, and other 
caffeine-containing beverages.  Response options ranged from 0 (not at all) to 7 days/week 
(daily, or almost daily).   Participants were also asked separately about frequency of use of over-
the-counter caffeinated medicines (e.g., Vivarin, NoDoz, Excedrin, Vanquish, Anacin, Dristan).   
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Table 4.  
Spit for Science Survey Domains.   
 
Domains 
 
Measure 
  
 
Demographics* 
 
Age, race, and gender 
  
Personality*   Big Five Inventory   
Alcohol Use* Varied items  
Alcohol Expectancies  B-CEOA   
Drinking Motives  Drinking Motives Questionnaire   
Reasons for Not Drinking  Varied items    
Parenting Styles  Parenting Styles Inventory   
Family History*  Varied items   
Life Events  Life Events Checklist  
Caffeine Use* Varied items  
Peer Group Deviance  Varied items   
Nicotine Use* Varied items   
Illicit Drug Use Varied items   
Antisocial Behavior  SSAGA  
Religiosity  National Comorbidity Survey   
Anxiety/Depression*  SCL-90  
Binge Eating  EDE-Q 
 
  
                    Note: SSAGA = Semi-Structured Assessment for the Genetics of  
           Alcoholism; B-CEO-A = Brief Comprehensive Effects of Alcohol;  
                                      SCL-90 = Symptom Checklist -90; EDE-Q = Eating Disorder  
           Examination Questionnaire. 
 
Caffeine Withdrawal 
Participants reporting any recent caffeine use were asked about symptoms of caffeine 
withdrawal experienced after cessation of caffeine for a day or more.  Symptoms included: 
Headache, Fatigue, Anxiety, Depression, and Nausea or Vomiting.  
 Alcohol Use and Problems 
Participants who reported ever drinking alcohol (excluding small tastes and sips) 
proceeded to answer questions about recent frequency of use (days drank in the past 30) and 
quantity consumed (number of drinks consumed on recent days drinking).  Participants also 
selected the category that best described their drinking, with response options that included: 
Abstainer, Abstainer – former problem drinker in recovery, Infrequent drinker, Light drinker, 
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Moderate drinker, Heavy drinker, and Problem drinker.  Additionally, participants reported 
separately on how many of their peers a.) “drank alcohol,” b.) “got drunk,” and c.) “had 
problems with alcohol (like hangover, fights, accidents).”  For all 3 questions, participants had 5 
response options: None, A few, Some, Most, or All.  Participants were also asked if they had 
ever become tolerant to alcohol (defined as drinking a great deal more in order to get an effect, 
or found you could no longer get buzzed on the amount you used to drink).  Response options 
included: Yes, No, or Don’t Know.   
Lifetime Cigarette Smoking 
Participants were asked to estimate how many cigarettes they had smoked (lifetime), with 
the following response options: None, 1 – 9, 10 – 99, 100 – 200, or More than 200.  If the 
participant responded “None” then they were not asked subsequent questions regarding nicotine 
use.   
Recent Use (cigarettes and other tobacco products) 
Recent frequency of cigarette smoking was assessed for past 30 days, with response 
options of: Once or twice, A few days (3-4 days a month), A couple of days a week (5 to 11 days 
a month), Three times a week (12 to 14 days a month) Most days of the week (15 to 25 days a 
month), or, Daily or almost daily (26 to 30 days a month).  Number of cigarettes smoked per day 
was also assessed, with response options of: 10 or less, 11 – 20, 21 – 30, or 31 or more.  
Additionally, participants were asked about their recent (past 30 days) use of other nicotine 
products (i.e., cigar, little cigar, cigarillos (e.g., Black & Mild), and hookah), with the same 
response options as for cigarettes.  Additionally, they were asked how many of their peers 
smoked cigarettes over the past year, with 5 response options: None, A Few, Some, Most, or All. 
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Psychopathology 
The present study focused on two subscales of the Symptom Checklist-90 (SCL-90) 
(Derogatis, Lipman, & Covi, 1973); anxiety (7-items; α=0.85) and depression (11-items; 
α=0.89).  The SCL-90 is a well-recognized tool for identification of psychopathology and has 
been used in numerous studies as an indicator of mental health (Derecho, Wetzler, McGinn, 
Sanderson, & Asnis, 1996; Hauff & Vaglum 1995; Koh, Kim, & Park, 2002; Preston, Orr, Data, 
Nolan, & Castle, 2002).  It is particularly useful as a measure of mental health status in non-
psychiatric settings (Boudrez & De Basker 2001, Osterberg, Karlson, & Orbaek, 2002; 
Skydsbjerg, Lunn, & Hutchings, 2001; Yang, 2001).  Each item is scored on a five-point Likert 
scale, ranging from Not at all (1) to Extremely (5).  
Personality 
Personality was measured using the Big Five Inventory (BFI; John & Srivstava, 1999), a 
self-report instrument designed to measure the following 5 personality dimensions: Extraversion 
(8-items; α = .84), Agreeableness (9-items; α = .76), Conscientiousness (9-items; α = .79), 
Neuroticism (8-items; α = .81), and Openness (10-items; α = .74).  The BFI is a reliable and 
valid measure of personality (Benet-Martínez & John, 1998; John, Naumann, & Soto, 2008; 
Rammstedt & John, 2007; Soto, John, Gosling, & Potter, 2008; Srivastava, John, Gosling, & 
Potter, 2003).  Participants responded to each of the 44 items on a 5-point Likert scale ranging 
from 1 (Disagree strongly) to 5 (Agree strongly). 
Family history 
Participants were asked to report on maternal and paternal alcohol and/or drug problems 
(defined as drinking/drug use causing problems at home, at work, with their health, or with the 
police, or that they received alcohol/drug treatment).  Response options included: Yes, No, and I 
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Don’t Know.  Participants were also asked to report on maternal and paternal depression or 
anxiety symptoms, with similar response options of: Yes, No, and I Don’t Know.   
Study Variables 
Caffeine use.  For the present study, only those participants who responded yes or no to 
question, “Do you drink caffeinated beverages?” were included in the analyses.  If a participant 
responded “No” to the question “Do you drink caffeinated beverages,” they would then skip out 
of questions “In the last month in a typical week on how many days did you drink coffee, tea, 
…take over-the-counter caffeinated medicines?”  Therefore, these responses were recoded “0 
days.”  The present study focused specifically on coffee, tea, soda, energy drink, energy shot, 
other caffeinated beverage, and over-the-counter caffeinated medicine use.  Variables included: 
Caffeine users: defined as those reporting consuming at least one of the caffeinated products one 
day per week in the past month.  Frequency of caffeine use: days of use in a typical week 
during the past month, separately for: coffee; hot or cold tea; caffeinated sodas; energy drinks; 
energy shots, and other caffeine-containing beverages.  Recent daily caffeine users: categorical 
(yes/no) for consuming daily (7 days per week in the past month) for the same 7 caffeine-
containing beverage types and medications.  Daily use/any caffeine: categorical (yes/no), 
defined as those reporting consuming at least one of the caffeinated beverage types daily in the 
past month. 
Caffeine Withdrawal.  Caffeine withdrawal headaches were selected as the hallmark 
symptoms of caffeine withdrawal.  Other symptoms of caffeine withdrawal were also examined, 
including: fatigue; anxiety; depression, and nausea/vomiting.  In the analyses, response options 
and coding were as follows: yes = 1/no = 0.  If a caffeine user reported “None, Don’t know, 
never quit,” or “I choose not to answer,” to the question “If you quit all caffeine for a day or 
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more, do you experience any of the following withdrawal symptoms (headache, fatigue, anxiety, 
depression nausea or vomiting), they were coded as experiencing “No” withdrawal symptoms.  
Alcohol Use and Problems.  Continues variables included: Frequency of alcohol use: 
days of alcohol use in a typical week during the past month; Quantity of alcohol use: number of 
drinks consumed on recent drinking days, and Total amount of alcohol consumed: days of 
alcohol use in the past 30 multiplied by number of drinks consumed on drinking days.  
Categorical variables included: Current drinking type: participant self-attribution, with 
response options combined to create 4 categories: Non-users (abstainers); Minimal Users 
(infrequent and light drinkers); Moderate Users (moderate drinkers), or Heavy/Problem Users 
(heavy drinkers + problem drinkers + former problem drinkers); Alcohol tolerance (need to 
drink more alcohol to get the same effect): categorical (yes/no), and Peer alcohol problems: 
response items were combined to create 3 categories: None, A Few or Some of them, and Most 
of All of them.    
Nicotine Use.  Categorical variables included: Lifetime tobacco use (cigarettes): 3 
categories were created: 0 cigarettes (never smoked); 1-99 cigarettes, or 100+ cigarettes; Recent 
cigarette use and other tobacco use (cigar, little cigar, cigarillos e.g., Black & Mild; 
hookah): responses options for recent cigarette use were subsequently combined to create 4 
categories: none, once or twice, or multiple days per month (3-25 days a month), or daily or 
almost daily (26 to 30 days a month); response options for recent other tobacco use were 
combined to create 3 categories: none, once or twice, or multiple days per month (3-25 days a 
month), and Peer smoking (cigarettes): response items were combined to create 3 categories: 
None, A Few or Some of them, and Most of All of them.    
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Psychopathology.  Total scores for anxiety and depression scales were calculated 
(controlling for missing information). This yielded a raw score, which determined the severity of 
the participants’ symptoms for that scale. 
Personality.  Scale scores for each item, ranging from 1 (Disagree strongly) to 5 (Agree 
Strongly), were summed to yield a “score” for each of the five personality factors.  Higher scores 
indicated more of the trait being measured.       
Parental History.  Parental history measures included: maternal alcohol, drug, 
depression or anxiety; and paternal alcohol, drug, and depression or anxiety.  Responses were 
subsequently dichotomized (yes = 1/no = 0; with “I Don’t Know” coded as missing). 
Data Analyses and Procedures 
This investigation utilized pre-existing data collected through the Spit for Science 
freshman survey for 2011 (described above).  Statistical analyses were performed using SPSS 
v.23.0 (SPSS, Chicago, IL).  Prior to analysis, frequency patterns of all variables of interest were 
prepared and screened for missing values.  Additionally, means, standard deviations, and 95% 
confidence intervals (or medians and inter-quartile ranges) were computed for each continuous 
variable, as well as frequencies, proportions and 95% confidence intervals for each categorical 
variable.  
 To select variables that will result in a “best” model within the context of this study, 
univariable regression models and chi-square analyses tests were performed within a priori 
hypothesized domains (demographics, caffeine use, alcohol use, nicotine use, anxiety/depression, 
personality, and family history of drug/alcohol use and depression/anxiety) to identify variables 
associated with CWH.  Each analysis was performed separately for males and females.     
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A multivariable logistic regression model building strategy proposed by Mickey and 
Greenland (1989) was used to build a parsimonious model for predicting CWH.  The 
significance level was set higher than conventional levels to increase the likelihood the 
multivariable logistic regression analyses performs acceptably.  Variables meeting a ≤ 0.25 p-
value significance test were considered for the multivariate logistic regression analysis (Mickey 
& Greenland, 1989).  In the first stage, all univariable regression models were tested using each 
potential predictor on CWH with particular attention paid to the nature of the relationship 
between CWH and each predictor.  In the second stage, all predictors demonstrating at least a 
moderate ability to predict CWH (p ≤ .25) became candidate predictors in a multiple backward 
stepwise regression algorithm.  This approach was used to remove all main effects found not 
predictive (p > .05).  This model was considered the final model.    
Aim 1: Examine prevalence rates of recent caffeine consumption in the sample of 
college freshmen.  To address the first study aim, frequency patterns of caffeine consumption 
and beverage intake patterns were created, separately for both males and females.  Frequency 
patterns of caffeine withdrawal symptoms were also summarized.  Following these descriptive 
analyses each hypothesis was tested systematically.       
Hypotheses: 
 A univariable logistic regression analysis was used to examine hypothesis one: the 
likelihood of experiencing a CWH would increase as frequency of caffeine use (days/weeks) 
increased.  Chi-square analyses were performed to examine hypothesis two: daily caffeine users 
would be more likely to report CWH than non-daily caffeine users. 
Aim 2: Univariable and multivariable analyses were used to identify variables 
associated with caffeine withdrawal headache.  To address the second aim, univariable 
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regression and chi-square analyses were used to identify demographic and psychosocial variables 
associated with CWH.  Variables meeting a p ≤ 0.25 level of significance where then entered 
into a multivariable logistic regression and a backwards elimination procedure was used to arrive 
at a parsimonious model for predicting CWH.  In the final model the only variables that 
remained were significant at the p ≤ 0.05 level.  
Results 
Demographic Correlates of Caffeine Use 
  
 Invitations to participate were sent to 3623 individuals across the fall data collection 
period.  A total of 2056 individuals (57%) completed the survey; survey completion was 
considerably higher among on-campus freshman (62%) than among off-campus freshmen (36%).  
From the full cohort of 2011 freshmen (N = 2,056) (n = 45) were excluded due to missing data 
(gender and/or race), and another (n = 53) were excluded because they did not answer the 
question, “Do you drink any caffeinated beverages?” leaving a final sample size of N = 1958 for  
Analyses (Figure 1).   
Descriptive statistics for the final sample and separately for those with and without 
CWH’s are summarized in Table 5.  Because of the low endorsement rates of CWH among 
minority groups, the decision was made to consolidate the responses of all minority group 
members (American Indian/Alaska Native; Asian; Black/African American; Hispanic/Latino; 
More than one race; and Native Hawaiian/Other Pacific Island) and categorize those responses as 
“non-White” (see Table 5).  Race will be included in the multivariable analyses.  Due to the 
significant differences in reported CWH, subsequent analyses are presented by gender. 
As shown in Table 5, the sample of N = 1958 had a mean (M) age of 18.5 years (SD = 
.61), and nearly two-thirds (61%) were female (n = 1200).  Approximately one-half (53%)  
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Figure 1.  
Spit for Science recruitment and enrollment consort diagram.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
identified as White (n = 1031), and 47% were classified as non-White (n = 927).  Nearly 80% 
reported drinking caffeinated beverages.  That is, in the sample of N = 1958 study participants who 
responded to the item, “Do you drink any caffeinated beverages?” N = 1560 responded yes, and 
of these participants, nearly two-thirds (65.3%) were female (n = 1019), and over half (55.8%) 
Invited to 
participate 
N = 3,623 
 N = 45 (2.19%) excluded due 
to missing gender/race 
 N = 53 (2.58%) did not answer 
initial caffeine question 
 
Completed survey 
N = 2,056 (57%) 
Declined survey 
N = 1,567 (43%) 
Present Study 
Sample 
N = 1,958 
N = 1,560 (80%) 
Caffeine users 
N = 398 (20%) 
Non-users 
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were White (n = 870).  Among these participants, 15.4% (n = 241) reported CWH, and 
approximately three-fourths of this subgroup was female (74%; n = 179).  
 
Table 5. 
Demographic Characteristics of All Caffeine Users and Participants with and without CWH. 
 
 
 
 
 
 
Total Sample 
% or M (SD) 
(n = 1958) 
 
CWH Yes 
% or M 
(SD) 
(n = 241) 
 
CWH No 
% or M 
(SD) 
(n  = 1717) 
 
 
 
CWH 
X2 
 
 
 
CWH 
p 
 
Age (years) 
 
18.5 (.61) 
 
18.5 (.69) 
 
18.5 (.60) 
  
Gender --- --- --- 19.54 < .001 
     Male 38.7 25.7 40.5   
     Female 61.3 74.3 59.5   
Race --- --- ---   
     Caucasian 52.7 79.3 48.9   
     African American 19.4 5.8 21.3   
     Hispanic/Latino 5.9 4.1 6.2   
     Asian 15.2 4.1 16.8   
     American Indian/Alaska Native  
     Native Hawaiian/Other Pacific Islander 
0.5 
0.8 
1.2 0.4   
0.4 0.8   
     More than one race 5.5 5.0 5.6   
     White vs. non-White --- --- --- 77.99 < .001 
 
 
Aim 1: Prevalence of recent caffeine use and withdrawal by beverage type and gender.  
Caffeine Use 
 Eighty percent (n = 1560) of the sample reported recent caffeine use (see Table 6), with 
females more likely to use caffeine than males (χ2 (1) = 52.63; p < .001).  Prevalence rates 
varied by beverage type, with two-thirds of the sample drinking sodas (65.7%), followed by tea 
(54.2%) and coffee (51.6%).  Prevalence of energy drink and/or shot use was lower (16% and 
4%, respectively).  Females were more likely to drink coffee (p < .001), tea (p < .001), soda 
(p = .042) and other caffeinated beverages (p = .004), and more likely to report use of caffeinated 
medicines (p = .019) than males.     
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Table 6.   
Prevalence of Recent Caffeine Use by Gender and Beverage Type. 
 
 
Caffeine Source 
 
Sample N (%) 
(n = 1958) 
 
Males N (%) 
(n =758) 
 
Females N (%) 
(n =1200) 
 
χ2 
 
df 
 
p 
 
Any Caffeine Use 
 
1560 (79.7) 
 
541 (71.4) 
 
1019 (84.9) 
 
52.63 
 
1 
 
< .001 
Coffee 1011 (51.6) 297 (39.2) 714 (59.5) 76.80 1 < .001 
Tea 1062 (54.2) 341 (45.0) 721 (60.1) 42.66 1 < .001 
Soda 1286 (65.7) 477 (62.9) 809 (67.4) 4.15 1 .042 
Energy Drinks 313 (16.0) 141 (18.6) 172 (14.4) 6.29 1 .012 
Energy Shots 78 (4.0) 35 (4.6) 43 (3.6) 1.30 1 .254 
Other Caffeinated Beverages 350 (17.9) 112 (14.8) 238 (19.8) 8.10 1 .004 
Caffeinated Medicines 122 (6.2) 35 (4.6) 87 (7.2) 5.51 1 .019 
 
Frequency of Caffeine Use by Gender and Beverage Type 
 For each caffeine beverage type, frequency of use (days used on a typical week in the 
past month) is summarized in Table 7.  For the full sample, daily use was most prevalent for 
sodas (12.8%), followed by tea (9.0%) and then coffee (6.4%), with far fewer students reporting 
daily use of energy drinks (0.7%) and other types of caffeine.  This pattern was found for both 
males and females. 
 
Table 7. 
Frequency of Caffeine Use by Gender and Beverage Type (N = 1958). 
 
 
Caffeine Source 
 
0 Days/ 
Week 
 
1 Day/ 
Week 
 
2 Days/ 
Week 
 
3 Days/ 
Week 
 
4 Days/ 
Week 
 
5 Days/ 
Week 
 
6 Days/ 
Week 
 
7 Days/ 
Week 
 
Coffee  
        
    %Total 48.2 14.7 10.3 8.4 6.4 3.5 2.2 6.4 
    %Male 60.7 10.6 7.7 6.8 5.0 2.5 0.9 5.8 
    %Female 40.3 17.3 12.0 9.4 7.3 4.1 3.0 6.7 
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Tea  
    %Total 45.6 10.3 10.7 9.7 6.1 6.0 2.6 8.9 
    %Male 55.0 10.2 9.8 7.1 5.0 3.8 1.6 7.5 
    %Female 39.8 10.4 11.4 11.3 6.8 7.4 3.2 9.8 
 
Soda  
        
    %Total 34.2 9.7 11.9 11.6 9.3 7.1 3.5 12.8 
    %Male 37.0 7.1 10.2 12.8 9.2 6.7 3.6 13.3 
    %Female 32.5 11.3 13.0 10.9 9.3 7.3 3.4 12.4 
Energy Drinks          
    %Total 84.0 8.2 3.1 1.7 1.3 0.8 0.1 0.7 
    %Male 81.4 9.8 3.2 2.1 1.7 1.2 0.0 0.7 
    %Female 85.6 7.3 3.1 1.5 1.1 0.6 0.2 0.7 
Energy Shots          
    %Total 96.0 2.5 0.7 0.3 0.3 0.1 0.1 0.1 
    %Male 95.4 3.0 0.9 0.3 0.3 0.0 0.1 0.0 
    %Female 96.4 2.2 0.5 0.3 0.3 0.2 0.0 0.2 
Other Caffeinated 
Beverages  
        
    %Total 81.9 4.5 5.2 3.0 2.1 0.9 0.4 1.9 
    %Male 85.1 3.9 5.1 1.9 1.5 0.9 0.3 1.5 
    %Female 80.0 5.0 5.2 3.8 2.5 0.8 0.4 2.3 
Caffeinated 
Medicine 
        
    %Total 93.7 2.4 1.4 0.7 0.7 0.5 0.1 0.4 
    %Male 95.4 1.7 1.2 0.8 0.3 0.1 0.0 0.5 
    %Female 92.7 2.8 1.6 0.7 0.9 0.8 0.2 0.3 
 
 
Caffeine Withdrawal 
 As displayed in Table 8, approximately one-fifth of the sample of caffeine users reported 
symptoms of caffeine withdrawal (20.4%).  Headaches were most prevalent (15.4%), followed 
by fatigue (12.9%); anxiety (3.6%); depression (1.7%) and nausea/vomiting (1.0%).  Symptom 
prevalence differed by gender, with females more likely than males to report headaches (17.6% 
vs. 11.5%, χ2 (1) = 10.09; p < .001) and fatigue (14.8% vs. 9.2%, χ2 (1) = 9.79; p < .001).  
Females were also more likely than males to report one or more symptoms of caffeine 
withdrawal (22.9% vs. 15.9%, χ2 (1) = 10.55; p < .001).  
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Table 8. 
Caffeine Withdrawal Symptoms by Gender. 
 
 
Caffeine Withdrawal Symptom 
 
Sample N (%) 
(n  = 1560) 
 
Males N (%) 
(n  = 541) 
 
Females N (%) 
(n  = 1019) 
 
χ2 
 
df 
 
p 
 
Headache 
 
241 (15.4) 
 
62 (11.5) 
 
179 (17.6) 
 
10.09 
 
1 
 
.001 
Fatigue 201 (12.9) 50 (9.2) 151 (14.8) 9.79 1 .002 
Anxiety 56 (3.6) 13 (2.4) 43 (4.2) 3.37 1 .066 
Depression 26 (1.7) 5 (0.9) 21 (2.1) 2.79 1 .095 
Nausea/Vomiting 16 (1.0) 5 (0.9) 11 (1.1) 0.08 1 .772 
1+ Symptom 319 (20.4) 86 (15.9) 233 (22.9) 10.55 1 .001 
 
Aim 1/Hypothesis 1 and 2: 
  
 Hypothesis 1: the likelihood of experiencing a CWH will increase as frequency of 
caffeine use (days/weeks) increases: 
 Hypothesis 1: results of the univariable regression analysis for the whole sample and 
separately for males and females are summarized in Table 9 for each of the 7 caffeine sources 
(coffee, tea, soda, energy drinks, energy shots, other caffeinated beverages, and caffeinated 
medicines) and CWH. 
 Overall, as frequency of nearly every caffeine source increased the likelihood of 
experiencing a CWH also increased.  When examined separately by gender, there were three 
significant OR’s in males for coffee (1.32), tea (1.20), and soda (1.17) users.  For females, 
significant OR’s were found for all caffeine beverage types with OR’s ranging from 1.07 for tea 
to 1.47 for coffee, and 1.38 for caffeine-containing medicines.  Taken together, Hypothesis  
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Table 9. 
Univariable Regression Model of Frequency of Caffeine Use Predicting Caffeine Withdrawal 
Headache (N=1560) 
 
 
 
Variables 
 
 
B 
 
 
S.E. 
 
 
Wald 
 
 
df 
 
 
p 
 
Odds 
Ratio 
 
95% C.I. for Ex(B) 
Lower          Upper 
     
    Coffee use  
 
.352 
 
.030 
 
135.30 
 
1 
 
< 
.001 
 
1.42 
 
1.34 
 
1.51 
        Males .279 .054 26.82 1 < 
.001 
1.32 1.19 1.47 
        Females .383 .037 105.32 1 < 
.001 
1.47 1.36 1.58 
    Tea use  .108 .028 14.63 1 < 
.001 
1.12 1.05 1.18 
        Males .178 .053 11.28 1 .001 1.20 1.08 1.33 
        Females .072 .034 4.51 1 .034 1.07 1.01 1.15 
    Soda use  .140 .029 22.60 1 < 
.001 
1.15 1.09 1.22 
        Males .158 .060 7.00 1 .008 1.17 1.04 1.32 
        Females .151 .034 19.43 1 < 
.001 
1.16 1.09 1.24 
    Energy drink use  .192 .052 13.76 1 < 
.001 
1.21 1.10 1.34 
        Males .142 .092 2.39 1 .122 1.15 0.96 1.38 
        Females .246 .065 14.43 1 < 
.001 
1.28 1.13 1.45 
    Energy shot use  .190 .111 2.93 1 .087 1.21 0.97 1.50 
        Males -.043 .290 .02 1 .881 0.96 0.54 1.69 
        Females .260 .127 4.19 1 .014 1.30 1.01 1.66 
    Other caffeinate beverage use  .169 .039 18.85 1 < 
.001 
1.18 1.10 1.28 
         Males .055 .088 .39 1 .531 1.06 0.89 1.26 
         Females .200 .045 19.73 1 < 
.001 
1.22 1.12 1.33 
    Caffeinate medicine use .241 .064 14.42 1 < 
.001 
1.27 1.12 1.44 
         Males -.122 .216 .32 1 .574 0.89 0.58 1.35 
         Females .323 .074 18.83 1 < 
.001 
1.38 1.19 1.60 
 
 
 
1 was supported with the likelihood of CWH increasing with increasing frequency of use for all 
7 caffeine sources in females and 3 of 7 caffeine sources in males.   
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 Hypothesis 2: Daily caffeine consumers will be more likely to report caffeine withdrawal 
headaches than non-daily caffeine consumers: 
Hypothesis 2: This hypothesis was tested separately for each caffeine source, looking at 
the total sample of caffeine users as well as separately by gender.  For caffeine overall and  
 
Table 10.   
Chi-square Analyses Comparing Daily and Non-daily Caffeinated Beverage Use and CWH. 
 
 
 
 
Sample 
 
Daily Caffeine 
Drinkers 
N (%) 
 
Non-Daily Caffeine 
Drinkers 
N (%) 
 
 
 
χ2 
 
 
 
df 
 
 
 
p 
 
Full Sample (1560) 
 
467 (29.9) 
 
1093 (70.1) 
 
---- 
 
---- 
 
---- 
    CWH (241) 142 (30.4) 99 (9.1) 114.17 1 < .001 
Males (541)  168 (31.1) 373 (68.9) ----  ---- 
    CWH (62) 44 (26.2) 18 (4.8) 52.11 1 < .001 
Females (1019)  299 (29.3) 720 (70.7) ----  ---- 
    CWH (179) 98 (32.8) 81 (11.3) 67.60 1 < .001 
 
 
 
Sample 
 
Daily Coffee 
Drinkers 
N (%) 
 
Non-Daily Coffee 
Drinkers 
N (%) 
 
 
 
χ2 
 
 
 
df 
 
 
 
p 
 
Full Sample (1560) 
 
124 (7.9) 
 
1436 (92.1) 
 
---- 
 
---- 
 
---- 
    CWH (241) 68 (54.8) 173 (12.0) 160.01 1 < .001 
Males (541)  44 (8.1) 497 (91.9) ----  ---- 
    CWH (62) 18 (40.9) 44 (8.9) 40.94 1 < .001 
Females (1019)  80 (7.9) 939 (92.1) ----  ---- 
    CWH (179) 50 (62.5) 129 (13.7) 121.05 1 < .001 
 
 
 
Sample 
 
Daily Tea 
Drinkers 
N (%) 
 
Non-Daily Tea  
Drinkers 
N (%) 
 
 
 
χ2 
 
 
 
df 
 
 
 
p 
 
Full Sample (1556) 
 
175 (11.2) 
 
1381 (88.8) 
 
---- 
 
---- 
 
---- 
    CWH (241) 39 (22.3) 202 (14.6) 6.96 1 .008 
Males (540) 57 (10.6) 483 (89.4) ----  ---- 
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    CWH (62) 14 (24.6) 48 (9.9) 10.73 1 .001 
Females (1016) 118 (11.6) 898 (88.4) ----  ---- 
    CWH (179) 25 (21.2) 154 (17.1) 1.17 1 .279 
 
 
 
Sample  
 
Daily Soda 
Drinkers 
N (%) 
 
Non-Daily Soda 
Drinkers 
N (%) 
 
 
 
χ2 
 
 
 
df 
 
 
 
p 
 
Full Sample (1557) 
 
250 (16.1) 
 
1307 (83.9) 
 
---- 
 
---- 
 
---- 
    CWH (241) 66 (26.4) 175 (13.4) 27.15 1 < .001 
Males (540) 101 (18.7) 439 (81.3) ----  ---- 
    CWH (62) 23 (22.8) 39 (8.9) 15.58 1 < .001 
Females Only (1017) 149 (14.7) 868 (85.3) ----  ---- 
    CWH (179) 43 (28.9) 136 (15.7) 15.26 1 < .001 
 
Note: ED = Energy Drinks; OCB = Other Caffeinated Beverages 
 
 
 
Sample  
Daily ED 
Drinkers 
N (%) 
Non-Daily ED 
Drinkers 
N (%) 
 
 
χ2 
 
 
df 
 
 
p 
 
Full Sample (1557) 
 
13 (0.8) 
 
1544 (99.2) 
 
---- 
 
---- 
 
---- 
    CWH (241) 2 (15.4) 239 (15.5) 0.00 1 .993 
Males (540) 5 (0.9) 535 (99.1) ----  ---- 
    CWH (62) 1 (20.0) 61 (11.4) 0.36 1 .548 
Females (1017) 8 (0.8) 1009 (99.2) ----  ---- 
    CWH (179) 1 (12.5) 178 (17.6) 0.15 1 .704 
 
 
 
Sample  
 
Daily OCB 
Drinkers 
N (%) 
 
Non-Daily OCB 
Drinkers 
N (%) 
 
 
 
χ2 
 
 
 
df 
 
 
 
p 
 
Full Sample (1541) 
 
38 (2.5) 
 
1503 (97.5) 
 
---- 
 
---- 
 
---- 
    CWH (236) 15 (39.5) 221 (14.7) 17.53 1 < .001 
Males (533) 11 (2.1) 522 (97.9) ----  ---- 
    CWH (60) 2 (18.2) 58 (11.1) 0.54 1 .463 
Females (1008) 27 (2.7) 981 (97.3) ----  ---- 
    CWH (176) 13 (48.1) 163 (16.6) 18.13 1 < .001 
 
  77 
separately for all other caffeine sources, results are summarized in Table 10.  Female daily users 
of one or more forms of caffeine were 3 times more likely to report CWH than females not 
reporting daily use of any caffeine product (p < .001).  For males, CWH’s were 6 times more 
likely to occur in daily as compared to non-daily caffeine users (p < .001).  For individual 
caffeine beverage types, prevalence of daily use varied from 16.1% for sodas, followed by 11.2% 
for tea, and 7.9% for coffee.  Prevalence rates for energy shot use and caffeinated medicine use 
was even lower.  Because of the low rates of daily use, caffeine energy shots and caffeinated 
medicines were not compared (N = 2, 0.1% for energy shots and N = 8, 0.5% for caffeinated 
medicine use).    
 For the total sample, Hypothesis 2 was confirmed for caffeine overall as well as for 4 of 
the 5 caffeine beverage types, not including caffeine energy shots and caffeinated medicines.  
Only energy drinks did not show this pattern, in part because of the low prevalence of daily ED 
use (N = 13 individuals; 0.8%).  The pattern was largely consistent in both females and males, 
excluding tea for females and other caffeinated beverages for males.  
Aim 2: Univariable and multivariable analyses identifying variables associated with 
caffeine withdrawal headache. 
Alcohol 
 The number of caffeine-using participants who also reported having at least one alcoholic 
drink in their entire life was 1151 (73.8%).  Participants who reported recent alcohol use (N = 
983; 63.0%) reported drinking a mean of 3.5 days in the past 30 days (SD = 4.8), with an average 
of 3.7 (SD = 4.5) drinks consumed per drinking occasion (Table 11).  Of these participants who 
drank, most self-described as light drinkers (45.3%), with 16.4% as moderate drinkers, 36.1% as 
abstainers, and 2.2% as heavy or problem drinkers (Table 12).  Among female caffeine users,  
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Table 11. 
Recent Alcohol Use Among Caffeine-Using Participants (N=1560). 
 
EtOH Use 
Past 30 Days 
 
% or M (SD) 
 
Total Sample 
 
     ---- 
    Number of Days 3.52 (4.81) 
    Number of Drinks 3.67 (4.46) 
    Total Quantity 12.22 (27.92) 
Males      ---- 
    Number of Days 3.95 (5.31) 
    Number of Drinks 4.56 (6.42) 
    Total Quantity 15.65 (34.47) 
Females      ---- 
    Number of Days 3.30 (4.52) 
    Number of Drinks 3.19 (2.82) 
    Total Quantity 10.38 (23.48) 
      Note: Etoh = alcohol. 
 
CWH was most often reported by moderate (25.8%) drinkers and lowest in abstainers (11.3%) 
(2(1) = 18.60, p < .001).  For males, no difference was found across the four alcohol groups 
(Table 12).  As shown in Table 17, there was no significant association between alcohol   
 
Table 12. 
Alcohol Consumption Patterns by Gender and CWH. 
 
 
Alcohol Class 
Sample 
N (%) 
CWH+ 
N (%)  
CWH- 
N (%) 
 
2 
 
df 
 
p 
Total Sample (1538) ---- 239 (15.5) 1299 (84.5) 14.42 3  .002 
    Abstainer  555 (36.1) 62 (11.2) 493 (88.8)    
    Light Drinker  697 (45.3) 119 (17.1) 578 (82.9)    
    Moderate Drinker  252 (16.4) 52 (20.6) 200 (79.4)    
    Heavy Drinker  34 (2.2) 6 (17.6) 28 (82.4)    
Males (534) ---- 62 (11.6) 472 (88.4) .185 3 .980 
    Abstainer 193 (36.1) 21 (10.9) 172 (89.1)    
    Light Drinker  233 (43.6) 28 (12.0) 205 (88.0)    
    Moderate Drinker  93 (17.4) 11 (11.8) 82 (88.2)    
    Heavy Drinker  15 (2.8) 2 (13.3) 13 (86.7)    
Females (1004) ---- 177 (17.6) 827 (82.4) 18.60 3 < .001 
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    Abstainer  362 (36.1) 41 (11.3) 321 (88.7)    
    Light Drinker  464 (46.2) 91 (19.6) 373 (80.4)    
    Moderate Drinker  159 (15.8) 41 (25.8) 118 (74.2)    
    Heavy Drinker  19 (1.9) 4 (21.1) 15 (78.9) 
 
   
 
frequency in males and CWH (p = .491); however, there was a significant association among 
females (2(1) = 3.81, p = .051).  Further, according to the Wald criterion, the total quantity of 
alcohol consumed was a significant predictor of CWH in females (2(1) = 10.83, p < .001), but 
not males (p = .832).  There was no significant gender association between alcohol quantity and 
CWH (p = .552 for males; p = .468 for females).    
Among participants who reported caffeine use, N = 235 (15.4%) reported alcohol 
tolerance.  Gender specific analyses found that one-third of females with alcohol tolerance 
(30.1%) reported CWH as compared to 15.5% of those without alcohol tolerance (χ2 (1) = 
17.83, p < .001).  This relationship was not found in males (p = .659). 
 
Table 13. 
 
Alcohol Tolerance and Peer Alcohol Use by CWH and Gender. 
 
 
 
Variables  
 
Total Sample  
N (%) 
 
CWH+ 
N (%) 
 
CWH- 
N (%) 
 
2 
 
df 
 
p 
 
Alcohol Tolerance – Total (1529) 
 
---- 
 
238 (15.6) 
 
1291 (84.4) 
 
12.98 
 
1 
 
< .001 
    Yes 235 (15.4) 55 (23.4) 180 (76.6)    
    No 1294 (84.6) 183 (14.1) 1111 (85.9)    
Alcohol Tolerance – Males (530) ---- 62 (11.7) 468 (88.3) 0.19 1 .659 
    Yes 92 (17.4) 12 (13.0) 80 (87.0)    
    No 438 (82.6) 50 (11.4) 388 (88.6)    
Alcohol Tolerance – Females (999) ---- 176 (17.6) 823 (82.4) 17.83 1 < .001 
    Yes 143 (14.3) 43 (30.1) 100 (69.9)    
    No 856 (85.7) 133 (15.5) 723 (84.5)    
 
Peer Problems w/ EtOH – Total (1550) 
    
 ---- 
 
241 (15.5) 
 
1309 (84.5) 
 
40.85 
 
2 
 
< .001 
    None 619 (39.9) 63 (10.2) 556 (89.8)    
    A few or Some 826 (53.3) 143 (17.3) 683 (82.7)    
    Most or All  105 (6.8) 35 (33.3) 70 (66.7)    
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Peer Problems w/ EtOH – Males (536)     ---- 62 (11.6) 474 (88.4) 19.53 2 < .001 
    None 225 (42.0) 11 (4.9) 214 (95.1)    
    A few or Some 284 (53.0) 44 (15.5) 240 (84.5)    
    Most or All 27 (5.0) 7 (25.9) 20 (74.1)    
Peer Problems w/ EtOH –Females 
(1014) 
    ---- 179 (17.7) 835 (82.3) 23.38 2 < .001 
    None 394 (38.9) 52 (13.2) 342 (86.8)    
    A few or Some  542 (53.5) 99 (18.3) 443 (81.7)    
    Most or All  78 (7.7) 28 (35.9) 50 (64.1)    
Note: EtOH = alcohol.   
 
 
Table 13 presents CWH rates in participants who reported peer problems with alcohol.  
Over half N = 826 (53.3%) reported “a few or some” of their peers have problems with alcohol; 
prevalence rates of CHW were highest among those who reported “most or all” of their peers had 
alcohol problems (33.3%).  For both males and females, CWH was highest among those 
individuals reporting “most or all” of their peers had problems with alcohol (25.9% for males 
and 35.9% for females) and lowest in those reporting “none” of their peers had problems with 
alcohol (4.9% for males and 13.2% for females).  Chi-square analyses revealed a significant 
association between peer alcohol problems and CWH for both males and females (see Table 13). 
Nicotine 
 Smoking cigarettes was the most common form of tobacco use, with N = 599 participants 
(38.4%) reporting ever having smoked a cigarette.  Over one-fourth, N = 43 (27.7%) of caffeine 
users reported smoking 100+ cigarettes in their lifetime (Table 14).  Cigar use was most 
prevalent among males when compared to females (13.7% vs. 5.6%, respectively) as well as 
hookah use (10.1% vs. 8.4%, respectively) (see Table 15).  CWH’s were more often reported   
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Table 14.   
Lifetime Cigarette Smoking by CWH and Gender.  
 
 
 
Lifetime Cigarette Use 
 
Total Sample 
N (%) 
 
CWH+ 
N (%) 
 
CWH- 
N (%) 
 
 
2 
 
 
df 
 
 
p 
 
Total (1552) 
 
    ---- 
 
 241 (15.5) 
 
1311 
(84.5) 
 
27.80 
 
2 
 
< .001 
    None  953 (61.4) 117 (12.3) 836 (87.7)    
    1-99 Cigarettes  444 (28.6) 81 (18.2) 363 (81.8)    
    100+ Cigarettes  155 (10.0) 43 (27.7) 112 (72.3)    
Males (537)     ---- 62 (11.5) 475 (88.5) 17.15 2 < .001 
    None  302 (56.2) 24 (7.9) 278 (92.1)    
    1-99 Cigarettes  164 (30.5) 20 (12.2) 144 (87.8)    
    100+ Cigarettes  71 (13.2) 18 (25.4) 53 (74.6)    
Females (1015)     ---- 179 (17.6) 836 (82.4) 16.85 2 < .001 
    None  651 (64.1) 93 (14.3) 558 (85.7)    
    1-99 Cigarettes  280 (27.6) 61 (21.8) 219 (78.2)    
    100+ Cigarettes  84 (8.3) 25 (29.8) 59 (70.2)    
 
 
among persons smoking 100+ cigarettes in their lifetime, followed by 1-99 cigarettes and finally 
no cigarettes.  This was true for both males and females.  Less than 20% of those who reported 
caffeine use reported recent (past month) cigarette smoking, with 6% reporting daily smoking. 
When examined separately by gender, nearly one-third of male daily smokers (29.7%) reported 
CWH as compared to only 7.3% of non-smokers (p<.001).  In contrast, while female rates of 
CWH also varied across current smoking groups (p<.012), highest rates were found in both daily 
(26.8%) and multiple day/week (28.2%) smokers, with lowest rates among non-smokers 
(15.9%).   Chi-square analyses revealed a significant relationship between gender and lifetime 
and monthly cigarette use, and CWH; however, no significant relationship existed between cigar 
or hookah use and CWH for either gender (Table 15).    
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Table 15. 
Monthly Cigarette, Cigar and Hookah Use by CWH and Gender. 
 
 
 
Cigarette Use 
 
Total Sample 
N (%) 
 
CWH+ 
N (%) 
 
CWH- 
N (%) 
 
 
2 
 
 
df 
 
 
p 
Total (1560)     ----  241 (15.4) 1319 
(84.6) 
19.54 3 < .001 
    None 1254 (80.4) 173 (13.8) 1081 
(86.2) 
   
    Once or Twice  88 (5.6) 13 (14.8) 75 (85.2)    
    Multiple Days  125 (8.0) 29 (23.2) 96 (76.8)    
    Daily 93 (6.0) 26 (28.0) 67 (72.0)    
       
Males (541)     ---- 62 (11.5) 479 (88.5) 15.80 3 .001 
    None  409 (75.6) 39 (9.5) 370 (90.5)    
    Once or Twice  41 (7.6) 3 (7.3) 38 (92.7)    
    Multiple Days  54 (10.0) 9 (16.7) 45 (83.3)    
    Daily 37 (6.8) 11 (29.7) 26 (70.3)    
Females (1019)     ---- 179 (17.6) 840 (82.4) 10.95 3 .012 
    None  845 (82.9) 134 (15.9) 711 (84.1)    
    Once or Twice  47 (4.6) 10 (21.3) 37 (78.7)    
    Multiple Days 71 (7.0) 20 (28.2) 51 (71.8)    
    Daily 56 (5.5) 15 (26.8) 41 (73.2)    
 
 
Cigar Use 
 
Total Sample 
N (%) 
 
CWH+ 
N (%) 
 
CWH- 
N (%) 
 
 
2 
 
 
df 
 
 
p 
 
Total (1544) 
 
---- 
 
239 (15.5) 
 
1305 
(84.5) 
 
0.23 
 
2 
 
.890 
    None 1221 (79.1) 187 (15.3) 1034 
(84.7) 
   
    Once or Twice  193 (12.5) 30 (15.5) 163 (84.5)    
    Multiple Days  130 (8.4) 22 (16.9) 108 (83.1)    
Males (534)     ---- 62 (11.6) 472 (88.4) 0.05 2 .975 
    None  376 (70.4) 43 (11.4) 333 (88.6)    
    Once or Twice  85 (15.9) 10 (11.8) 75 (88.2)    
    Multiple Days  73 (13.7) 9 (12.3) 64 (87.7)    
Females (1010)     ---- 177 (17.5) 833 (82.5) 1.21 2 .519 
    None  845 (83.7) 144 (17.0) 701 (83.0)    
    Once or Twice  108 (10.7) 20 (18.5) 88 (81.5)    
    Multiple Days  57 (5.6) 13 (22.8) 44 (77.2)    
 
 
Hookah Use 
 
Total Sample 
N (%) 
 
CWH+ 
N (%) 
 
CWH- 
N (%) 
 
 
2 
 
 
df 
 
 
p 
 
Total (1543) 
  
---- 
 
239 (15.5) 
 
1304 
(84.5) 
 
1.25 
 
2 
 
.535 
     None 1115 (72.3) 168 (15.1) 947 (84.9)    
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    Once or Twice  289 (18.7) 45 (15.6) 244 (84.4)    
    Multiple Days  139 (9.0) 26 (18.7) 113 (81.3)    
Males (533)     ---- 62 (11.6) 471 (88.4) 0.83 2 .661 
    None  378 (70.9) 44 (11.6) 334 (88.4)    
    Once or Twice  101 (18.9) 10 (9.9) 91 (90.1)    
    Multiple Days  54 (10.1) 8 (14.8) 46 (85.2)    
Females (1010)     ---- 177 (17.5) 833 (82.5) 1.19 2 .552 
    None  737 (73.0) 124 (16.8) 613 (83.2)    
    Once or Twice  188 (18.6) 35 (18.6) 153 (81.4)    
    Multiple Days  85 (8.4) 18 (21.2) 67 (78.8) 
 
   
 
 
As summarized in Table 16, rates of CWH varied across peer smoking groups, with 
similar patterns in males and females.  Specifically, highest rates of CWH were reported by 
participants with most/all peers described as smokers and lowest rates of CWH were found in 
those with largely non-smoking peers (all p<.001).     
 
Table 16. 
 
Peer Cigarette Use by CWH and Gender. 
 
 
 
Variables  
 
Total Sample  
N (%) 
 
CWH+ 
N (%) 
 
CWH- 
N (%) 
 
2 
 
df 
 
p 
 
Peer Cigarette Use – Total (1556)  
     
---- 
 
241 (15.5) 
 
1315 (84.5) 
 
30.24 
 
2 
 
< .001 
    None 435 (28.0) 45 (10.3) 390 (89.7)    
    A Few or Some  910 (58.5) 139 (15.3) 771 (84.7)    
    Most or All  211 (13.6) 57 (27.0) 154 (73.0)    
 
Peer Cigarette Use – Males (538) 
    
 ---- 
 
62 (11.5) 
 
476 (88.5) 
 
17.65 
 
2 
 
< .001 
    None 115 (21.4) 6 (5.2) 109 (94.8)    
    A Few or Some  340 (63.2) 36 (10.6) 304 (89.4)    
    Most or All  83 (15.4) 20 (24.1) 63 (75.9) .   
 Peer Cigarette Use – Females (1018)     ---- 179 (17.6) 839 (82.4) 17.85 2 < .001 
    None 320 (31.4) 39 (12.2) 281 (87.8)    
    A Few or Some  570 (56.0) 103 (18.1) 467 (81.9)    
    Most or All  128 (12.6) 37 (28.9) 91 (71.1)    
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Psychopathology, Personality, and Parental History 
 Mood and personality scale ratings for participants with and without a history of CWH 
are summarized in Table 17.   According to the Wald criterion, the participant’s self-reported 
depression (2(1) = 20.02, p < .001) and anxiety (2(1) = 23.49, p < .001) symptoms were 
significant predictors of CWH.  Further, the personality factor openness (2(1) = 6.76, p = .009) 
was associated with CWH, where the change in odds associated with a one-unit change in a 
participant’s openness score was 1.03, indicating that a one-unit change resulted in the 
participant having a 1.06 times greater likelihood to experience CWH.  The personality factor 
neuroticism was also found to be a significant predictor of CWH (2(1) = 24.94, p < .001).  By 
comparison, the probability of CWH increases as agreeableness (OR = 0.96) decreases (p = 
.002).      
 
Table 17. 
Univariable Regression Analyses for Each Continuous Psychosocial Variable and their 
Relationship to Caffeine withdrawal (N = 1560). 
 
 
 
Variables 
 
 
B 
 
 
S.E. 
 
 
Wald 
 
 
df 
 
 
p 
 
Odds 
Ratio 
 
95% C.I. for Ex(B) 
Lower          Upper 
 
Alcohol 
        
    Alcohol Frequency .029 .016 3.17 1 .075 1.03 0.99 1.06 
        Males .020 .029 .474 1 .491 1.02 0.96 1.01 
        Females .039 .020 3.81 1 .051 1.04 1.00 1.08 
    Alcohol Quantity -.011 .025 0.18 1 .668 0.99 0.94 1.04 
        Males -.029 .049 .353 1 .552 0.97 0.88 1.07 
        Females .028 .039 .527 1 .468 1.03 0.95 1.11 
    Total Alcohol Consumed  .005 .002 4.66 1 .031 1.01 1.00 1.01 
        Males -.001 .005 .045 1 .832 1.00 0.99 1.01 
        Females .012 .003 10.829 1 .001 1.01 1.01 1.02 
Mood - Depression         
    Total .398 .089 20.02 1 < 
.001 
1.49 1.25 1.77 
    Male .400 .183 4.769 1 .029 1.49 1.04 2.13 
    Female .353 .104 11.64 1 .001 1.42 1.16 1.74 
Mood - Anxiety         
    Total .449 .093 23.49 1 < 1.57 1.31 1.88 
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.001 
    Males .547 .208 6.88 1 .009 1.73 1.15 2.60 
    Females .374 .105 12.62 1 < 
.001 
1.45 1.18 1.79 
Personality Factors         
   Extraversion         
     Total .013 .011 1.34 1 .248 1.01 0.99 1.04 
     Males -.028 .021 1.81 1 .178 0.97 0.93 1.01 
     Females .026 .013 3.70 1 .055 1.03 1.00 1.05 
  Agreeableness         
     Total -.037 .012 9.46 1 .002 0.96 0.94 0.99 
     Males -.076 .024 10.19 1 .001 0.93 0.88 0.97 
     Females -.029 .014 4.24 1 .040 0.97 0.94 1.00 
  Conscientiousness         
     Total -.014 .012 1.23 1 .267 0.99 0.96 1.01 
     Males -.042 .024 3.03 1 .082 0.96 0.92 1.01 
     Females -.007 .014 0.26 1 .612 0.99 0.97 1.02 
   Neuroticism         
     Total .057 .011 24.94 1 < 
.001 
1.06 1.04 1.08 
     Males .074 .023 10.30 1 .001 1.08 1.03 1.13 
     Females .042 .014 9.48 1 .002 1.04 1.02 1.07 
    Openness         
     Total .033 .013 6.76 1 .009 1.03 1.01 1.06 
     Males .044 .025 2.99 1 .084 1.05 0.99 1.10 
     Females .032 .014 4.93 1 .026 1.03 1.00 1.06 
 
 
Table 18 summarizes the results of chi-square analyses examining the relationship 
between CWH and self-report of parental problems with alcohol, drugs, and/or 
anxiety/depression.  For the entire sample as well as both males and females, prevalence rates 
were highest for maternal depression or anxiety, with almost one-half (46.5) of the sample 
reporting maternal depression or anxiety, and 40.8% of males and 49.7% of females reporting 
the same.  Prevalence rates for CWH were highest among females reporting maternal alcohol use 
(27.7%), maternal drug use (24.6%), and paternal depression or anxiety (24.6%), and lowest 
among those reporting paternal drug use (18.9%).  In males, CWH was highest among those 
reporting maternal alcohol use (25.6%) and lowest among those reporting paternal drug use 
(11.6%).  There were a number of significant relationships between parental alcohol use, drug 
use, and anxiety/depression and CHW, with the most significant relationships found between 
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CWH and maternal alcohol use (p < .001) and maternal depression or anxiety (p <.001) (see 
Table 18).       
  
Table 18.  
 
 
Variables (N) 
 
Total 
Sample 
N (%) 
 
CWH+ 
N (%) 
 
CWH- 
N (%) 
 
 
2 
 
 
df 
 
 
p 
 
Family History – (Total Sample)  
 
 
 
 
 
 
 
 
 
 
 
 
    Maternal Alcohol Use (1489) ---- 229 (15.4) 1260 (84.6) 16.43 1 < .001 
       Yes 140 (9.4) 38 (27.1) 102 (72.9)    
       No 1349 (90.6) 191 (14.2) 1158 (85.8)    
    Maternal Drug Use (1489) ---- 228 (15.3) 1261 (84.7) 5.01 1 .025 
        Yes 89 (6.0) 21 (23.6) 68 (76.4)    
        No 1400 (94.0) 207 (14.8) 1193 (85.2)    
    Maternal Depression or Anxiety (1384) ---- 215 (15.5) 1169 (84.5) 22.60 1 < .001 
        Yes 644 (46.5) 132 (20.5) 512 (79.5)    
        No 740 (53.5) 83 (11.2) 657 (56.2)    
    Paternal Alcohol Use (1408) ---- 218 (15.5) 1190 (84.5) 8.58 1 .003 
        Yes 342 (24.3) 70 (20.5) 272 (79.5)    
        No 1066 (75.7) 148 (13.9) 918 (86.1)    
    Paternal Drug Use (1398) ---- 209 (14.9) 1189 (85.1) 0.48 1 .489 
        Yes 212 (15.2) 35 (16.5) 177 (83.5)    
        No 1186 (84.8) 174 (14.7) 1012 (85.3)    
    Paternal Depression or Anxiety (1282) ---- 207 (16.1) 1075 (83.9) 10.25 1 .001 
        Yes 405 (31.6) 85 (21.0) 320 (79.0)    
        No 877 (68.4) 122 (13.9) 755 (86.1)    
Family History – (Males)       
    Maternal Alcohol Use (516) ---- 59 (11.4) 457 (88.6) 8.41 1 .004 
        Yes 39 (7.6) 10 (25.6) 29 (74.4)    
        No 477 (92.4) 49 (10.3) 428 (89.7)    
    Maternal Drug Use (514) ---- 59 (11.5) 455 (88.5) 2.17 1 .141 
        Yes 24 (4.7) 5 (20.8) 19 (79.2)    
        No 490 (95.3) 54 (11.0) 436 (89.0)    
    Maternal Depression or Anxiety (488) ---- 56 (11.5) 432 (88.5) 10.41 1 .001 
        Yes 199 (40.8) 34 (17.1) 165 (82.9)    
        No 289 (59.2) 22 (7.6) 267 (92.4)    
    Paternal Alcohol Use (498) ---- 56 (11.2) 442 (88.8) 1.88 1 .171 
        Yes 107 (21.5) 16 (15.0) 91 (85.0)    
        No 391 (78.5) 40 (10.2) 351 (89.8)    
    Paternal Drug Use (498) ---- 54 (10.8) 444 (89.2) 0.05 1 .829 
        Yes 69 (13.9) 8 (11.6) 61 (88.4)    
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        No 429 (86.1) 46 (10.7) 383 (89.3)    
    Paternal Depression or Anxiety (463) ---- 54 (11.7) 409 (88.3) 0.40 1 .528 
        Yes 129 (27.9) 17 (13.2) 112 (86.8)    
        No 334 (72.1) 37 (11.1) 297 (88.9)    
Family History – (Females)       
    Maternal Alcohol Use (973) ---- 170 (17.5) 803 (82.5) 8.21 1 .004 
        Yes 101 (10.4) 28 (27.7) 73 (72.3)    
        No 872 (89.6) 142 (16.3) 730 (83.7)    
    Maternal Drug Use (975) ---- 169 (17.3) 806 (82.7) 2.58 1 .108 
        Yes 65 (6.7) 16 (24.6) 49 (75.4)    
        No 910 (93.3) 153 (16.8) 757 (83.2)    
    Maternal Depression or Anxiety (896) ---- 159 (17.7) 737 (82.3) 11.08 1 .001 
        Yes 445 (49.7) 98 (22.0) 347 (78.0)    
        No 451 (50.3) 61 (13.5) 390 (86.5)    
    Paternal Alcohol Use (910) ---- 162 (17.8) 748 (82.2) 5.80 1 .016 
        Yes 235 (25.8) 54 (23.0) 181 (77.0)    
        No 675 (74.2) 108 (16.0) 567 (84.0)    
    Paternal Drug Use (900) ---- 155 (17.2) 745 (82.8) 0.33 1 .567 
        Yes 143 (15.9) 27 (18.9) 116 (81.1)    
        No 757 (84.1) 128 (16.9) 629 (83.1)    
    Paternal Depression or Anxiety (819) ---- 153 (18.7) 666 (81.3) 9.72 1 .002 
        Yes 276 (33.7) 68 (24.6) 208 (75.4)    
        No 543 (66.3) 85 (15.7) 458 (84.3) 
       
    
       
Multivariable Regression Analysis: 
 
 Direct logistic regression was employed to predict CWH, with a pool of 15 variables 
identified through univariable analyses.  They included: gender (male/female); race (white/non-
white); daily caffeine use (y/n); alcohol tolerance (y/n); current daily cigarette smoking (y/n); 
peers problem with drinking (y = “most or all”/no); peer cigarette use (y = “most or all”/no); 
self-reported depression and anxiety (continuous variable); the personality factors of neuroticism 
and openness (continuous variables); maternal depression or anxiety (y/n); maternal alcohol use 
(y/n); paternal depression or anxiety (y/n), and paternal alcohol use (y/n).  
 A test of the full model against a constant-only model was significant, 2(15) = 156.53, p 
< .001, indicating that as a set, the predictors distinguished between those with and without 
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CWH better than an intercept alone model.  The final parsimonious model was significant (2(6) 
= 149.91, p < .001) and accounted for approximately 23% of the variance.  This model included: 
gender (2(1) = 5.41, p = .020); race (2(1) = 22.66, p < .001); daily caffeine use (2(1) = 51.65, 
p < .001); peer problems with alcohol (2(1) = 8.59, p = .003); the personality factor neuroticism 
(2(1) = 7.60, p = .006), and maternal depression or anxiety (2(1) = 6.13, p = .013).  
Accurate classification of cases from all 6 predictors was high for the prediction of not 
experiencing CWH (98.2%) but poor for the prediction of CWH (10.4%), for an overall success 
rate of 84.6%. Thus while these variables reliably distinguished between participants 
experiencing CWH vs. not experiencing CWH, the distinction is not strong. 
  
Table 19. 
Prediction of CWH using a Multivariable Regression Analysis.  
 
 
Variables 
 
 
B 
 
 
S.E. 
 
 
Wald 
 
 
df 
 
 
p 
 
Odds 
Ratio 
 
95% C.I. for Ex(B) 
Lower          Upper 
 
Gender 
 
.486 
 
.209 
 
5.41 
 
1 
 
.020 
 
1.63 
 
1.08 
 
2.45 
Race 1.02 .215 22.66 1 < 
.001 
2.78 1.82 4.23 
Daily Caffeine Use 1.30 .181 51.65 1 < 
.001 
3.66 2.57 5.22 
Peer Problems with Alcohol .828 .283 8.59 1 .003 2.29 1.32 3.98 
Neuroticism  .041 .015 7.60 1 .006 1.04 1.01 1.07 
Maternal Depression or Anxiety .461 .186 6.13 1 .013 1.59 1.10 2.28 
 
 
 As shown in Table 19, the odds ratios ranged from 1.04 (CI = 1.01 – 1.07) for 
neuroticism to 3.66 (CI = 2.57 – 5.22) for daily caffeine use.  Taken together, the probability of 
experiencing CWH significantly increased for females and for non-white minority group 
members; the probability of experiencing CWH also significantly increased for those who were 
daily users (7 days/week) of any caffeine product, reported peer problems with alcohol, scored 
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high in neuroticism, and reported that their biological mother had problems with depression or 
anxiety. 
Discussion 
 Caffeine is remarkable in that it is a behaviorally active drug that is widely and regularly 
consumed by individuals of nearly all ages.  Despite the estimated use and prevalence of 
caffeine, and its well-documented pharmacological effects, no validated measure to accurately 
quantify caffeine use exists to date.  Furthermore, caffeine is a drug that is subject to symptoms 
consistent with problematic use, including tolerance and withdrawal.  However, only recently 
has caffeine withdrawal been recognized in the Diagnostic and Statistical Manual-5 (DSM-5) 
(APA, 2013), and to date there has been little research on individual differences in the 
experience of caffeine withdrawal.  Since heavy caffeine use increases risk for many adverse 
consequences, it is important that we understand consumption patterns and their relationship to 
caffeine withdrawal.  
 The present study examined caffeine consumption patterns and the experience of caffeine 
withdrawal in a freshman sample of males and females from the VCU Spit for Science project.  
The present study also identified demographic and psychosocial variables associated with having 
CWH’s and determined which of these variables, in combination with caffeine use measures, 
best predicted caffeine withdrawal-headache.  This is the first study to examine demographic and 
psychosocial variables associated with CWH in a college sample of males and females.   
Summary of Findings 
 Approximately 80% of young adults reported caffeine use, which was similar to, or 
slightly lower than, other national estimates (Fulgoni et al., 2015), and caffeine withdrawal 
headache was the most frequently reported symptom.  Females were more likely than males to 
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consume caffeine, but sodas were the main source of caffeine for both genders.  Likelihood of 
experiencing a CWH varied by consumption patterns, beverage type, and gender.  Overall, daily 
caffeine consumers were more likely to report CWH than non-daily caffeine consumers, with 
daily coffee drinking females reporting the highest rates of CWH. 
 In univariable analyses, associations were found between a number of psychosocial 
variables and CWH.  Alcohol consumption and peer alcohol use were positively associated with 
CWH, with highest rates of CWH found in females reporting problems with alcohol.  For 
tobacco use, male daily cigarette smokers were more likely to report CWH when compared to 
females, while female rates of CWH varied across all smoking groups.  Further, rates of CWH 
varied across peer smoking groups, with the highest rates of CWH being reported by participants 
with most/all peers described as smokers and lowest rates were found in those with largely non-
smoking peers.  Similar patterns were found in males and females.  Both male and female 
participants reporting maternal depression/anxiety or alcohol problems displayed significant 
associations with CWH.  Positive associations were also found between self-reported depression 
and anxiety and CWH.  When personality measures were tested, openness and neuroticism 
predicted CWH, but agreeableness did not.  
 The variables found significant (p<.25) through univariable analyses were entered into a 
multiple backward stepwise regression analysis.  Overall, the probability of experiencing CWH 
significantly increased for females and non-white minority group members, and for those who 
were daily users (7 days/week) of any caffeine product, reported peer problems with alcohol, 
scored high in neuroticism, and reported that their biological mother had problems with 
depression or anxiety.   
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Discussion of Findings 
Caffeine consumption among college students.  In the present study, eighty percent of 
the college freshman reported recent caffeine use.  Other studies examining patterns of caffeine 
use in college samples have come to similar conclusions.  For example, Norton and colleagues 
(2011) found that overall, 89% of their sample (n = 685; mean age 18.89 years) reported caffeine 
use in the past 30 days, with an average daily consumption of 196 mg/day.  Of those reporting 
any caffeine consumption, 81% reported consumption in soft drinks, 42% in energy drinks and 
shots, 41% in coffee, 29% in tea, and 14% in espresso and lattes.  In addition, recent work 
among first-year college students suggests that 65% of students drink caffeinated beverages on a 
daily basis, and 94.7% of students used some form of caffeine in the last 2 weeks (McIlvain, 
Noland, & Bickel, 2011).   
While our overall caffeine consumption rates compare to these studies, our beverage use 
patterns vary considerably, especially regarding energy drinks.  For example, the findings noted 
by Norton and colleagues (2011) are considerably different from our findings, which reported 
only 16% of caffeine consumers use energy drinks, with only 0.7% of consumers using energy 
drinks daily.  These inconsistencies are likely due to differences in age, however.  Caffeine 
intake has been positively associated with age in most studies (Ahluwalia & Herrick, 2015) and 
Norton et al. (2011) included participants from all grades, with an age range from 16-30, and 
found that older participants and upperclassmen reported higher levels of caffeine consumption 
in a typical week, with age and year in school being highly correlated.   
Because of the growing popularity of energy drinks, the increase in associated risks with 
energy drink consumption among college students (Arria & O-Brien, 2011), and markets for the 
energy drink industry aggressively targeting adolescents and young adults aged 18–34 years 
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(Heckman et al., 2010), the vast majority of studies estimating caffeine consumption patterns 
among this population focuses on energy drink use.  For instance, a study conducted by Poulos 
and Pasch (2016) found that approximately 56% of first-year college students consumed energy 
drinks, with 65% of these students consuming energy drinks in the past month and 38.5% 
consuming energy drinks in the past week.  However, even though Poulos and Pasch’s (2016) 
past-month energy drink consumption patterns corroborate with previous research (e.g., Arria et 
al., 2011), their past week consumption is almost double compared to Arria and colleagues 
(2011) (19.8%).  Poulos and Pasch (2016) note that these differences may be due to the timing of 
the survey.  For example, their survey was conducted towards the end of the spring semester, 
which covered the final exam period, whilst Arria and colleagues (2011) assessed their 
participants at some point during their academic year.  Because of caffeine’s physiological and 
psychological effects, students may have consumed more recent energy drinks than is typical due 
to the increased stress of studying for exams.  These differences in survey timing could also 
account for the low energy drink consumption found in the present study.   
It should also be noted that interestingly, both Poulos and Pasch (2016), using first-year 
college students (n = 585), and Arria et al. (2011), using fourth-year college students (n = 1253), 
found approximately 56-61% of their sample consumed energy drinks.  This is almost 4 times 
the amount found in the present study.  However, both Poulos and Pasch (2016) Arria and 
colleagues (2014) stratified their data analyses according to past year energy drink consumption 
versus past month energy drink consumption assessed in the present study.    
Moreover, previous research conducted by Malinauskas and colleagues (2007) estimated 
that 51% percent of their college sample (mean age of 21.5 years; n = 496) consumed greater 
than one energy drink each month in an average month.  Pettit and DeBarr (2011), who surveyed 
  93 
136 undergraduate students (aged 18 to 24 years), found that more than half (59.1%) of 
participants consumed an energy drink on at least 1 of the past 7 days, and found 70.1% of 
participants consumed at least 1 energy drink during the past 30 days. Research conducted by 
Velazquez et al., 2012) reported that among 585 undergraduate students (mean age = 18.7 years), 
nearly 40% of students reported consuming energy drinks in the past month and 17.5% of 
students reported consuming energy drinks in the past week. 
Interestingly, our energy drink consumption rates most closely matched that of Berger, 
Fendrick, Chen, Arria, and Cisler (2011), who assessed a large community sample (n = 946, aged 
18 to 92 years) and found that close to one-fourth of respondents consumed at least one energy 
drink in the past year. This estimate is lower than what is reported in studies of college students 
(38 to 51%) (Malinauskas et al., 2007; Miller, 2008a; Miller, 2008b) most likely because of the 
broad age range analyzed; however, the author’s note that that energy drink users were more 
likely to be younger (Berger et al., 2011). 
The above differences in energy drink consumption patterns must be interpreted in light 
of several possible reasons, especially when comparing the results to the present study.  First, 
like mentioned above, many of the differences could be attributable to the timing of the surveys.  
First- year students were able to participate in the present study at any point in the semester, 
while Poulos and Pasch (2016) and Velazquez et al. (2012) assessed their participants at the end 
of their first year in college.  Second, each of the studies are self-report studies, which are always 
subject to response bias, such as over- or under-reporting.  Third, many of the above studies 
ascertained young adults from one large public university in various U.S. locations, and because 
students’ consumption patterns may be associated with changes in their environment, the 
influences of different social situations may account for differences in caffeine consumption.  
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Lastly, with widely varying caffeine content both within and across beverage types and minimal 
standardization (Irons, Bassett, Prendergast, Landrum, & Heinz, 2016), young adults have shown 
surprisingly little knowledge surrounding energy drinks.  For example, some students have been 
found to be unfamiliar with many of the common energy drink ingredients and/or their potential 
side effects, in addition to being unable to distinguish energy drinks from sports drinks (Attila & 
Çakir, 2011).  These inconsistencies in caffeine reporting suggest a potential knowledge gap 
regarding what exactly constitutes an energy drink.  This lack of knowledge could result in 
survey reporting errors, and such reporting errors can weaken accurate assessments of use. 
Gender differences in caffeine consumption.  The present study found that overall, 
females (65.3%) were more likely to use caffeine than males (34.7%), and they were more likely 
to drink coffee, tea, soda, and other caffeinated beverages; females were also more likely to 
report use of caffeinated medicines than males.  Males, however, were more likely than females 
to consume energy drinks.  In addition, we found that among daily caffeine consumers, males 
consumed coffee and soda more than females, while females consumed more tea.  There was an 
equal percentage of daily energy drink consumption for both genders, although like mentioned 
above, the percentage was very low.  In terms sample representation, our sample has a 
disproportionate amount of females represented compared to males (61% were female). 
In general, research examining gender differences in caffeine consumption patterns has 
been mixed.  In healthy and clinical samples, men generally consume more caffeine than women 
(Ciapparelli et al., 2010; Lee, McEnany, & Weekes, 1999; Waldeck & Miller, 1997).  Also, a 
study conducted by Demura et al., (2013) found that among 1189 young people (567 males aged 
19.3 ± 1.5 years; 622 females aged 19.1 ± 1.2 years, coffee use was significantly higher in males 
(50.8%) than in females (32.8%).  However, other studies have examined caffeine use students 
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and in the general population and found consumption did not vary as a function of gender (Brice 
& Smith, 2002; Jones & Lejuez, 2005; Whalen et al., 2007).  Other studies examining energy 
drink use among college students found that men were more likely to consume energy drinks 
when compared to women (Arria, Caldeira, Kasperski, et al., 2010; Arria et al., 2011; Berger et 
al., 2011; Hoyte, et al., 2013; Miller, 2008a, 2008b; Nordt et al., 2012; O’Brien, McCoy, Rhodes 
Wagoner, & Wolfson, 2008; Pettit & DeBarr, 2011; Velazquez et al., 2012).  However, 
Lieberman et al., (2015) found in a sample of college students that caffeine intake was higher 
among women, and Malinauskas and colleagues (2007), also in a sample of college students, 
found that women were more likely to consume energy drinks when compared to men.   
Despite demographic comparisons, many studies do not examine reasons why gender 
specific differences exist.  Some researchers suspect gender differences exist because of 
circulating hormones (Temple & Ziegler, 2011) and other physiological differences (Harley, 
Lavallo, & Whitsett, 2004; Lovallo, Farag, Vincent, Thomas, & Wilson, 2006; Keogh & Witt, 
2003; Temple et al., 2014).  Furthermore, according to Yamazawa, Hirokawa, and Shimizu 
(2007) gender differences in preferences for sweet coffee were related to coffee drinking habits 
in a sample of undergraduate students.  In addition, Adan, Prat, Fabbri, and Sànchez-Turet, 
(2008), found that caffeine at lower doses induced greater effects in undergraduate men (less 
somnolence and greater activation) than in women, suggesting that females may need to 
consume more caffeine to experience caffeine’s physiological effects.  Further, Claire, Hayward, 
and Rogers (2010) found that female undergraduate students performed much better on 
collaborative tasks under stress when compared to males. 
Like the present study, which had a higher number of females compare to males, the 
studies conducted by Arria et al., (2011), O’Brien and colleagues (2008), and Pettit and DeBarr 
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(2011) had higher survey response rates in females when compared to males, but all three studies 
found males to consume more energy drinks, similar to the present study.  These findings are 
consistent with reported marketing practices that target young adults, and in particular, males 
through the sponsorship of male-dominated extreme sports (e.g., motocross) (Reissig et al., 
2009; Simon and Mosher, 2007).  
National prevalence rates and beverage intake patterns.  The rate of caffeine 
consumption found in the present study is also comparable to those found in national and more 
diverse samples (Ahluwalia et al., 2014; Branum et al., 2014; Fulgoni, 2014; Fulgoni et al., 2015; 
Mitchell et al., 2014); although, these studies have come from samples examining caffeine 
consumption data over varying study periods (e.g., 1999–2010 (Branum et al., 2014), 2001–2010 
(Ahluwalia et al., 2014; Fulgoni et al., 2015)) and in broad age ranges including opposite ends of 
the age spectrum from young children to older adults.  Additionally, these studies examined 
dietary data from a single day (Ahluwalia et al., 2014; Branum et al., 2014; Fulgoni et al., 2015), 
2-day (Fulgoni, 2014), and 7-day (Mitchell et al., 2014); they also did not include intakes from 
medicines (e.g., diet pills, antidrowsiness pills), and Mitchell et al. (2014) was the only study to 
report on supplements such as energy shots.  However, regardless of the methodological 
differences in data collection and/or data analysis, the results of the present study provide good 
evidence for the overall relative stability of caffeine consumption from beverages in the U.S. 
(Mitchell et al., 2014). 
For beverages, we found that prevalence rates varied with two-thirds of the sample 
drinking sodas (65.7%), followed by tea (54.2%) and coffee (51.6%).  Prevalence of energy 
drink and/or shot use was lower (16% and 4%, respectively).  Our findings compare to Fulgoni 
and colleagues (2015) who found that coffee (64%), tea (16%), and soft drinks (18%) to be 
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predominant sources of caffeine among those ≥ 19 years old; however, our percentage rates 
substantially differed.  Additionally, our findings corroborate with other studies (Ahluwalia & 
Herrick, 2015; Branum et al., 2014; Fulgoni (2014); Mitchell et al., 2014) where among caffeine 
consumers, soda, tea, and coffee were the major sources of caffeine among all age groups 
examined (2-59 years).  Contrary to our findings, however, Drewnowski and Rehm (2016), 
based on the NHANES data, reported a decline in caffeine from soda over the past 14 years, 
noting that coffee and tea represent a greater proportion of caffeine intakes across all age groups.   
Caffeine Withdrawal. The present study found that approximately one-fifth of the sample 
of caffeine users reported symptoms of caffeine withdrawal (20.4%; n = 319).  Headaches were 
most prevalent (15.4%), followed by fatigue, anxiety, depression, and nausea/vomiting.  Females 
more likely than males to report headaches, fatigue, and to report one or more symptoms of 
caffeine withdrawal when compared to males.  Further, three-fourths of the subgroup reporting 
CWH were female. 
Most research on caffeine withdrawal has examined symptoms in adults (Julian & 
Griffiths, 2004), however, there have been a few empirical studies demonstrating that young 
adults (e.g., college students) also experience caffeine withdrawal.  In 2012, Anderson and 
Juliano found that among college students (n = 225; 81.8% female), 32.8% indicated having had 
experienced caffeine withdrawal symptoms.  Another study, which surveyed 300 freshmen 
(60.7% women) attending a southeastern university, found that 51% reported having at least one 
sign/symptom of caffeine withdrawal.  The most common symptoms of withdrawal were fatigue 
(20%), headache (36%) and cravings (25%), and the experience of caffeine withdrawal 
headaches did not significantly differ by gender (McIlvain et al., 2011).   
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Additionally, Malinauskas and colleagues (2007), found that among energy drink 
consumers (n = 253; 53% female), 22% reported ever having headaches and 19% reporting 
experiencing heart palpitations.  Another study, conducted by Jones and Lejuez (2005), found 
that among 60 caffeine consuming college students (50% female), 73% reported experiencing 
withdrawal; however, their inclusion criteria included only students who fulfilled DSM-IV 
diagnosis of Substance Dependence as applied to caffeine based on a modified version of the 
Module E of the Structured Clinical Interview for DSM-IV Axis 1 Disorders – Non-Patient 
Edition (SCID-NP).  This type of semistructured interview procedure is also vastly different 
from self-report surveys.   
Findings from the present study yield conflicting results.  One possible explanation is that 
there are substantial differences within and across individuals with regard to incidence of 
caffeine withdrawal.  For example, approximately 50% of regular caffeine users report headache 
by the end of the first day of abstinence (Juliano & Griffiths, 2004); however, in experimental 
studies investigating caffeine withdrawal, one study examining repeated abstinence trials showed 
distinct differences within and across subjects: one individual never showed CWH, some showed 
consistent headaches, and others reported headaches on some trials but not on other trials 
(Griffiths et al., 1990).  Moreover, in another repeated abstinence experimental study, 
approximately 36% of the subjects who displayed significant elevations in headaches failed to 
report this effect consistently across trials (Hughes et al., 1993).   
Furthermore, caffeine may have varying effects from one person to the next due to 
differing age, lifestyle, or personality (Brice & Smith, 2002), and the severity of signs or 
symptoms of caffeine withdrawal can vary from mild to extreme (Juliano & Griffiths, 2004). 
Relatively low doses of caffeine (e.g. as little as 25 mg) can also partially suppress withdrawal 
  99 
symptoms.  Thus, some people may fail to report withdrawal because they unknowingly 
consumed small amounts of caffeine on days they thought they were abstinent of caffeine.  
Additionally, many caffeine consumers may be unaware of their physical dependence on 
caffeine because their frequent habitual consumption precludes a period of sustained abstinence 
(e.g. 2 days).  Lastly, participants may have attributed their caffeine withdrawal symptoms to 
other causes or ailments (e.g., viral infection), or they did not believe their symptoms to be 
incapacitating enough to report. 
Another possible explanation is regarding the persistent methodological challenges in 
caffeine research.  For example, the present study included a screening question, “Do you drink 
any caffeinated beverages?”  If a participant answered “No” to this question, they would skip any 
subsequent questions asking about caffeine use, including the question asking about the 
frequency of use of over-the-counter medications (e.g., Vivarin, NoDoz, Excedrin, Vanquish, 
Anacin, Dristan).  Therefore, the present study could have excluded participants who only used 
over-the-counter caffeinated medicines.  Moreover, and similar to Dews et al., (1999), our survey 
was not solely focused on caffeine withdrawal symptoms, which could have attributed to the low 
frequency of symptoms not found in previous reports.  In addition, Anderson & Juliano (2012), 
asked their participants, “Have you ever had caffeine withdrawal symptoms or bad physical or 
emotional feelings after not having caffeine at a time when you usually have it?’’ (p. 40).  If 
participants do not have an understanding of the characteristics of caffeine withdrawal, or if a 
withdrawal symptom is broadly defined, there becomes a potential increased risk for 
discrepant/inconsistent reporting that could influence results.  
The caffeine withdrawal syndrome has been well-characterized in numerous rigorous 
double-blind studies (Juliano & Griffiths, 2004).  Despite the lower rates found in the present 
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study, our results extents the research on the prevalence of caffeine withdrawal, especially the 
absent data on gender differences in the experience of caffeine withdrawal.  Future research on 
the prevalence of caffeine withdrawal should continue given the potential for caffeine 
withdrawal to cause clinically significant distress or impairment in functioning as reflected by 
the inclusion of caffeine withdrawal in the Diagnostic and Statistical Manual-5 (DSM-5) (APA, 
2013). 
Psychosocial factors predicting caffeine withdrawal headache.  Although there are 
considerable differences within and across individuals regarding the incidence and/or severity of 
caffeine withdrawal (Evans & Griffith, 1999; Hughes et al., 1993; Juliano & Griffiths, 2004), to 
our knowledge only one study has investigated predisposing determinants of caffeine 
withdrawal.  This was lab-based study including the general population, and scientists found no 
predictors of caffeine withdrawal.  The study, however, had only a homogenous sample of only 
40 participants, and a limited range of predictor variables (e.g., age, sex, weight, average caffeine 
intake, duration of caffeine use, smoking status, etc.) (Hughes et al., 1993).  Another study, 
conducted by Evans and Griffiths (1999), did not specifically examine predictors of caffeine 
withdrawal; however, they did investigate specific dosing conditions under which withdrawal 
symptoms occur, suggesting that withdrawal can occur under more modest conditions (i.e., fewer 
doses per day, lower daily dose, and shorter duration of exposure).  Despite the present study not 
looking at quantity consumed, the incidence of caffeine withdrawal found in the literature (Evans 
& Griffiths, 1999; Juliano & Griffiths, 2004) supports our hypothesis that daily caffeine users 
would be more likely to experience CWH than non-daily users.   
The probability of experiencing CWH also significantly increased for those who reported 
peer problems with alcohol.  To our knowledge, there has been no prior investigation exploring 
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this relationship. There are possible anecdotal explanations for why this relationship exists, 
however.  First, there has been growing evidence supporting the positive correlation between 
caffeine consumption, namely energy drink consumption, and alcohol use among young adults 
and college students (Arria et al., 2011; Anderson & Juliano, 2012; Caldeira et al., 2009; Knight 
et al., 2002; Velazquez et al., 2012; Wu et al., 2007).  If an individual is wanting to refrain from 
drinking alcohol, an alternate beverage of choice could be caffeine, in particular, energy drinks 
or caffeinated sodas.  Since the social norm may be encouraging overconsumption to the point of 
intoxication, some individuals may intentionally seek some of the negative effects of caffeine 
(Ahluwalia & Herrick, 2015).  These adverse effects, which may be intentionally sought by high-
dose consumers, may be a manifestation of stimulation-seeking behavior (Terry-McElrath et al., 
2014).  This type of behavior is often seen in young males; however, most individuals, including 
young males, choose to use moderate doses of caffeine and have characteristic and regular 
patterns of consumption (Fulgoni et al., 2015, Mitchell et al., 2014). 
Another potential reason is to consider the aggressive marketing of energy drinks to 
youthful and inexperienced consumers (Byerley, 2016).  Even though energy drink consumption 
was relatively low in our sample, the promotion of the use of caffeine for its recreational and 
stimulant properties sends a potentially harmful message to young adults that glamorizes and 
encourages its use.  Further, with the variable and sometimes very high caffeine content of 
energy drinks and lack of full disclosure of the amount of caffeine and other ingredients in 
energy drinks on the product labeling, individuals may be unaware of adverse consequences of 
caffeine consumption, and thus become more prone to withdrawal (Reissig et al., 2009).  The 
advertised rapid onset of stimulant behavior provided by energy drinks and other caffeinated 
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beverages may be what drives the use of these beverages in alcohol-related situations, even if 
one is abstaining from alcohol.  
An additional primary finding of the present study was that females were more likely to 
experience CWH when compare to males.  First, it must be noted that females were more likely 
to use caffeine than males, which could be the principal reason why more females reported CWH 
when compared to males.  However, as mentioned above, some epidemiology studies have 
concluded that females consume more caffeine than males.  Further, with the growing evidence 
supporting caffeine use in social settings among college students (Lieberman et al., 2015; 
Malinauskas et al., 2007; Norton et al., 2011), the results of the current study could suggest that 
females are participating in number of social activities, although this was not specifically 
investigated.  Results of previous studies support the idea that females metabolize caffeine 20% 
to 30% faster than males (Franconi et al., 2003) and with research suggesting that responses to 
caffeine differ by gender due to differences in steroid hormone concentrations (Temple & 
Ziegler, 2011), suggesting an increased susceptibility to caffeine withdrawal.  Additionally, our 
findings corroborate with Kendler and Prescott (1999), who found that genetic factors 
substantially influence a woman’s vulnerability to caffeine use and withdrawal.  Nevertheless, 
reasons for gender differences in caffeine use and dependence are not yet clear and further 
research regarding pharmacodynamics, pharmacodynamics, and psychosocial factors is 
warranted.  Further, as suggested by the National Institute of Health, analyzing data by 
sex/gender at all levels of analysis in both animal and human studies will provide valuable 
insight into these gender differences. 
Another intriguing finding from the present study is that the probability of experiencing 
CWH increased significantly for participants of the non-white minority group.  Few studies have 
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examined patterns and reasons for consumption by race/ethnicity among diverse samples 
(Marczinski, 2011), and to our knowledge, no studies have examined the direct correlation 
between caffeine withdrawal and race/ethnicity.  Contrary to our results, demographic analyses 
from epidemiological studies show that for both children and adults, caffeine consumption is 
highest in the non-Hispanic white population and lowest in the non-Hispanic black population 
(Drewnowski & Rehm, 2016; Lieberman et al., 2016).  However, a recent study found that 
caffeine-related problems were not associated with age, gender, or race/ethnicity among 
adolescents (Sojar, Shrier, Ziemnik, Sherritt, Spalding, & Levy, 2015).   
Potential genetic liability towards caffeine metabolism or withdrawal could be a possible 
explanation for the present study’s finding.  However, this is an area that has received little 
attention due to concerns about subject population and/or population stratification (Yang, et al., 
2010).  Nonetheless, wide ethnic variations have been found for CYP1A2 polymorphisms, and 
there appear to be variations in the association between ADORA2A and caffeine-induced anxiety 
in different ethnic groups (Lam et al. 2005; Yamada et al. 2001).  Furthermore, the individual 
differences in response to caffeine at the metabolic (pharmacokinetic) or at the drug-receptor 
(pharmacodynamics) level, could contribute to the magnitude of caffeine withdrawal among this 
population.  For example, Asian and African populations, appear to metabolize caffeine at slower 
rate than Caucasians (Gunes & Dahl, 2008).  More studies in non-white ethnicities are needed to 
complete our understanding of genotype effects in responses to caffeine, however. 
The present study also found that the probability of experiencing CWH significantly 
increased for participants who reported their biological mothers had problems with depression or 
anxiety.  Unfortunately, due to the survey question and the correlational nature of our analysis, it 
is not possible to determine whether maternal problems with depression or anxiety are related to 
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CWH, but this finding extends research examining caffeine dependence and family histories.  
For example, Svikis and colleagues (2005) found in a sample of pregnant women, those with a 
lifetime diagnosis of caffeine dependence and a family history of alcoholism had higher levels of 
caffeine use, which as Svikis and colleagues postulated, suggests that a genetic susceptibility 
reflected in the family history of alcoholism may be essential to express the problematic features 
of caffeine dependence.  Indeed, the results of the present study found that prevalence rates for 
CWH were highest among females and males reporting maternal alcohol use (27.7% and 25.6%, 
respectfully), and that significant relationships existed between CWH maternal and paternal 
alcohol use.  However, multivariable analyses did not reveal these significant relationships in the 
final model.  Nevertheless, the overall results of the present study do add to the literature which 
shows a greater co-occurrence of caffeine withdrawal in monozygotic than in dizygotic twin 
pairs, with heritabilities of these characteristics between 35% and 77% (Kendler & Prescott, 
1999; Swan et al., 1996).   
The present study also provides valuable new information about personality and caffeine 
withdrawal.  Previous studies have described caffeine consumption being related to both general 
and specific personality traits; however, research on caffeine withdrawal and personality 
correlates has been limited (Jones & Lejuez, 2005).  For example, Landrum (1992) demonstrated 
a positive correlation between caffeine consumption and Extroversion in a sample of college 
students, which could have been mediated by the specific constructs of Impulsivity and/or 
Sensation Seeking.  In addition, Waldeck and Miller (1997) found that caffeine consumption was 
positively correlated with impulsivity in males, although not in females, and Jones & Lejuez 
(2005) found that caffeine consumption and dependence were positively correlated with 
Sensation Seeking and Impulsivity.  Furthermore, a recent study conducted by Glen & Stephen 
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(2015) found a positive correlation between caffeine withdrawal and Impulsivity; however, the 
authors note that these results could be explained by other symptoms of stimulant withdrawal 
such as confusion or anxiety.  It is hypothesized that because these personality constructs appear 
to share a temperamental low basal level of resting arousal (Pickering & Gray, 1999), people 
scoring high in these traits consume larger amount of caffeine to reach optimum level of 
activation.   
The present study did not examine the relationship between CWH and Sensation Seeking 
or Impulsivity, however, results indicated that CWH was not significantly correlated with 
Extroversion.  This is conflicting with the results found by Landrum (1992), though Landrum 
(1992) used the Caffeine Consumption Questionnaire which allowed for a precise and consistent 
measure of caffeine use but did not investigate symptoms of caffeine withdrawal, both of which 
could explain the differences in results.    
Results of the present study did find that CWH was significantly associated with high 
scores in Neuroticism.  Individuals who score high in neuroticism are typically people who tend 
to be anxious, high strung, tense and worrying, prone to depression, and cope poorly with stress 
(Friedman, 2011).  This finding is of particular interest because additional results of the present 
study found significant associations between CWH and self-reported symptoms of depression 
and anxiety, corroborating results from a study examining caffeine use in teenagers (Bernstein, 
Carroll, Thuras, Cosgrove, and Roth, 2002) and in the general population (Broderick & 
Benjamin, 2004; Dosh, Helmbrecht, Anestis, Guenthner, Kelly, & Martin, 2010; James & 
Crosbie, 1987; Juliano et al., 2012).  Furthermore, several personality factors, such as anxiety 
proneness, depression-proneness, impulsivity, and sensation seeking, have all been shown to be 
associated with risk for substance use patterns and disorders (Jones & Lejuez, 2005; Woicik et 
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al., 2009).   
One possible explanation for this observation is that anxiety and Major Depressive 
Disorder have been found to share genetic and environmental factors with caffeine use and 
withdrawal (Bergin & Kendler, 2012; Kendler et al., 2006), which also substantiates our 
hypothesis to why we found CWH to be significantly associated with maternal depression or 
anxiety.  Another explanation for our results could be due to the positive psychological and 
behavioral effects of caffeine.  Desirable effects attributed to low or moderate intake levels, such 
as changes in mood, energy, alertness, and vigor, may mildly reinforce consumption for some 
individuals (Fredholm et al. 1999) and lead to withdrawal.  Furthermore, some studies have 
identified a positive effect of caffeine on depression. For example, one study suggests that the 
chemical effects of caffeine can prevent brain receptors from responding to stressful situations, 
indicating that stressful responses don’t manifest as easily in those with caffeine in their systems 
(Kaster, 2015).  This response may also reinforce consumption for some and increase their risk 
for experiencing withdrawal.  
Given that personality research has been helpful in identifying individual vulnerabilities 
to substance use and dependence (cf. Sher, Bartholow, & Wood, 2000), these results provide 
information that advances the caffeine withdrawal literature by identifying personality correlates 
that differentiate those people who experience the more negative symptoms of caffeine whereas 
others do not.  Regardless of these results, it is imperative that research examining the 
constellation of correlated personality constructs with caffeine withdrawal continue so 
researchers and clinicians can generate relevant theoretical models for identifying the 
characteristics of caffeine dependence in clients and research participants.   
 
  107 
Implications  
The present study contributes new information to the existing literature on caffeine 
withdrawal.  Specifically, while more than 66 experimental and survey studies have 
characterized various aspects of the caffeine withdrawal syndrome (Juliano & Griffith, 2004), 
and many contributed to caffeine withdrawal becoming recognized as a DSM-5 diagnosis (APA, 
2013), few studies have focused on individual determinants and psychosocial correlates of 
caffeine withdrawal. The variables identified in the present study have the potential to inform 
development of targeted education and intervention efforts to prevent the development of 
caffeine-related problems. 
Present study focus on college students is of particular importance as the use of energy 
drinks is quite common in this group, yet their knowledge of ingredients and potential health 
hazards of such drinks is often limited (Attila, 2011).  Mixing energy drinks with alcohol is also 
common and has been associated with heavy drinking and adverse consequences.   
Also, the finding that daily caffeine users are more likely to report CWH than non-daily 
users supports validity of self-report.  This is important for both self-report data researchers and 
practitioners to know.  
Study Limitations, Strengths and Future Directions 
Limitations 
First, our study relied solely on self-report measures of caffeine use frequency and CWH.  
While quantity of use is also important, measurement is more problematic because the variability 
in caffeine content and size across beverage types makes it difficult to standardize and assess 
accurately.  Nonetheless, our findings offer some support for reliance upon frequency data, given 
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that daily users were in fact more likely to report CWH than non-daily users across beverage 
types.   
A second limitation is that the data base did not contain information about daily caffeine 
use overall (i.e., “Do you consume something with caffeine in it every sing day?”).  Instead, we 
looked separately at beverage type.  We also looked at daily use of at least one caffeinated 
beverage typed.  The present study also did not capture daily caffeine users who consumed 
different beverage types on different days (e.g., coffee 5 days per week and sodas on the two 
weekend days).  Such daily users would be missed in the present study database and warrant 
further study.   
Third, present study analyses focused on only one symptom of caffeine withdrawal 
(headaches).  This was done because endorsement rates of the other symptoms were lower and 
headaches are the hallmark symptom of caffeine withdrawal.  Future research should look at 
other symptoms as well.   
Fourth, present study findings may be limited by the characteristics of the sample and 
should not be generalized without further study.  
Fifth, this study did not examine all potentially important covariates of CWH.  It is 
possible that other factors such as academic stress, physical activity, etc. may be important 
predictors of CWH.  Also, other comorbid internalizing mood or substance use disorders were 
not measured and may be important.   
A sixth limitation is use of univariable and multivariable analyses used for data analysis, 
which was unable to determine the direction of causality regarding 3-category variables.  
Additional statistical analyses such as Area Under the cure for the Receiver Operator 
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Characteristic curve, could have provided an “optimal” cut point for a score of the predictor 
variables, which simultaneously maximizes sensitivity and specificity. 
Strengths   
The current study has a number of strengths.  First, it used a dataset collected from a 
large cohort of college freshmen.  Second, whenever possible, standardized measures were used 
to assess study variables.  When not available, existing measures were modified for the larger 
study.  Third, the sample included nearly 70% of eligible participants.  This is exceptional, given 
that when a meta-analysis (Cook, Health, & Thompson, 2000) looked at 68 US web-based 
surveys of college populations, they found a mean response rate of only 39.6%.  
Fourth, the present study examined not only caffeine frequency of use measures, but also 
incidence of caffeine withdrawal symptoms.  Fifth, since the Spit for Science project follows 
participants longitudinally over a four-year period (freshman to senior year), future research can 
examine longitudinal changes in caffeine use overtime.  DNA data is also planned and can better 
contribute to our understanding of caffeine use, dependence, and withdrawal. In addition, new 
freshmen cohorts are now available and could be used to replicate present study findings. 
Future Directions   
Future research should seek to identify additional correlates of caffeine-related 
withdrawal symptoms, including whether genetic factors associated with caffeine metabolism 
further improves the ability to identify those at risk for caffeine withdrawal syndrome.  For 
example, research findings have suggested that caffeine, as a component in coffee, may have 
adverse effects on cardiovascular health.  In addition, linkage studies have shown that 
polymorphisms in the adenosine A2A receptor gene are associated with individual differences in 
caffeine consumption and caffeine’s effects on EEG, anxiety, and sleep (Alsene et al., 2003; 
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Cornelis et al., 2007; Retey et al., 2007).  These studies may help guide future research in the 
role of genetics in modulating the acute and chronic effects of caffeine.  More work is likely 
needed to better understand the impact of genotypic differences in the human population and the 
subsequent interaction of lifestyle factors such as exposure to caffeine. 
In addition, future research should determine whether caffeine serves as a gateway to 
other forms of drug dependence as suggested by some studies (Collins, El-Sohemy, & Campos, 
1997; Pallanti, Bernardi, & Quercioli, 2006). With regard to energy drinks in particular, one 
study of 1,253 college students found that energy drink consumption significantly predicted 
subsequent nonmedical prescription stimulant use (Arria et al., 2010).  It is plausible that the use 
of energy drinks that are promoted as alternatives to illicit drugs (e.g., “Cocaine”) may, in fact, 
increase interest in the use of such drugs. 
Also, and as previously discussed, individuals often underestimate their caffeine 
consumption because the caffeine content and other ingredients of caffeinated products are not 
always provided on nutritional labels. Future research should include a tool that yields a more 
accurate estimate of caffeine consumption (like the Caffeine Consumption Questionnaire or the 
Time-Line Follow Back survey) (Irons et al., 2016) that allows for researchers to invest more 
confidence in their data and resultant research findings, and for clinicians to gain a better 
understanding of consumption patterns that may be maladaptive.  Furthermore, the evidence 
gathered from studies such as these could help inform government policy and educational 
programs to help the public become more aware of what they are consuming. 
Conclusion 
 
To our knowledge, this is the first study to examine individual and psychosocial factors 
associated with CWH in a large sample of college freshmen.  Prevalence rates of caffeine use 
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were comparable to those in the literature.  Further, a frequency measure, daily use of individuals 
of any caffeine source(s) was associated with CWH.  Gender differences were found, with 
females being more likely to consume caffeine and experience CWH compared to males.  In 
addition, the present study found that the probability of experiencing CWH significantly 
increased for females and non-white minority group members, and for those who were daily 
users of any caffeine product, reported peer problems with alcohol, scored high in neuroticism, 
and reported that their biological mother had problems with depression or anxiety.  Future 
research will examine whether genetic factors also contribute to the experience of CWH.  This 
study and others like will provide further valuable insights into the world’s most widely 
consumed psychoactive substance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  112 
List of References 
 
 
 
Adan, A., Prat, G., Fabbri, M., & Sànchez-Turet, M. (2008). Early effects of caffeinated and 
 decaffeinated coffee on subjective state and gender differences. Progress in 
 NeuroPsychopharmacology & Biological Psychiatry, 32(7), 1698-1703.   
Addicott, M. A. (2014). Caffeine use disorder: A review of the evidence and future  
implications. Current Addiction Reports, 1(3), 186–192. 
Addicott, M.A., Yang, L.L., Peiffer, A.M., & Laurienti, P.J. (2009). Methodological 
 considerations for the quantification of self-reported caffeine use. Psychopharmacology, 
 203, 571-578. 
Ahlijanian, M.K, & Takemori, A.E (1986). Cross-tolerance studies between caffeine and (-)-N6-
 (Phenylisopropyl)-adenosine (PIA) in mice. Life Science, 38, 577-588. 
Ahluwalia, N., & Herrick, K. (2015). Caffeine intake from food and beverage sources and trends  
among children and adolescents in the United States: Review of national quantitative 
studies from 1999 to 2011. Advances in Nutrition: An International Review Journal, 6(1), 
102–111.  
Ahuja, J. K. C., Goldman, J. D., & Perloff, B. P. (2006). The effect of improved food  
composition data on intake estimates in the United States of America. Journal of Food 
Composition and Analysis, 19, S7–S13. 
Alford, C., Bhatti, J., Leigh, T., Jamieson, A, & Hindmarch, I. (1996). Caffeine-induced sleep 
 disruption: effects on waking the following day and its reversal with an hypnotic.  Human 
 Psychopharmacology: Clinical and Experimental, 11(3), 185-198.  
  113 
Alsene, K., Deckert, J., Sand, P., & de Wit, H. (2003). Association between A2a receptor gene 
 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacolog, 28, 1694-
 1702. 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 
 Third Edition, Revised.  Washington, DC, American Psychiatric Association, 1987. 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 
 Fourth Edition.  Washington, DC, American Psychiatric Association, 1994. 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 
 Fourth Edition, Text Revision.  Washington, DC, American Psychiatric Association, 
 2000. 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 
 Fifth Edition.  Washington, DC, American Psychiatric Association, 2013. 
Ammon, H.P.T., Biekc, P.R., Mandalaz, D., & Verspohl, E.J. (1983). Adaptation of blood 
 pressure to continuous heavy coffee drinking in young volunteers.  A double-blind 
 crossover study.  British Journal of Clinical Pharmacology, 15, 701-706.   
Anderson, B. L., & Juliano, L. M. (2012). Behavior, sleep, and problematic caffeine  
consumption in a college-aged sample. Journal of Caffeine Research, 2(1), 38–44. 
Aranda, M. & Morlock, G. (2206). Simultaneous determination of riboflavin, pyridoxine, 
 nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple 
 detection with confirmation by electrospray ionization mass spectrometry.  Journal of 
 Chromatography A, 1131(1-2), 253-260. 
 
 
  114 
Arria, A. M., Bugbee, B. A., Caldeira, K. M., & Vincent, K. B. (2015). Evidence and knowledge  
gaps for the association between energy drink use and high-risk behaviors among 
adolescents and young adults. Nutrition Reviews, 72, 87–97.  
Arria, A.M., Caldeira, K.M., Kasperski, S.J., O’Grady, K.E., Vincent, K.B., Griffiths, R.R. & 
 Wish, E.D. (2010). Increased alcohol consumption, nonmedical prescription drug use, 
 and illicit drug use are associated with energy drink consumption among college students.  
 Journal of Addiction Medicine, 4(2), 74-80. 
Arria, A. M., Caldeira, K. M., Kasperski, S. J., Vincent, K. B., Griffiths, R. R., & O’Grady, K. E.  
(2010). Energy drink consumption and increased risk for alcohol 
dependence. Alcoholism: Clinical and Experimental Research, 35(2), 365–375.  
Arria, A.M. & O’Brien, M.C. (2011).  The “high” risk of energy drinks.  The Journal of the 
 American Medical Association, 305(6), 600-601. 
Arnaud, M.J. (1999). Caffeine: chemistry and physiological effects. In Sadler, M.J., Strain, J.J., 
 & Caballero, B. (Eds.), Encyclopedia of human nutrition, (pp. 206-213).  San Diego, CA: 
 Academic Press. 
Attila, S. & Çakir, B. (2011). Energy-drink consumption in college students and associated 
 factors. Nutrition, 27(3), 316-322. 
Aubin, H.J., Laureaux, C., Tilikete, S., & Barrucand, D. (1999). Changes in cigarette smoking 
 and coffee drinking after alcohol detoxification in alcoholics.  Addiction, 94(3), 411-416.   
Azagba, S., Lagnille, D., & Asbridge, M. (2014). An emerging adolescent health risk: 
 caffeinated energy drink consumption patterns among high school students.  Prevention 
 Medicine, 62, 54-59. 
  115 
Babu, K.M., Church, R.J., & Lewander, W. (2008). Energy drinks: the new eye-opener for 
 adolescents.  Clinical Pediatric Emergency Medicine, 9, 35-42. 
Back, S. E., Payne, R. L., Simpson, A. N., & Brady, K. T. (2010). Gender and prescription  
opioids: Findings from the national survey on drug use and health. Addictive 
Behaviors, 35(11), 1001–1007.  
Bailey, R. L., Saldanha, L. G., Gahche, J. J., & Dwyer, J. T. (2014). Estimating caffeine intake  
from energy drinks and dietary supplements in the United States. Nutrition Reviews, 72, 
9–13. 
Barone, J. & Roberts, H. (1996). Caffeine consumption. Food and Chemical Toxicology 34, 
 119-129.  
Beck, J.G. & Berisford, M.A. (1992). The effects of caffeine on panic patients: Response 
 components of anxiety.  Behavior Therapy, 23(3), 405-422. 
Benowitz, N.L. (1990). Clinical pharmacology of caffeine.  Annual Review of Medicine, 41, 
 277-288. 
Benowitz, N.L., Hall, S.M., & Modin, G. (1989). Persistent increase in caffeine concentrations 
 in people who stop smoking.  British Journal of Medicine, 298, 1075-1076. 
Benowitz, N., Swan, C.G., & Jacobill, P. (2006). Female sex and oral contraceptive use  
accelerate nicotine metabolism. Clinical Pharmacology & Therapeutics, 79(5), 480–488.  
Berger, L. K., Fendrich, M., Chen, H.-Y., Arria, A. M., & Cisler, R. A. (2011).  
Sociodemographic correlates of energy drink consumption with and without alcohol: 
Results of a community survey. Addictive Behaviors,36(5), 516–519. 
 
 
  116 
Bergin, J. E., & Kendler, K. S. (2012). Common psychiatric disorders and caffeine use,  
tolerance, and withdrawal: An examination of shared genetic and environmental 
effects. Twin Research and Human Genetics, 15(04), 473–482.  
Bernstein, G.A., Carroll, M.E., Thuras, P.D., Cosgrove, K.P., & Roth, M.E. (2002). Caffeine 
 dependence in teenagers. Drug and Alcohol Dependence, 66, 1–6. 
Biaggioni, I, Paul, S., Puckett, A, & Arzubiaga, C. (1991). Caffeine and theophylline as 
 adenosine receptor antagonists in humans.  Journal of Pharmacology and Experimental 
 Therapeutics, 258, 588-593.   
Blank, M.D., Kleykamp, B.A., Jennings, J.M., & Eissenberg, T. (2007). Caffeine’s influence on 
 nicotine’s effects in nonsmokers. American Journal of Health Behaviors, 31, 473–483.  
Bodenmann, S., Hohoff, C., Freitag, C., Deckert, J., Rétey, J.V., Bachmann, V., & Landolt, H.P.  
 (2011).  Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects 
 of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation.  
 British Journal of Pharmacology. 165(6), 1904-1913. 
Boomsama, D.I., Koopmans, J.R., Van Doornen, L.J., & Orlebeke, J.F. (1994). Genetic and 
 social influences on starting to smoke: a study of Dutch adolescent twins and their 
 parents.  Addiction, 89(2), 219-226. 
 Bonait, M., Latini, R., Galletti, F., Young, J.F., Tognoni, G., Garattini, S. (1982). Caffeine 
 disposition after oral doses.  Clinical Pharmacology and Therapeutics, 32(1), 98-106. 
Bonnet, M.H. & Arand, D.L. (1992). Caffeine use as a model of acute and chronic insomnia.  
 Sleep, 15, 526-536. 
  117 
Boulenger, J.P., Uhde, T.W., Wolff, E.A., 3rd, & Post, R.M. (1984). Increased sensitivity to 
 caffeine in patients with panic disorders.  Preliminary evidence.  Archives of General 
 Psychiatry, 41(11), 1067-1071. 
Boyd, E.M., Dolman, M., Knight, L.M., & Sheppard, E.P. (1965). The chronic oral toxicity of 
 caffeine.  Canadian Journal of Physiology and Pharmacology, 43, 995-1007. 
Brady, K.T. & Randall, C.L. (1999). Gender differences in substance use disorders.  Psychiatric 
 Clinics of North America, 22(2), 241-252. 
Branum, A. M., Rossen, L. M., & Schoendorf, K. C. (2014). Trends in caffeine intake among US  
children and adolescents. Pediatrics, 133(3), 386–393. 
Brauer. L.H., Buican, B., & de Wit H. (1994). Effects of caffeine deprivation on taste and mood. 
 Behavior Pharmacology, 5, 111-118. 
Brice, C.F. & Smith, A.P. (2002). Factors associated with caffeine consumption.  International 
 Journal of Food Sciences and Nutrition, 53, 55-64. 
Broderick, P. and Benjamin, A.B. (2004). Caffeine and psychiatric symptoms: a review. Journal  
of Oklahoma State Medical Association, 97(12), 538-542. 
Brown, C. R., Jacob, P. III, Wilson, M., &Benowitz, N. L. (1988). Changes in rate and pattern of 
 caffeine metabolism after cigarette abstinence. Clinical Pharmacology and Therapeutics, 
 43(5), 488-91. 
Bruce, M., Scott, N., Shine, P., & Lader, M. (1991).  Caffeine withdrawal: a contrast of 
 withdrawal symptoms in normal subjects who have abstained from caffeine for 24 hours 
 and for 7 days. Journal of Psychopharmacology, 5, 129-134. 
  118 
Bruce, M., Scott, N., Lader, M., & Marks, V.  (1986). The psychopharmacological and 
 electrophysiological effects of single doses of caffeine in healthy human subjects. British 
 Journal of Clinical Pharmacology, 22, 81-87.   
Broderick, P. & Benjamin, A.B. (2004). Caffeine and psychiatric symptoms: a review.  Journal 
 of Oklahoma State Medical Association, 97(12), 538-542. 
Butt, M.S. & Sultan, M.T. (2011). Coffee and its consumption: benefits and risks.  Critical 
 Reviews in Food Science and Nutrition, 51(4), 363-73. 
Buxton, C. & Hagan, J.E. (2012). A survey of energy drinks consumption practices among 
 student -athletes in Ghana: lessons for developing health education intervention 
 programmes.  Journal of the International Society of Sports Nutrition, 9(1), 1-9.   
Byerley, L.O. (2016). Energy Drink Consumption by Online College Students. The FASEB 
 Journal, 30(1), 898.7. 
Byrne, E.M., Johnson, J., McRae, A.F., Nyhold, D.R., Medland, S.E., Gehrman, P.R., Heath, 
 A.C., Madden, P.A., Montgomery, G.W., Chenevix-Trench, G., & Martin, N.G. (2012).  
 A genome-wide association study of caffeine-related sleep disturbance: confirmation of a 
 role for a common variant in the adenosine receptor.  Sleep, 35(7), 967-975. 
Cacciatore, R., Helbling, A., Jost, C., & Hess, B. (1996). Episodic headache, diminished 
 performance and depressive mood. Schweiz Rundsch Med Prax, 85, 727-729. 
Caldeira, K. M., Kasperski, S. J., Sharma, E., Vincent, K. B., O’Grady, K. E., Wish, E. D., &  
Arria, A. M. (2009). College students rarely seek help despite serious substance use 
problems. Journal of Substance Abuse Treatment, 37(4), 368–378.  
Carmelli, D., Swan, G.E., Robinette, D., & Fabsitz, R.R. (1990).  Heritability of substance use in 
 the NAS NRC twin registry. Acta Genet Med Gemellol, 39:91-98. 
  119 
Carney, J.M. (182). Effects of caffeine, theophylline and theobromine on scheduled controlled 
 responding in rats.  British Journal of Pharmacology, 75, 451-454. 
Carroll, M.E., Hagen, E.W., Asencio, M., & Brauer, L.H. (1989). Behavioral dependence on 
 caffeine and phencyclidine in rhesus monkeys: interactive effects.  Pharmacology 
 Biochemistry and Behavior, 31: 927-932. 
Carrillo, J.A. & Benitez, J. (200). Clinically significant pharmacokinetic interactions between 
dietary caffeine and medications.  Clinical Pharmacokinetics, 39(2), 127-53. 
Charney, D.S., Galloway, M.P., & Heninger, G.R. (1994). The effects of caffeine on plasma 
 MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans.  
 Life Science, 35, 135-144.   
Charney, D.S., Heninger, G.R., & Jatlow, P.I. (1985).  Increased anxiogenic effects of caffeine 
 in panic disorders.  Archives of General Psychiatry, 42(3), 233-243. 
Chait, L.D. & Griffiths, R.R.  (1983).  Effects of caffeine on cigarette smoking behavior and 
 subjective response.  Clinical Pharmacology and Therapeutics, 34, 612-622. 
Childs, E., Honoff, C., Deckert, J., Xu, K., Badner, J., & de Wit, H. (2008). Association 
 between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.  
 Neuropsychopharmacology, 33(12), 2791-2800. 
Chou, D.T., Khan, S., Forde, J, & Hirsh, K.R. (1985). Caffeine tolerance: behavioral, 
 electrophysiological and neurochemical evidence.  Life Science, 36, 2347-2358. 
Ciapparelli, A., Paggini, R., Carmassi, C., Taponecco, C., Consoli, G., Ciampa, G., …  
Dell’Osso, L. (2010). Patterns of caffeine consumption in psychiatric patients. An Italian 
study. European Psychiatry, 25(4), 230–235.  
 
  120 
Clayton, J.A. and Collins, F.S. (2014). NIH to balance sex in cell and animal studies. Nature,  
509, 282-283. 
Cobbs, L.W. (1982). Lethargy, anxiety, and impotence in a diabetic.  Hospital Practice, 17, 67. 
Comer, S.D., Haney, M., Foltin, R.W., & Fischman, M.W. (1997). Effects of caffeine 
 withdrawal on humans living in a residential laboratory.  Experimental and Clinical 
 Psychopharmacology, 5, 399-403. 
Conterio, F. & Chiarelli, B. (1962). Study of the inheritance of some daily life habits.  Heredity, 
 17, 347-359. 
Cook, C., Heath, F., & Thompson, R. L. (2000). A Meta-Analysis of response rates in web- or  
Internet-Based surveys. Educational and Psychological Measurement, 60(6), 821–836.  
Cooper, Z. D., & Haney, M. (2014b). Investigation of sex-dependent effects of cannabis in daily  
cannabis smokers. Drug and Alcohol Dependence, 136, 85–91. 
Cornelis, M.C., El-Sohemy, A., Kabagambe, E.K., & Campos, H.  (2006).  Coffee, CYP1A2 
 genotype, and risk of myocardial infarction. The Journal of the American Medical 
 Association, 295, 1135-1141. 
Cornelis, M.C., El-Sohemy, A., & Campos, H. (2007). Genetic polymorphism of the adenosine 
 A2A receptor is associated with habitual caffeine consumption. American Journal of 
 Clinical Nutrition, 86, 240-244. 
Couturier, E.G., Laman, D.M., van Duijn, M.A., & van Duijn, H. (1997). Influence of caffeine 
 and caffeine withdrawal on headache and cerebral blood flow velocities. Cephalalgia, 17, 
 188-190. 
Daly, J.W. (1993). Mechanism of action of caffeine.  In Garattin, S. (Eds.), Caffeine, Coffee, 
 and Health (pp. 97-150).  New York, NY: Raven Press. 
  121 
Daly, J.W. & Fredholm, B.B. (1998). Caffeine – an atypical drug of dependence.  Drug and 
 Alcohol Dependence, 51, 199-206. 
Danaro, C.P., Brown, C.R., Jacob, P., & Benowitz, N.L. (1991). Effects of caffeine with 
 repeated dosing.  European Journal of Clinical Pharmacology, 40, 273-278. 
Debry, G. (1994).  Coffee and Health. Paris, France: John Libbey. 
Demura, S., Aoki, H., Mizusawa, T., Soukura, K., Noda, M., & Sato, T. (2013). Gender  
differences in coffee consumption and its effects in young people. Food and Nutrition 
Sciences, 04(07), 748–757.  
Derogatis L.R., Lipman R.S., & Covi L. (1973). SCL-90: an outpatient psychiatric rating scale –  
preliminary report. Psychopharmacology Bulletin, 9, 13-28.  
Dews, P.B., Curtis, G.L., Hanford, K.J., & O’Brien, C.P. (1999). The frequency of caffeine 
 withdrawal in a population-based survey and in a controlled, blinded pilot experiment. 
 Journal of Clinical Pharmacology, 39,1221-1232. 
Dick, D., Nasim, A., Edwards, A.C., Salvatore, J., Cho, S.B., Adkins, A,...Kendler, K.S  (2014). 
 Spit for science: launching a longitudinal study of genetic and environmental influences 
 on substance use and emotional health at a large US university.  Frontiers in Behavioral 
 and Psychiatric Genetics, 5, 1-12.  
Dosh, T., Helmbrecht, T., Anestis, J., Guenthner, G., Kelly, T.H., & Martin, C.A.  (2010).  A 
 comparison of the associations of caffeine and cigarette use with depressive and ADHD 
 symptoms in a sample of young adult smokers.  Journal of Addiction Medicine, 4(1), 52-
 54. 
Drewnowski, A., & Rehm, C. (2016). Sources of caffeine in diets of US children and adults:  
Trends by beverage type and purchase location. Nutrients, 8(3), 154.  
  122 
Driesbach, R.H., & Pfeiffer, C. (1943) Caffeine-withdrawal headache. Journal of Laboratory 
 and Clinical Medicine, 28, 1212-1219. 
Dusseldorp, M. van. & Katan, M.B. (1990). Headache caused by caffeine withdrawal among 
 moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week 
 double blind trial. British Medical Journal, 300, 1558-1559. 
Edelstein, B.A., Keaton-Brasted, C., & Burg, M.M. (1983). The effects of caffeine withdrawal 
 on cardiovascular and gastrointestinal responses. Health Psychology, 2, 343-352. 
Emurian, H.H., Nellis, M.J., Brady, J.V., & Ray, R.L. (1982). Event time-series relationship 
 between cigarette smoking and coffee drinking. Addictive Behaviors, 7(4), 441-444. 
Evan, S.M. & Griffiths, R.R.  (1992).  Caffeine tolerance and choice in humans.  
 Psychopharmacology, 108, 51-59. 
Evans, S.M. & Griffiths, R.R. (1999) Caffeine withdrawal: a parametric analysis of caffeine 
 dosing conditions. Journal of Pharmacology and Experimental Therapeutics, 289, 285-
 294. 
Evans, S.M., Cirtchfield, T.S., & Griffiths, R.R. (1994). Caffeine reinforcement demonstrated 
 in a majority of moderate caffeine users.  Behavioral Pharmacology, 5, 231-238. 
Eysenck, H.J., & Eysenck, S.B.G. (1968). Manual for the Eysenck Personality Inventory.  San 
 Diego: Educational and Industrial Testing Service. 
Floegel, A., Pischon, T., Bergmann, M.M., Teucher, B., Kaaks, R., & Boeing, H. (2012).   
 Coffee consumption and risk of chronic disease in the European Prospective 
 Investigation into Cancer and Nutrition (EPIC)-Germany study.  The American Journal 
 of Clinical Nutrition, 95(4), 901-908. 
  123 
Finn, I.B. & Holtzman, S.G. (1986). Tolerance to caffeine-induced stimulation of locomotor 
 activity in rats.  Journal of Pharmacology and Experimental Therapeutics, 238, 542-
 546. 
Finn, I.B. & Holtzman, S.G. (1987). Pharmacologic specificity of tolerance to caffeine-induced 
 stimulation of locomotor activity.  Psychopharmacology, 93, 428-434.  
Finn, I.B. & Holtzman, S.G. (1988). Tolerance and cross-tolerance to theophylline-induced 
 stimulation of locomotor activity in rats.  Life Science, 42, 2475-2482.      
Fisone, G., Borgkvist, A., & Usiello, A. (2004). Caffeine as a psychomotor stimulant: 
 mechanism of action.  Cellular and Molecular Life Sciences, 61(7-8), 857-872).  
Franconi, F., Brunelleschi, S., Steardo, L., and Cuomo, V. (2007). Gender differences in drug  
responses. Pharmacological Research, 55(2), 81–95.  
Frary, C.D., Johnson, R.K., & Wang, M.Q. (2005) Food sources and intakes of caffeine in the 
 diets of persons in the United States.  Journal of the American Dietetic Association, 
 105(1), 110-113. 
Fredholm, B.B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E.E. (1999). Actions of caffeine 
 in the brain with special reference to factors that contribute to its widespread use.  
 Pharmacological Reviews, 51(1), 83-133. 
Friedman, H.S. (2011). Personality, disease, and Self-healing. In Friedman, H.S. (Eds.), The  
Oxford Handbook of Health Psychology, (pp. 215-240). New York, New York: Oxford 
University Press.  
 
 
 
  124 
Fulgoni, V. (2014). Intake and exposure to caffeine. Various aspects of caffeine intake in  
America: Analysis of NHANES. In: Caffeine in food and dietary supplements: 
Examining safety: Workshop Summary. Washington, DC: The National Academies 
Press, pp. 30–7. 
Fulgoni, V. L., Keast, D. R., & Lieberman, H. R. (2015). Trends in intake and sources of  
caffeine in the diets of US adults: 2001-2010. American Journal of Clinical 
Nutrition, 101(5), 1081–1087.  
Garrett, B.E. & Griffiths, R.R. (1998). Physical dependence increases the relative reinforcing 
 effects of caffeine versus placebo.  Psychopharmacology, 139, 195-202.  
Garrett, B.E. & Holtzman, S.G. (1994). Caffeine cross-tolerance to selective dopamine 
 D1 and D2 receptor agonists but not to their synergistic interaction.  European Journal of 
 Pharmacology, 262, 65-75. 
Gasior, M., Jaszyna, M., Munzar, P., Witkin, J.M., & Goldberg, S.R. (2002). Caffeine 
 potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology, 
 162, 385-395.  
Gilbert, R.M. (1984). Caffeine consumption.  Progress in clinical and biological research, 158, 
 185-213. 
Gilliland, K., and Andress, D. (1981) Ad lib caffeine consumption, symptoms of caffeinism, and  
academic performance. American Journal of Psychiatry, 138, 512–514. 
Tanner, G., & Provost, S. (2015). Delay and probability discounting: Examining the relationship  
between caffeine withdrawal and impulsivity. Frontiers in Psychology. Conference  
Abstract: 12th Annual Psychology Research Conference, 2015.  
 
  125 
Goldstein, A. (1964) Wakefulness caused by caffeine. Archives of Experimental Pathology and 
 Pharmakology, 248, 269-278. 
Goldstein, A. & Kaizer, S. (1969). Psychotropic effects of caffeine in man. III. A questionnaire 
 survey of coffee drinking and its effects in a group of housewives. Clinical 
 Pharmacology Therapeutics, 10, 477-488. 
Goldstein, A., Kaizer, S., & Whitby, O. (1969). Psychotropic effects of caffeine in man. IV. 
 Quantitative and qualitative differences associated with habituation to coffee. Clinical 
 Pharmacology and Therapeutics, 10, 489-497. 
Greden, J., Fontaine, P., Lubetsky, M., & Chamberlin, K. (1978). Anxiety and depression  
 associated with caffeinism among psychiatric inpatients. American Journal of Psychiatry, 
 135, 963-966. 
Greden, J.F. & Walters, A. (1992). Caffeine.  In Lowinson, J.H., Ruiz, P., Millman, R.B., & 
 Langrod, J.G. (Eds.), Substance abuse: a comprehensive textbook, 3rd edition, (pp. 357-
 370).  Baltimore, MD: Williams & Wilkins.   
Greden, J.F., Victor, B.S., Fontaine, P., Lubetsky, M. (1980). Caffeine withdrawal headache: a 
 clinical profile. Psychosomatics, 21, 411-413. 
Green, R.M. & Stiles, G.L. (1986). Chronic caffeine ingestion sensitizes the A1 adenosine 
 receptor-adenylate cyclase system in rat cerebral cortex.  Journal of Clinical 
 Investigation, 77, 222-227. 
Greenfield, S.F., Back, S.E., Lawson, K., & Brady, K.T. (2010). Substance abuse in women.  
 Psychiatric Clinics of North America, 33(2), 339-355. 
 
  126 
Griffiths, R.R. & Chausmer, A.L. (2000). Caffeine as a model drug of dependence: recent 
 developments in understanding caffeine withdrawal, the caffeine dependence syndrome, 
 and caffeine negative reinforcement.  Japanese Journal of Neuropsychopharmacology, 
 20, 223-231.       
Griffiths, R.R., Evans, S.M., Heishman, S.J., Preston, K.L., Sannerud, C.A., Wolf, B., Woodson, 
 P.P. (1990). Low-dose caffeine physical dependence in humans.  Journal of 
 Pharmacology and Experimental Techniques, 255, 1123-1132. 
Griffiths, R.R. & Mumford, G.K. (1996). Caffeine reinforcement, discrimination, tolerance and 
 physical dependence in laboratory animals and humans.  In Schuster, C.R. & Kuhar, M.J. 
 (Eds.), Pharmacological aspects of drug dependence: toward an integrated 
 neurobehavioral approach (pp. 315-341).  Germany: Sprinter-Verlag. 
Griffiths, R.R. & Mumford, G.K. (2000). Caffeine: a drug of abuse? In Bloom, F.E. & Kupfer, 
 D.J. (Eds.), Psychopharmacology: the 4th generation of progress (pp. 1699-1713).  New 
 York, NY: Raven Press.  
Griffiths, R.R. & Woodson, P.P. (1988a).  Reinforcing effects of caffeine in humans.  Journal of 
 Pharmacology and Experimental Therapeutics, 246, 21-29. 
Griffiths, R.R. & Woodson, P.P. (1988b). Reinforcing properties of caffeine: studies in humans 
 and laboratory animals.  Pharmacology Biochemistry and Behavior, 29, 419-427.   
Griffiths, R.R. & Woodson, P.P.  (1998c).  Caffeine physical dependence: a review of human a
 and laboratory animal studies.  Psychopharmacology, 94, 437-451. 
Griffiths, R.R., Bigelow, G.E., & Liebson, I.A. (1986a). Human coffee drinking: reinforcing 
 and physical dependence producing effects of caffeine.  Journal of Pharmacology and 
 Experimental Therapeutics, 239, 416-425.   
  127 
Griffiths, R.R., Bigelow, G.E., & Liebson, I.A. (1989). Reinforcing effects of caffeine in coffee 
 and capsules.  Journal of the Experimental Analysis of Behavior, 52, 127-140. 
Griffiths, R.R., Bigelow, G.E., Liebson, I.A., O’Keeffe, M., O’Leary, D., & Russ, N. (1986b).  
 Human coffee drinking: manipulation of concentration and caffeine dose.  Journal of the 
 Experimental Analysis of Behavior, 45(2), 133-148.   
Griffiths, R.R., Juliano, L.M., & Chausmer, A.L. (2003). Caffeine pharmacology and clinical 
 effects. In: Graham AW, Schultz TK, Mayo-Smith M, Ries RK, Wilford BB (Eds.).  
 Principles of Addiction Medicine (pp 193–224).  Chevy Chase, MD: ASAM. 
Gu, L., Gonzalez, F.J., Kalow, W., Tang, B.K. (1992). Biotransformation of caffeine, 
 paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and 
 CYP2E1.  Pharmacogenetics, 2(2), 73-77. 
Gunes, A., & Dahl, M.-L. (2008). Variation in CYP1A2 activity and its clinical implications:  
Influence of environmental factors and genetic polymorphisms. Pharmacogenomics,  
9(5), 625-637.  
Gurpegui, M., Jurado, D., Luna, J.D., Fernádez-Molina, C., Moreno-Abril, O., & Gálvez, R. 
 (2007).  Personality traits associated with caffeine intake and smoking.  Progress in 
 NeuroPsychopharmacology & Biological Psychiatry, 31(5), 997-1005.   
Hale, K.L, Hughes, J.R., Oliveto, A.H, & Higgins, S.T.  (1995). Caffeine self-administration and 
 subjective effects in adolescents.  Experimental and Clinical Psychopharmacology, 3(4), 
 364-370. 
Han, X.M., Ou-Yang, D.S., Lu, P.X., Jiang, C.H., Shu, Y., Chen, X.P., Tan, Z.R., & Zhou, H.H.   
 (2001).  Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A 
 and C734A polymorphisms of human CYP1A2.  Pharmacogenetics, 11(5), 429-435. 
  128 
Hart, P., Farrell, G.C., Cooksley, W.G., & Powell, L.W. (1976). Enhanced drug metabolism in 
 cigarette smokers.  British Journal of Medicine, 2, 147-149. 
Hartley, T. R., Lovallo, W. R., & Whitsett, T. L. (2004). Cardiovascular effects of caffeine in  
men and women. The American Journal of Cardiology, 93(8), 1022–1026. 
Hasin, D.S., O'Brien, C.P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, 
 W.M., Crowley, T., Ling, W., Petry, N.M., Schuckit, M., & Grant, B.F. (2013) DSM-5 
 criteria for substance use disorders: recommendations and rationale.  American Journal of 
 Psychiatry, 170(8), 834-851. 
Heath, A.C., Meyer, J., Eaves, L.J., & Martin, N.G. (1991). The inheritance of alcohol 
 consumption patterns in a general population twins sample: I. Multidimensional scaling 
 of quantity/frequency data.  Journal of Studies on Alcohol and Drugs, 52, 345-351.   
Heckman, M.A., Sherry, K., & De Mejia, E.G. (2010). Energy Drinks: An Assessment of Their 
 Market Size, Consumer Demographics, Ingredient Profile, Functionality, and Regulations 
 in the United States.  Comprehensive Reviews in Food Science and Food Safety, 9(3), 
 303-317. 
 Heckmon, M.A., Weil, J., & De Mejia, E.G  (2010). Caffeine (1, 3, 7-trimethylxanthine) in 
 foods: a comprehensive review on consumption, functionality, safety, and regulatory 
 matters.  Journal of Food Science, 75(3), 78-87.   
Hettema, J.M., Corey, L.A., & Kendler, K.S. (1999). A multivariate genetic analysis of the use 
 of tobacco, alcohol, and caffeine in a population based sample of male and female 
 twins. Drug Alcohol Dependence, 57, 69-78. 
Hewlett, P. & Smith, A. (2006). Acute effects of caffeine in volunteers with different patterns 
 of regular consumption.  Human Psychopharmacology, 21(3), 167-180. 
  129 
Hicks, R.A., Kilcourse, J., & Sinnott, M.A. (1983). Type A-B behavior and caffeine use in 
 college students.  Psychological Reports, 52, 338. 
Higgins, J.P., Tuttle, T.D., & Higgins, C.L. (2010). Energy beverages: content and safety.  
 Mayo Clinic Proceedings, 85(11), 1033-1041. 
Hinmarch, I., Rigney, U., Stanley, N., Quinlan, P., Rycroft, J., & Lane, J.  (2000). A 
 naturalistic investigation of the effects of day-long consumption of tea, coffee and water 
 on alertness, sleep onset and sleep quality.  Psychopharmacology, 49(3), 203-216. 
Hirsh, K. (1984). Central nervous system pharmacology of the dietary methylxanthines.  In 
 Spiller, G.A. (Eds.), The Methylxanthine Beverages and Foods: Chemistry, Consumption, 
 and Health Effects, (pp. 235-301).  New York, NY: Liss.  
Höfer, I, & Bättig, K. (1994a). Cardiovascular, behavioral, and subjective effects of caffeine 
 under field conditions. Pharmacology Biochemistry and Behavior, 48, 899-908. 
Höfer, I, & Bättig, K. (1994b). Psychophysiological effects of switching to caffeine tablets or 
 decaffeinated coffee under field conditions.  Pharmacopsychoecologia, 7, 169-177. 
Holle, C., Heimberg, R.G., Sweet, R.A., & Holt, C.S. (1995). Alcohol and caffeine use by 
 social phobics: an initial inquiry into drinking patterns and behavior.  Behavioral 
 Research and Therapy, 33(5), 561-566. 
Holtzman, S.G. (1983). Complete, reversible, drug-specific tolerance to simulation of 
 locomotor activity by caffeine.  Life Science, 33, 779-787. 
Hoyte, C.O., Albert, D., & Heard, K.J. (2013). The use of energy drinks, dietary supplements, 
 and prescription medications by United States college students to enhance athletic 
 performance.  Journal of Community Health, 38(3), 575-580. 
  130 
Hughes, J.R., Higgins, S.T., Bickel, W.K., Hunt, W.K., Fenwick, J.W., & Gulliver, S.B., & 
 Mireault, G.C. (1991). Caffeine self-administration, withdrawal, and adverse effects 
 among coffee  drinkers. Archives of General Psychiatry, 48, 611-617. 
Hughes, J.R., Hunt, W.K., Higgins, S.T., Bickel, W.K., Fenwick, J.W., & Pepper, S.L. (1991).  
 Caffeine self-administration, withdrawal, and adverse effects among coffee drinkers.  
 Archives of General Psychiatry, 48, 611-617. 
Hughes, J.R., Hunt, W.K., Higgins, S.T., Bickel, W.K., Fenwick, J.W., & Pepper, S.L. (1992a).  
 Effect of dose on the ability of caffeine to serve as a reinforcer in humans. Behavior 
 Pharmacology, 3, 211-218. 
Hughes, J.R., Oliveto, A.H., Bickel, W.K., Higgins, S.T., & Gary, J. (1995). The ability of low 
 doses of caffeine to serve as reinforces in humans: a replication.  Experimental and 
 Clinical Psychopharmacology, 3(4), 358-363. 
Hughes, J.R., Oliveto, A.H., Bickel, W.K., Higgins, S.T., & Valliere, W. (1992b). Caffeine self-
 administration and withdrawal in soda drinkers. Journal of Addiction Disorders; 4,178. 
Hughes, J.R., Oliveto, A.H., Helzer, J.E., Higgins, S.T., & Bickel, W.K. (1992c). Should 
 caffeine abuse, dependence or withdrawal be added to DSM-IV or ICD-10? American 
 Journal of Psychiatry, 149, 33-40.  
Hughes, J.R., Oliveto, A.H., Bickel, W.K., Higgins, S.T. & Badger, G.J.  (1993). Caffeine self-
 administration and withdrawal: incidence, individual differences and interrelationships. 
 Drug and Alcohol Dependence, 32, 239-246. 
 
  131 
Hughes, J.R., Oliveto, A.H., Liguori, A., Carpenter, J., & Howard, T. (1998). Endorsement of 
 DSM-IV dependence criteria among caffeine users.  Drug and Alcohol Dependence, 
 52(2), 99-107. 
International Food Information Council Foundation (IFIC). (2008) Caffeine & health: clarifying 
 the controversies.  
Irons, J. G., Bassett, D. T., Prendergast, C. O., Landrum, R. E., & Heinz, A. J. (2016).  
Development and initial validation of the caffeine consumption questionnaire-
revised. Journal of Caffeine Research, 6(1), 20–25.  
Istvan, J., & Matarazzo, J.D. (1984). Tobacco, alcohol, and caffeine use: a review of their 
 interrelationships.  Psychological Bulletin, 95(2), 301-326. 
Jacobson, B.H. & Bouher, B.J. (1991). Caffeine consumption by selected demographic 
 variables.  Health Values, 15, 49-55. 
James, J.E. (1991). Caffeine and Health.  London: Academic Press.   
James, J.E. (1998). Acute and chronic effects of caffeine on performance, mood, headache, and 
 sleep. Neuropsychobiology, 38, 32-41. 
Jarvis, M.J. (1993). Does caffeine intake enhance absolute levels of cognitive performance?  
 Psychopharmacology, 110(1-2), 45-52.   
James, J.E. & Crosbie, J. (1987). Somatic and psychological health implications of heavy 
 caffeine use.  British Journal of Addiction, 82(5), 503-509. 
Joeres, R., Klinker, H., Heusler, H., Epping, J., Zilly, W., & Richter, E. (1988). Influence of 
 smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver 
 cirrhosis.  Hepatology, 8(3), 575-579. 
  132 
Johnson, R.S., Tobin, J.W., & Cellucci, T. (1992). Personality characteristics of cocaine and 
 alcohol abusers: more alike than different.  Addictive Behaviors, 17(2), 159-166. 
Jones, H.A. & Lejuez, C.W. (2005). Personality correlates of caffeine dependence: The role of 
 sensation seeking, impulsivity, and risk taking.  Experimental and Clinical 
 Psychopharmacology, 13(3), 259-266. 
Jones, H.E., Herning, R.I., Cadet, J.L., and Griffiths, R.R.  (2000). Caffeine withdrawal 
 increases cerebral blood flow and alters quantitative electroencephalography (EEG) 
 activity.  Psychopharmacology, 147, 371-377. 
Josse, A.R., De Costa, L.A., Campos, H., & El-Sohemy, A. (2012). Associations between 
 polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine 
 consumption.  American Journal of Clinical Nutrition, 96(3), 665-671. 
Julian, R.M., Advokat, C.D., & Comaty, J.E. (2011). A primer of drug action: a 
 comprehensive guide to the actions, uses, and side effects of psychoactive drugs,  (pp. 
 361-368).  New York, NY: Worth Publishers.      
Juliano, L.M., Huntley, E.D., Harrell, P.T., & Westerman, A.T. (2012). Development of the 
 caffeine withdrawal symptom questionnaire: caffeine withdrawal symptoms cluster into 7 
 factors.  Drug and Alcohol Dependence, 124(3), 229-234. 
Juliano, L,M., & Griffiths, R.R. (2004). A critical review of caffeine withdrawal: empirical 
 validation of symptoms and signs, incidence, severity, and associated features.  
 Psychopharmacology, 176, 1-29. 
Juliano, L.M., Ferré, S., & Griffiths, R.R. (2009). The pharmacology of caffeine.  In Ries, R.K., 
 Miller, S.C., & Fiellin, D.A. (Eds.), Principals of addiction medicine, (pp. 159-178).  
 Philadelphia, PA: Lippincott Williams & Wilkins.   
  133 
Juliano, L.M., Ferré, S., & Griffiths, R.R. (2014). The pharmacology of caffeine.  In Ries, R.K., 
 Fiellin, D.A., Miller, S.C., & Saitz, R. (Eds.), The ASAM principals of addiction 
 medicine (pp. 180-200).  Chevy Chase, MD: ASAM. 
Kaplan, G.B., Creenblatt, D.J., Kent, M.A., & Cotreau-Bibbo, M.M. (1993). Caffeine treatment 
 and withdrawal in mice: relationships between dosage, concentrations, locomotor activity 
 and A1 adenosine receptor bind.  Journal of Pharmacology and Experimental 
 Therapeutics, 266, 1563-1572.     
Kaprio, J., Sarna, S., Koskenvuo, M., & Rantasalo, I. (1978). The Finnish Twin Registry: 
 Baseline Characteristics, Section II. Helsinki, University of Helsinki Press. 
Kaster, M. P., Machado, N. J., Silva, H. B., Nunes, A., Ardais, A. P., Santana, M., Baqi, Y.,  
Müller, C. E., Rodrigues, A. L. S., Porciúncula, L. O., … Cunha, R. A. (2015). Caffeine 
acts through neuronal adenosine A 2A receptors to prevent mood and memory 
dysfunction triggered by chronic stress. Proceedings of the National Academy of 
Sciences, 112(25), 7833–7838.  
Kendler, K.S., Prescott, C.A. (1999). Caffeine intake, tolerance, and withdrawal in women: a 
 population-based twin study. American Journal of Psychiatry, 156, 223-228. 
Kendler, K.S., Chen, X., Dick, D., Maes, H., Gillespie, N., Neale, M.C., & Riley, B. (2012).  
 Recent advances in the genetic epidemiology and molecular genetics of substance use 
 disorders.  Nature Neuroscience, 15(2) 181-9.  
Kendler, K.S., Heath, A.C., Neale, M.C., Kessler, R.C., & Eaves, L.J. (1992). A population 
 based twin study of alcoholism in women.  The Journal of the American Medical 
 Association, 268, 1877-1882. 
  134 
Kendler, K.S., Myers, J., & Gardner, O.C. (2006). Caffeine intake, toxicity and dependence and 
 lifetime risk for psychiatric and substance use disorders: an epidemiologic and co-twin 
 control analysis.  Psychological Medicine, 36(12), 1717-1725.   
Kendler, K.S., Myers, J., & Prescott, C.A. (2005). Sex differences in the relationship between 
 social support and risk for major depression: a longitudinal study of opposite-sex twin 
 pairs.  American Journal of Psychiatry, 162(2), 250-256.   
Keogh, E., & Witt, G. (2001). Hypoalgesic effect of caffeine in normotensive men and women.  
Psychophysiology, 38(6), 886–895.  
Khan, S. S., Secades-Villa, R., Okuda, M., Wang, S., Pérez-Fuentes, G., Kerridge, B. T., &  
Blanco, C. (2013). Gender Differences in Cannabis Use Disorders: Results from the 
National Epidemiologic Survey of Alcohol and Related Conditions. Drug and Alcohol 
Dependence, 130(0), 101-108.  
Knight, C.A., Knight, I., Mitchell, D.C., & Zepp, J.E. (2004). Beverage caffeine intake in US 
 consumers and subpopulations of interest: estimates from the Share of Intake Panel 
 survey.  Food and Chemical Toxicology, 42, 1923-1930. 
Knight, J. R., Wechsler, H., Kuo, M., Seibring, M., Weitzman, E. R., & Schuckit, M. A. (2002).  
Alcohol abuse and dependence among U.S. College students. Journal of Studies on 
Alcohol, 63(3), 263–270.  
Kozlowski, LT., Henningfield, J.E. Keenan, R.M., Lei, H., Leigh, G., Jelinek, L.C., Pope, M.A., 
 & Haertzen, C.A. (1993). Patterns of alcohol, cigarette, and caffeine and other drug use 
 in two drug abusing populations.  Journal of Substance Abuse Treatment, 10(2), 171-179. 
Lader, M., Cardwell, C., Shine, P., & Scott, N. (1996). Caffeine withdrawal symptoms and rate 
 of metabolism. Journal of Psychopharmacology, 10,110–118. 
  135 
Lamarine, R.J. (1998). Caffeine as an ergogenic aid.  In Spiller, G.A. (Eds.), Caffeine.  Boca 
 Raton, FL: CRC Press.   
Landrum, R.E. (1992). College students’ use of caffeine and its personality.  College Student 
 Journal, 26, 151-155. 
Lane, J.D. (1994). Neuroendocrine responses to caffeine in the work environment. 
 Psychosomatic Medicine, 56, 267-270. 
Lane, J.D. (1997). Effects of brief caffeinated-beverage deprivation on mood, symptoms, and 
 psychomotor performance. Pharmacology Biochemistry and Behavior, 58, 203-208. 
Lane, J.D. & Phillips-Bute, B.G. (1998). Caffeine deprivation affects vigilance performance and 
 mood. Physiology & Behavior, 65, 171-175. 
Lee, M.A., Cameron, O.G., & Greden, J.F. (1985). Anxiety and caffeine consumption in people 
 with anxiety disorders.  Psychiatry Research, 15(3), 211-217. 
Lee, M.A., Flegel, P., Greden, J.F., & Cameron, O.G. (1988). Anxiogenic effects of caffeine on 
 panic and depressed patients.  American Journal of Psychiatry, 145(5), 632-635. 
Lee, K. A., Mcenany, G., & Weekes, D. (1999). Gender differences in sleep patterns for early  
adolescents. Journal of Adolescent Health, 24(1), 16–20.  
Lerman, C., Tyndale, R., Patterson, F., Wileyto, E., Shields, P., Pinto, A., and Benowitz, N.  
(2006). Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking 
cessation. Clinical Pharmacology & Therapeutics, 79(6), 600–608.  
Lieberman, H., Marriott, B., Judelson, D., Glickman, E., Geiselman, P., Giles, G, & Mahoney, C.  
(2015). Intake of caffeine from all sources including energy drinks and reasons for use in 
US college students. The FASEB Journal, 29(1), 392.1. 
  136 
Lieberman, H.R., Stavinoha, T., McGraw, S., White, A., Hadden, L., & Marriott, B.P. (2012). 
 Caffeine use among active duty US Army soldiers.  Journal of the Academy of Nutrition 
 and Dietetics, 112(6), 902-912. 
Liguori, A. & Hughes, J.R. (1997). Caffeine self-administration in humans: 2. a within-subjects 
 comparison of coffee and cola vehicles.  Experimental and Clinical 
 Psychopharmacology, 5(3), 295-303. 
Liguori, A., Grass, J.A., & Hughes, J.R. (1999). Subjective effects of caffeine among introverts 
 and extraverts in the morning and evening.  Experimental and Clinical 
 Psychopharmacology, 7(3), 244-249. 
Liguori, A., Hughes, J.R., & Oliveto, A.H. (1997). Caffeine self-administration in humans: 1. 
 efficacy of cola vehicle.  Experimental and Clinical Psychopharmacology, 5(3), 286-294.  
Liu, X. & Jernigan, C. (2012). Effects of caffeine on persistence and reinstatement of nicotine-
 seeking behavior in rats: interaction with nicotine-associated cues.  Psychopharmacology, 
 220(3), 541-550. 
Lovallo, W. R., Farag, N. H., Vincent, A. S., Thomas, T. L., & Wilson, M. F. (2006). Cortisol  
responses to mental stress, exercise, and meals following caffeine intake in men and 
women. Pharmacology Biochemistry and Behavior, 83(3), 441–447.  
Lucas, M., Mirzaei, F., Pan, A., Okereke, O.I., Willett, W.C., O'Reilly, É.J,, Koenen, K., & 
 Ascherio, A. (2011). Coffee, caffeine, and risk of depression among women.  Archives 
 of Internal Medicine, 171(17), 1571-1578. 
Lundsberg, L.S. (1998). Caffeine Consumption.  In Spiller, G.A. (Eds.), Caffeine. Boca Raton, 
 FL: CRC Press.   
  137 
Maughan , R.J. & Griffin, J. (2003). Caffeine ingestion and fluid balance: a review.  Journal of 
 Human Nutrition and Dietetics, 16(6), 411-420. 
Malinauskas, B.M., Aeby, V.G., Overton, R.F., Carpenter-Aeby, T., & Barber-Heidal, K.  
 (2007). A survey of energy drink consumption patterns among college students.  
 Nutrition Journal, 6, 335-42. 
Marczinski, C. A. (2011). Alcohol mixed with energy drinks: Consumption patterns and  
motivations for use in U.S. College students. International Journal of Environmental 
Research and Public Health, 8(12), 3232–3245.  
Masdrakis, V.G., Papakostas, Y.G., Vaidakis, N., Papageorgiou, C., & Phlivanidis, A. (2008).  
 Caffeine challenge in patients with panic disorder: baseline differences between those 
 who panic and those who do not.  Depression and Anxiety, 25(9), E72-E79. 
McCusker, R.R., Goldberger, B.A., & Cone, E.J. (2006). Caffeine content of energy drinks, 
 carbonated sodas, and other beverages.  Journal of Analytical Toxicology, 30(2), 11-114. 
McIlvain, G. E., Noland, M. P., & Bickel, R. (2011). Caffeine consumption patterns and beliefs  
of college freshmen. American Journal of Health Education, 42(4), 235–244.  
Meredith, S.E., Juliano, L.M., Hughes, J.R., & Griffiths, R.R. (2013). Caffeine use disorder: A 
 comprehensive review and research agenda. Journal of Caffeine Research, 3(3), 114-
 130. 
Mickey R.M & Greenland S. (1989). The impact of confounder selection criteria on effect 
 estimation.  American Journal of Epidemiology, 129(1), 125-137. 
Miller, K.E. (2008a). Energy drinks, race, and problem behaviors among college students.  The 
 Journal of Adolescent Health, 43(5), 490-497. 
 
  138 
Miller, K. E. (2008b). Wired: Energy drinks, jock identity, masculine norms, and risk  
taking. Journal of American College Health, 56(5), 481–490.  
Mitchell, S.H., de Wit, H., & Zacny, J.P. (1995). Caffeine withdrawal symptoms and self-
 administration following caffeine deprivation.  Pharmacology Biochemistry and 
 Behavior, 51(4), 941-945. 
Mitchell, D.C., Knight, C.A., Hockenberry, J., Teplansky, R., & Hartman, T.J. (2014).  
 Beverage caffeine intakes in the U.S.  Food and Chemical Toxicology, 63, 136-142. 
Mumford, G.K., Neil, D.B., & Holzman, S.G. (1988). Caffeine elevates reinforcement 
 threshold for electrical brain stimulation: tolerance and withdrawal changes.  Brian 
 Research, 459, 163-167. 
Mumin, A., Akhter, K.F., Abedin, Z., & Hossain, Z. (2006). Determination and characterization 
 of caffeine in tea, coffee and soft drinks by solid phase extraction and high performance 
 liquid chromatography (SPE-HPLC). Malaysian Journal of Chemistry, 8(1): 045-051. 
Murphy, T.L., Mcivor, C., Yap, A., Cooksley, W.G., Halliday, J.W., & Powell, L.W. (1988).  
 The effect of smoking of caffeine elimination: implications for its use as a 
 semiquantitative test of liver function.  Clinical Experimental Pharmacology and 
 Physiology, 15(1), 9-13. 
Naismith, D.J., Akinyanju, P.A., Szanto, S., Yudkin, J. (1970). The effect, in volunteers, of 
 coffee and decaffeinated coffee on blood glucose, insulin, plasma lipids and some factors 
 involved in blood clotting. Nutrition Metabolism, 12, 144-151. 
Nastase, A., Ioan, S., Braga, R.I., Zagrean, L., & Moldovan, M. (2007). Coffee drinking 
 enhances the analgesic effect of cigarette smoking.  Neuroreport, 18(9), 921-924. 
  139 
Nawrot, P., Jordan, S., Eastwood, J., Rotstein, J., Hugenholtz, A., & Feeley, M. (2003). Effects 
 of caffeine on human health.  Food Additives and Contaminants.  20(1), 1-30. 
Nehlig A. (1999).  Are we dependent upon coffee and caffeine? A review on human and animal 
 data.  Neuroscience and Biobehavior Review, 23, 563-576. 
Nehlig, A. & Debry, G. (1994). Potential teratogenic and neurodevelopmental consequences of  
 coffee and caffeine exposure: a review on human and animal data. Neurotoxicology and  
 Teratology, 16(6) 5311-543.  
Nehlig, A., Daval, J.L., & Debry, G. (1992). Caffeine and the central nervous system: 
 mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain 
 Research Reviews, 17, 139-170. 
Nordt, S. P., Vilke, G. M., Clark, R. F., Lee Cantrell, F., Chan, T. C., Galinato, M., … Castillo,  
E. M. (2012). Energy drink use and adverse effects among emergency department 
patients. Journal of Community Health, 37(5), 976–981.  
Norton, T.R., Lazev, A.B., & Sullivan, M.J. (2011). The “buzz” on caffeine: patters of caffeine 
 use in a convenience sample of college students.  Journal of Caffeine Research, 1(1), 35-
 40. 
Oberstar, J.V., Bernstein, G.A., & Thuras, P.D. (2002). Caffeine use and dependence in 
 adolescents: one-year follow-up.  Journal of Child and Adolescent Psychopharmacology, 
 12, 127-135. 
O’Brien, M. C., McCoy, T. P., Rhodes, S. D., Wagoner, A., & Wolfson, M. (2008). Caffeinated  
cocktails: Energy drink consumption, high-risk drinking, and alcohol-related 
consequences among college students. Academic Emergency Medicine, 15(5), 453–460.  
  140 
Ogawa, N, & Ueki, H. (2007). Clinical importance of caffeine dependence and abuse.  
 Psychiatry and Clinical Neuroscience, 61, 263-268. 
Oliveto, A.H., Bickel, W.K., Hughes, J.R., Terry, S.Y., Higgins, S.T., & Badger, G.J. (1993).  
 Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of 
 theophylline, methylphenidate and buspirone.  Behavioral Pharmacology, 4, 237-246. 
Oliveto, A.H., Hughes, J.R., Higgins, S.T., Bickel, W.K., Pepper, S.L., Shea, P,J,, & Fenwick, 
 J.W. (1992a). Forced-choice versus free-choice procedures: caffeine self-administration 
 in humans. Psychopharmacology, 109, 85-91. 
Oliveto, A.H., Hughes, J.R., Pepper, S.L., Bickel, W.K., & Higgins, S.T. (1992b). Low doses of 
 caffeine can serve as reinforcers in humans.  In Harris, L.S. (Eds.), Problems of Drug 
 Dependence, (pp. 442).  Washington DC:U.S. Government Printing Office. 
Packaged Facts. (2013). Energy Drinks and Shots: U.S. Market Trends.  Retrieved from 
 http://www.packagedfacts.com/Energy-Drinks-Shots-7124908/. 
Palatini, P., Ceolotto, G., Ragazzo, F., Dorigattie, F., Saladini, F., Papparelle, I., Mos, L., Zanata, 
 G., & Santonastaso, M. (2009). CYP1A2 genotype modifies the association between 
 coffee intake and the risk of hypertension.  Journal of Hypertension, 27(8), 1594-1601. 
Pallanti, S., Bernardi, S., & Quercioli, L. (2006). The shorter PROMIS questionnaire and the  
Internet addiction scale in the assessment of multiple addictions in a high-school 
population: Prevalence and related disability. CNS Spectrums, 11(12), 966–974.  
Partanen, J., Bruun, K., & Markkanen, T. (1966). Inheritance of Drinking Behavior. Helsinki, 
 Finnish Foundation for Alcohol Studies. 
  141 
Patwardhan, R.V., Desmond, P.V., Johnson, R.F., & Schenker, S. (1980). Impaired elimination 
 of caffeine by oral contraceptive steroids.  Journal of Laboratory and Clinical Medicine, 
 95(4), 603.608. 
Penolazzi, B., Natale, V., Leone, L., & Russo, P.M. (2012). Individual differences affecting 
 caffeine intake.  Analysis of consumption behaviours for different times of day and 
 caffeine sources.  Appetite, 58(3), 971-977. 
Perkins, K.A., Fonte, C., Stolinski, A., Blakesley-Ball, R., & Wilson, A.S. (2005). The 
 influence of caffeine on nicotine’s discriminative stimulus, subjective, and reinforcing 
 effects. Experimental Clinical Psychopharmacology, 13, 275-281. 
Peterson, E.A. (2013). Caffeine Catastrophe: Energy Drinks, Products Liability, and Market 
 Strategy.  International Journal of Marketing Studies, 5(2), 50-58. 
Pettit, M., & DeBarr, K. (2011). Perceived stress, energy drink consumption, and academic  
performance among college students. Journal of American College Health, 59(5), 335–
341.  
Phillips-Bute, B.G. & Lane, J.D. (1998). Caffeine withdrawal symptoms following brief 
 caffeine deprivation. Physiology & Behavior, 63, 35-39. 
Pickens R.W., Elmer, G.I., LaBuda, M.C., & Uhl, G.R. (1996). Genetic vulnerability to 
 substance abuse.  In Schuster, C.R. & Kuhar, M.J. (Eds.), Pharmacological aspects of 
 drug dependence: toward an integrated neurobehavioral approach (pp. 3-52).  Germany: 
 Sprinter-Verlag.  
Pickering, A. D., and Gray, J. A. (1999). The neuroscience of personality. In L. Pervin and O.  
John (Eds.), Handbook of personality, (pp. 277–299). New York, NY: Guilford Press. 
 
  142 
Poulos, N. S., & Pasch, K. E. (2015). Socio-demographic differences in energy drink  
consumption and reasons for consumption among US college students. Health Education 
Journal, 75(3), 318–330.  
Primavera, L.H., Simon, W.E., & Camisa, J.M. (1975). An investigation of personality and 
 caffeine use.  British Journal of Addiction to Alcohol and other drugs, 70(2), 213-215. 
Rainey, J.T. (1985).  Headache related to chronic caffeine addiction. Texas Dental Journal, 102, 
 29–30. 
Reeves, R.R., Struve, F.A., & Patrick, G. (1997). Somatic dysfunction increase during caffeine 
 withdrawal. Journal of the American Osteopathic Association, 97, 454-456. 
Rétey, J.V., Adam, M., Khatami, R., Luhmann, U.F., Jung, H.H., Berger, W., & Landolt, H.P.   
 (2007). A genetic variation in the adenosine A2A receptor gene (ADORA2A) 
 contributes to individual sensitivity to caffeine effects on sleep.  Clinical Pharmacology 
 and Therapeutics, 81(5), 692-298. 
Revelle, W., Humphreys, M.S., Simon, L., & Gilliland, K. (1980). The interactive effects 
 of personality, time of day, and caffeine. Journal of Experimental Psychology: General, 
 109(1), 1–31. 
Richards, G., & Smith, A. (2015). Caffeine consumption and self-assessed stress, anxiety, and  
depression in secondary school children. Journal of Psychopharmacology, 29(12), 1236–
1247.  
Richards, J.B., Zhang, L., Mitchell, S.H., & de Wit, H. (1999). Delay or probability discounting 
 in a model of impulsive behavior: effect of alcohol.  Journal of the Experimental Analysis 
 of Behavior, 71(2), 121-143. 
  143 
Richardson, N.J., Rogers, P.J., Elliman, N.A., & O’Dell, R.J. (1995). Mood and performance 
 effects of caffeine in relation to acute and chronic caffeine deprivation. Pharmacology 
 Biochemistry and Behavior, 52, 313-320. 
Rihs, M., Muller, C., & Baumann, P. (1996). Caffeine consumption in hospitalized psychiatric 
 patients.  European Archives of Psychiatry and Clinical Neuroscience, 246(2), 83-92. 
Rizzo, A.A., Stamps, L.E., & Fehr, L.A. (1988). Effects of caffeine withdrawal on motor 
 performance and heart rate changes.  International Journal of Psychophysiology, 6, 9-14.  
Reissig, C.J., Strain, E.C., & Griffiths, R.R.  (2009).  Caffeinated energy drinks – a growing 
 problem.  Drug and Alcohol Dependence, 99(1-3), 1-10. 
Rétey, J. V., Adam, M., Khatami, R., Luhmann, U. F. O., Jung, H. H., Berger, W., & Landolt,  
H.-P. (2007). A genetic variation in the Adenosine A2A receptor gene (ADORA2A) 
contributes to individual sensitivity to caffeine effects on sleep. Clinical Pharmacology & 
Therapeutics, 81(5), 692–698.  
Robertson, D., Wade, D., Workman, R, Woosley, R.L., & Oates, J.A. (1981). Tolerance to the 
 humoral and hemodynamic effects of caffeine in man.  Journal of Clinical Investigation, 
 67, 1111-1117. 
Rodenburg, E.M., Eijgelsheim, M., Geleijnse, J.M., Amin, N., van Duijn, C.M., Hofman, A., 
 Uitterlinden, A.G., Stricker, B.H., & Visser, L.E. (2012). CYP1A2 and coffee intake 
 and the modifying effect of sex, age, and smoking.  American Journal of Clinical 
 Nutrition, 96(1), 182-187. 
 
 
  144 
Rogers, P.J., Hohoff, C., Heatherley, S.V., Mullings, E.L., Maxfield, P.G., Evershed, R.P., 
 Deckert, J., & Nutt, D.J. (2010). Association of the anxiogenic and alerting effects of 
 caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine 
 consumption.  Neuropsychopharmacology, 35(9), 1973-1983. 
Rogers, P.J., Richardson, N.J., & Elliman, N.A. (1995). Overnight caffeine abstinence and 
 negative reinforcement of preference for caffeine-containing drinks. 
 Psychopharmacology, 120, 457-462. 
Roller, L. (1981). Caffeinism: subjective quantitative aspect of withdrawal syndrome. The 
 Medical Journal of Australia, 1, 146. 
Roth, M., Cosgrove, K., & Carroll, M. (2004). Sex differences in the vulnerability to  
drug abuse: A review of preclinical studies. Neuroscience & Biobehavioral 
Reviews, 28(6), 533–546.  
Rush, C.R., Sullivan, J.T., & Griffiths, R.R. (1995). Intravenous caffeine in stimulant drug 
 abusers: subjective reports and physiological effects. Journal of Pharmacology and 
 Experimental Therapeutics, 273, 351-358. 
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999). Functional significance of a C–>A 
 polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. 
 British Journal of Clinical Pharmacology, 47, 445-449.   
Schuh, K.J. & Griffiths, R.R. (1997). Caffeine reinforcement: the role of withdrawal.  
 Psychopharmacology, 130, 320-326.  
Schubert, M.M., Astorino, T.A., & Azevedo, J.L. (2013). The effects of caffeinated “energy 
 shots” on time trial performance.  Nutrients, 5(6), 2062-2075. 
  145 
Seifert, S.M., Schaechter, J.L., Hershorin, E.R., & Lipshultz, S.E. (2011). Health effects of 
 energy drinks on children, adolescents, and young adults.  Pediatrics, 127(3), 511-528. 
Sher, K. J., Bartholow, B. D., & Wood, M. D. (2000). Personality and substance use disorders: A  
prospective study. Journal of Consulting and Clinical Psychology, 68(5), 818–829.  
Shi, J., Benowtize, N.L., Denaro, C.P., & Sheiner, L.B. (1993). Pharmacokinetic-
 pharmacodynamic modeling of caffeine: tolerance to pressor effects.  Clinical 
 Pharmacology and Therapeutics, 53, 6-14. 
Shoaib, M., Swanner, L.S., Yasar, S., Goldberg, S.R  (1999). Chronic caffeine exposure 
 potentiates nicotine self-administration in rats. Psychopharmacology, 142, 327-333.  
Sigmon, S.C., Herning, R.I., Better, W., Cadet, J.L, & Griffiths, R.R. (2009). Caffeine 
 withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic 
 administration: cerebral blood flow velocity, quantitative EEG, and subjective effects.  
 Psychopharmacology, 204(4), 573-585. 
Silverman, K., Evans, S.M., Strain, E.C., & Griffiths, R.R. (1992). Withdrawal syndrome after 
 the double-blind cessation of caffeine consumption.  The New England Journal of 
 Medicine, 327, 1109-1114. 
Silverman, K., Mumford, G.K., & Griffiths, R.R. (1994). Enhancing caffeine reinforcement by 
 behavioral requirements following drug ingestion.  Psychopharmacology, 114, 424-432. 
Simon, M. and Mosher, J. (2007). Alcohol, energy drinks, and youth: A dangerous mix. Marin  
Institute; San Rafael CA: 2007. [Accessed on June 28, 2016 from 
http://www.marininstitute.org/alcopops/resources/EnergyDrinkReport.pdf. 
 
  146 
Sinha, R., Cross, A.J., Daniel, C.R., Graubard, B.I., Wu, J.W., Hollenbeck, A.R., Gunter, M.J., 
 Park, Y., & Freedman, N.D. (2012). Caffeinated and decaffeinated coffee and tea  intakes 
 and risk of colorectal cancer in a large prospective study.  The American Journal  of 
 Clinical Nutrition, 96(2), 374-378. 
Sinton, C.M. & Petitjean, F. (1989). The influence of chronic caffeine administration on sleep 
 parameters in the cat.  Pharmacology Biochemistry and Behavior, 32, 459-462. 
Skewes, M. C., Decou, C. R., & Gonzalez, V. M. (2013). Energy drink use, problem drinking  
and drinking motives in a diverse sample of Alaskan college students. International 
Journal of Circumpolar, 72: 21204 - http://dx.doi.org/10.3402/ijch.v72i0.21204 
Smillie, L.D. & Gökçen E. (2010). Caffeine enhances working memory for extraverts.  
 Biological Psychology, 85(3), 496-498. 
Smith, A. (2002). Effects of caffeine on human behavior.  Food and Chemical Toxicology, 40, 
 1243-1255. 
Smith, A. (2005). Caffeine. In Lieberman, H.R., Kanarek, R.B., & Prasad, C. (Eds.), 
 Nutritional Neuroscience (pp. 341-362).  Boca Raton, FL: CRC Press. 
Smith, A.P. (2012). Caffeine, extraversion and working memory.  Journal of 
 Psychopharmacology, 27(1), 71-76. 
Smith, B.D. & Tola, K. (1998). Caffeine: effects on psychological functioning and 
 performance.  In Spiller, G.A. (Eds.), Caffeine. Boca Raton, FL: CRC Press.   
Smith, B.D., Wilson, R.J., & Jones, B.E. (1983). Extraversion and multiple levels of caffeine-
 induced arousal: Effects on overhabituation and dishabituation. Psychophysiology, 20, 
 29-34. 
 
  147 
Sojar, S. H., Shrier, L. A., Ziemnik, R. E., Sherritt, L., Spalding, A. L., & Levy, S. (2015).  
Symptoms attributed to consumption of Caffeinated beverages in adolescents. Journal of 
Caffeine Research, 5(4), 187–191.  
Somogyi, L.P. (2010). Caffeine intake by the U.S. population.  United States Food and Drug 
 Administration.  Retrieved from 
 http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofFoods/CFSAN/CFSA
 NFOIAElectronicReadingRoom/UCM333191.pdf.    
Spiller, G.A. (1998). Basic metabolism and physiological effects of the methylxanthines.  In 
 Spiller, G.A. (Eds.), Caffeine. Boca Raton, FL: CRC Press.   
St. Claire, L., Hayward, R. C., & Rogers, P. J. (2010). Interactive effects of caffeine  
consumption and stressful circumstances on components of stress: Caffeine makes men  
less, but women more effective as partners under stress. Journal of Applied Social 
Psychology, 40(12), 3106–3129.  
Stern, K.N., Chait, L.D., & Johanson, C.E. (1989). Reinforcing and subjective effects of 
 caffeine in normal human volunteers.  Psychopharmacology, 98, 81-88. 
Strain, E.C., Mumford, G.K., Silverman, K., Griffiths, R.R. (1994). Caffeine dependence 
 syndrome: Evidence from case histories and experimental evaluation. The Journal of the 
 American Medical Association, 272, 1043-1048. 
Streufert, S., Pogash, R., Miller, J., Gingrich, D., Landis, R., Lonardi, L., Severs, W., Roache, 
 J.D. (1995). Effects of caffeine deprivation on complex human functioning. 
 Psychopharmacology, 118, 377-384. 
Stringer, K.A. & Watson, W.A. (1987). Caffeine withdrawal symptoms.  American Journal of 
 Emergency Medicine, 5, 469. 
  148 
Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral 
 Health Statistics and Quality. Rockville, MD: The DAWN Report: Update on Emergency 
 Department Visits Involving Energy Drinks: A Continuing Public Health Concern; 2013 
 January 10. Retrieved from http:// www.samhsa.gov/data/2k13/DAWN126/sr126-
 energydrinks-use.pdf. 
Substance Abuse and Mental Health Services Administration. (2016). Age- and Gender-Based  
Populations. Available at http://www.samhsa.gov/specific-populations/age-gender-based. 
Svikis, D.S., Berger, N., Haug, N.A., Griffiths, R.R. (2005). Caffeine dependence in c
 combination with a family history of alcoholism as a predictor of continued use of  
caffeine during pregnancy. American Journal of Psychiatry, 162, 2344-2351. 
Swan, G.E., Carmelli, D., & Cardon, L.R. (1996). The consumption of tobacco, alcohol, and 
 coffee in Caucasian male twins: a multivariate genetic analysis.  Journal of Substance 
 Abuse, 8(1), 19-31. 
Swan, G.E., Carmelli, D., & Cardon, L.R. (1996). Heavy consumption of cigarettes, alcohol 
 and coffee in male twins.  Journal of Studies on Alcohol, 58(2), 182-190.   
Swanson, J.A., Lee, J.W., & Hopp, J.W. (1994). Caffeine and nicotine: a review of their joint 
 use and possible interactive effects in tobacco withdrawal.  Addictive Behaviors, 19(3), 
 229-256. 
Swerdlow, N.R., Eastvold, A., Gerbranda, T., Uyan, K.M., Hartman, P., Doan, Q., & Auerbach, 
 P. (2000). Effects of caffeine on sensorimotor gating of the startle reflex in normal 
 control subjects: impact of caffeine intake and withdrawal. Psychopharmacology, 151, 
 368-378. 
  149 
Tanda, G. & Goldberg, S.R. (2000). Alteration of the behavioral effects of nicotine by chronic 
 caffeine exposure. Pharmacology Biochemistry and Behavior, 66, 47-64.  
Tarka, S.M. & Hurst, J.W. (1998). Introduction to the chemistry, isolation, and biosynthesis of 
 methylxanthines.  In Spiller, G.A. (Eds.), Caffeine. Boca Raton, FL: CRC Press.   
Temple, J.L. (2009). Caffeine use in children: what we know, what we have left to learn, and 
 why we should worry.  Neuroscience and Biobehavioral Reviews, 33(6), 793-806. 
Temple, J.L., Dewey, A.M., & Briatico, L.N. (2010). Effects of acute caffeine administration 
 on adolescents.  Experimental Clinical Psychopharmacology, 18(6), 510-520. 
Temple, J.L., Bulkley, A.M., Briatico, L., & Dewey, A.M. (2009). Sex differences in reinforcing 
 value of caffeinated beverages in adolescents. Behavioral Pharmacology, 20, 731-741. 
Temple, J. L., Ziegler, A. M., Graczyk, A., Bendlin, A., Sion, T., & Vattana, K. (2014).  
Cardiovascular responses to caffeine by gender and Pubertal stage. Pediatrics, 134(1), 
e112–e119.  
Temple, J.L. & Ziegler, A.M. (2011). Gender differences in subjective and physiological 
 responses to caffeine and the role of steroid hormones.  Journal of Caffeine Research, 
 1(1), 41-48. 
Terry-McElrath, Y., O'Malley, P.M., & Johnston, L. (2014). Energy drinks, soft drinks, and 
 substance use among United States secondary school students.  Journal of Addiction 
 Medicine, 8(1), 6-13. 
Tinley, E.M., Yeomans, M.R., & Durlach, P.J. (2003). Caffeine reinforces flavour preference in 
 caffeine-dependent, but not long-term withdrawn, caffeine consumers. 
 Psychopharmacology, 166, 416-423. 
  150 
Trapp, G.S., Allen, K., O’Sullivan, T.A., Robinson, M., Jacoby, P., & Oddy, W.H. (2013).  
 Energy drink consumption is associated with anxiety in Australian young adult males.  
 Depression and Anxiety, 31(5), 420-428. 
Tsuang, M.T., Lyons, M.J., Eisen, S.A., Goldberg, J., True, W., Meyer, J.M., Toomey, R., 
 Faraone, S.V., & Eaves, L. (1996). Genetic influences on DSM-III-R drug abuse and 
 dependence: a study of 3,372 twin pairs.  American Journal of Medical Genetics, 67(5), 
 473-477. 
Uhde, T.W. (1990). Caffeine provocation on panic: a focus on biological mechanisms.  
 Neurobiology of Panic Disorder, (pp. 219-242).  New York, NY: Liss. 
United States Food and Drug Administration. (2013).Retrieved from 
 http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm350570.htm.  
Van Soeren, M.H. & Graham, T.E. (1998). Effect of caffeine on metabolism, exercise endurance, 
 and catecholamine responses after withdrawal. Journal of Applied Physiology, 85, 1493-
 1501. 
Velazquez, C.E., Poulos, N.S., Latimer, L.A., & Pasch, K.E.  (2012). Associations between 
 energy drink consumption and alcohol use behaviors among college students.  Drug and 
 Alcohol Dependence, 123(1-3), 167-172. 
Veleber, D.M. & Templer, D.I. (1984). Effects of caffeine on anxiety and depression.  Journal 
 of Abnormal Psychology, 93(1), 120-122. 
Vitiello, M.V. & Woods, S.C. (1977). Evidence for withdrawal from caffeine by rats.  
 Pharmacology Biochemistry and Behavior, 5, 343-348. 
Von Borstel, R.W., Wurtman, R.J, & Conlay, L.A. (1983). Chronic caffeine consumption 
 potentiates the hypotensive action of circulating adenosine. Life Science, 32, 1151-1158. 
  151 
Waldeck, T. L., & Miller, L. S. (1997). Gender and impulsivity differences in licit substance 
use. Journal of Substance Abuse, 9, 269–275. 
Wayner, M.J., Jolicoeur, F.B, Rodeau, D.B, & Barone, F.C. (1976). Effects of acute and  chronic 
administration of caffeine on schedule dependent and schedule induced behavior. 
Pharmacology Biochemistry and Behavior, 5:343-348. 
Weinberg, B.A. & Bealer, B.K. (2001). The world of caffeine: the science and culture of the 
 world’s most popular drug.  New York, NY: Routledge. 
Whalen, D. J., Silk, J. S., Semel, M., Forbes, E. E., Ryan, N. D., Axelson, D. A., … Dahl, R. E.  
(2007). Caffeine consumption, sleep, and affect in the natural environments of depressed 
youth and healthy controls. Journal of Pediatric Psychology, 33(4), 358–367.  
Winston, A.P., Hardwick, E., & Jaberi, N. (2005). Neuropsychiatric effects of caffeine.  
 Advances in Psychiatric Treatment, 11, 432-439.   
Wolk, B.J., Ganetsky, M., & Babu, K.M. (2012). Toxicity of energy drinks.  Current Opinion 
 in Pediatrics, 24(2), 243-251. 
Woicik, P.A, Stewart, S.H., Pihl, R.O., & Conrod, P.J. (2009). The substance use risk profile 
 scale: a scale measuring traits linked to reinforcement-specific substance use profiles.  
 Addictive Behaviors, 34(12), 1042-1055. 
Wu, L. ., Pilowsky, D. J., Schlenger, W. E., & Hasin, D. (2007). Alcohol use disorders and the  
use of treatment services among college-age young adults. Psychiatric Services, 58(2), 
192–200.  
Yamada, K., Hattori, E., Shimizu, M., Sugaya, A., Shibuya, H., & Yoshikawa, T. (2001).  
Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes 
in panic disorder. Journal of Neural Transmission, 108(7), 837–848.  
  152 
Yamazawa, K., Hirokawa, K., & Shimizu, H. (2007). Sex differences in preferences for coffee  
sweetness among Japanese students 1, 2. Perceptual and Motor Skills, 105(2), 403–404.  
Yang, A., Palmer, A.A., & de Wit, H. (2010). Genetics of caffeine consumption and responses 
 to caffeine.  Psychopharmacology, 211, 245-257. 
Yeomans, M.R., Spetch, H., & Rogers, P.J. (1998). Conditioned flavor preference negatively 
 reinforced by caffeine in human volunteers. Psychopharmacology, 137, 401-409. 
Yeomans, M.R., Jackson, A., Lee, M.D., Nesic, J., & Durlach, P.J. (2000). Expression of flavour 
 preferences conditioned by caffeine is dependent on caffeine deprivation state.  
 Psychopharmacology, 150, 208-215.    
Yeomans, M.R., Ripley, T., Lee, M.D., & Durlach, P.J. (2001). No evidence for latent learning 
 of liking for flavours conditioned by caffeine. Psychopharmacology, 157, 172-179.  
Yeomans, M.R., Pryke, R., Durlach, P.J. (2002). Effect of caffeine deprivation on liking for a 
 non-caffeinated drink. Appetite, 39, 35-42. 
Zilberman, M. L., Tavares, H., Blume, S. B., & el-Guebaly, N. (2002). Towards best practices in  
the treatment of women with addictive disorders. Addictive Disorders & Their 
Treatment, 1(2), 39–46.  
Zilberman, M.L., Tavares, H., Blume, S.B., & el-Guebaly, N. (2003). Substance use disorders: 
 sex differences and psychiatric comorbidities.  Canadian Journal of Psychiatry, 48(1), 5-
 13. 
Zwyghuizen-Doorenbos, A., Roehrs, T.A., Lipschutz, L., Timms, V., & Roth, T. (1990).  Effects 
 of caffeine on alertness.  Psychopharmacology, 100, 36-39. 
 
 
